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Cardiovascular disease is the number one cause of death globally and is projected to 
remain the leading cause of death in the future. Estimates of the World Health 
Organization1 show that 17.5 million people died from cardiovascular disease (CVD) in 
2005, which represented 30% of all global deaths. It was estimated that if appropriate 
action is not taken, by 2015, 20 million people will die from CVD every year, mainly from 
myocardial infarction (MI) and stroke. The extensive frequency of CVD in the 
industrialized countries has been observed for decades. Therefore, in 1976 CVD risk 
equations were developed by the investigators of the Framingham Heart Study (FHS)2, 
enabling clinicians to predict the development of coronary disease in individuals free of 
disease. The FHS is a longitudinal study, which started follow-up of healthy residents of 
Framingham (Massachusetts, USA) in 1948 and has included subsequent generations 
ever since. In a 12-year follow-up of a defined cohort of the FHS, the Framingham risk 
score was developed. It provides a 10-year hazard ratio for CVD based on sex, age, low 
density lipoprotein-cholesterol (LDL-C), high density lipoprotein (HDL)-C, blood 
pressure, diabetes and smoking habits3,4.  
The European Society of Cardiology initiated the development of a European risk 
score system (SCORE) and used data from 12 European cohort studies (n=205,178) 
covering a wide geographic spread of countries at different levels of cardiovascular 
risks5. The SCORE was even calibrated for the different countries; the one for The 
Netherlands is presented in figure 1. These new SCORE risk estimates of cardiovascular 
death are based on the same factors as the Framingham risk score with exception of 
diabetes. With a relative risk of approximately five in women and three in men, the 
impact of diabetes on CVD appeared to be much greater in these European studies. 
Therefore it was not included in the SCORE estimate but identified as an independent 
risk factor.  
The single most important contributor to the growing burden of CVD is 
atherosclerosis, a progressive disease characterized by the accumulation of lipids and 
fibrous elements in the large arteries. The pathophysiology of this key problem has been 
studied extensively in the past century. Nowadays we consider atherosclerosis as a 
multifactorial disease in which lipids and inflammation play major roles6,7. The approach 
to primary prevention of atherosclerosis and CVD is founded on the public health 
approach that calls for lifestyle changes, including (I) reduced intakes of saturated fat 
and cholesterol, (II) increased physical activity, and (III) weight control. The clinical 
approach emphasizes preventive strategies for higher-risk persons. The major risk 
factors for CVD development and the general therapeutical options will be outlined in 
this chapter.  
 
 
 
11
_________________________________________________     _________________________GENERAL INTRODUCTION 
 11 
 
 
 
Figure 1 The SCORE estimate for The Netherlands providing a 10-year hazard ratio  
for fatal CVD5 
 
 
 
 
Risk Factors for the development of CVD 
 
Cholesterol 
Identified as an important risk factor in SCORE and FHS, also the current guidelines to 
treat CVD from the Adult Treatment Panel III8, the American Diabetes Association9 and 
American Heart Association10 emphasize targeting primarily LDL-C. HMG-CoA reductase 
inhibitors (statins) are widely used to lower LDL-C. In intervention trials using statins 
substantial reductions in major cardiovascular events in the treated groups were 
observed11. Furthermore, the magnitude of the reduction in events is a function of the 
amount of LDL-C, with each decrease of 1.0 mmol/L in LDL-C corresponding to a 23% 
reduction in major cardiovascular events11. However, in all the statin trials, substantial 
residual cardiovascular risk remains, even with very aggressive reductions in levels of 
LDL-C 11-14. This indicates that additional treatment is required. 
12
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Clinical studies have shown 
that HDL-C levels, independently of 
LDL-C, are inversely correlated with 
the risk of CVD (figure 2)15-18. In 
statin treated patients this 
relationship was also observed 
among patients with very low LDL-C 
levels (<1.8 mmol/L) 19. In the FHS, 
HDL-C level was more potent as a 
risk factor for CVD than was the level 
of LDL-C20. An analysis of data from 
four large studies concluded that 
each increase of  0.03 mmol/L in 
HDL-C is associated with a decrease 
of 2 to 3% in the risk of future CVD16. 
These findings have shifted the 
attention towards strategies for 
targeting HDL-C as adjunctive 
therapy to prevent and treat CVD. 
 
Hypertension 
Hypertension is considered a 'traditional' risk factor for developing atherosclerosis, 
which entails a threefold risk over that of normotensive persons of the same age22. 
Hypertension per se might facilitate atherosclerosis development by the pressure-
induced stretching of the arterial wall, which is a major determinant of arterial mass 
transport. Therewith it could enhance LDL-C accumulation in the inner media of the 
vessel wall23, inducing endothelial activation and vascular inflammation7. However, 
evidence is also accumulating that hypertension may be just a marker and that the 
underlying mechanism is the risk factor for the development of atherosclerosis. A 
central role herein is considered for angiotensin II, a key molecule of the renin-
angiotensin-aldosterone-system (RAAS), which regulates blood pressure24-26. However, 
in the fast majority of cases no single reason can be found for a patient causing the 
hypertension, indicating that hypertension is a very complex multifactorial disease, in 
which different mechanisms are involved. 
 
Diabetes 
Diabetes has been identified as a risk factor for CVD since many years and has gained the 
interest of research because of its increasing prevalence8,10,27. Estimates of current and 
future diabetes prevalence predict more than a doubling of the global burden of diabetes 
within 25 years from now28. In 75% of these subjects with type 2 diabetes mellitus 
Figure 2 For any given level of LDL-C in the 
Framingham population, the relative risk of CHD 
decreases with increasing serum concentrations of 
high-density lipoprotein cholesterol (HDL-C)  15,21.  
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(T2D) an atherogenic triad will be observed, whereas it also is a common characteristic 
of patients with insulin resistance and abdominal obesity29. The atherogenic lipid triad 
comprises raised plasma triglycerides (TGs), reduced HDL-C, and a predominance of 
small dense (sd) LDL, all of which are associated with an increased risk in CVD27.   
Besides inducing dyslipidemia, insulin resistance itself also affects other 
pathophysiologic mechanisms, which may increase the risk on CVD. Though not all 
mechanisms are clarified yet, insulin resistance is thought to contribute to the 
development of hypertension29,30, to impair thrombolysis30,31, to case endothelial 
dysfunction30 and to induce systemic and vascular inflammation32, all contributors to 
the development of atherosclerosis and CVD7,33.  
 
Atherothrombosis 
The main CVD events are MI and stroke, which occur when an atheromatous process 
precipitates thrombosis that prevents blood flow through the coronary or cerebral 
artery. Platelets, essential for primary hemostasis and repair of the endothelium, play a 
key role in the development of acute coronary syndromes and contribute to 
cerebrovascular events by triggering the acute onset of arterial thrombosis when 
atherosclerotic lesions rupture. In addition, they participate in the process of forming 
and extending atherosclerotic lesions. As atherosclerosis is a chronic inflammatory 
process, inflammation is an important component of acute coronary syndromes7. The 
relation between chronic and acute vascular inflammation is unclear, but platelets are a 
source of inflammatory mediators, which once activated, are able to activate vascular 
cells34,35. The activation of platelets by inflammatory triggers may be a critical 
component of atherothrombosis36. 
 
 
Pharmaceutical therapies  
 
Cholesterol 
The current armamentarium of lipid-lowering drugs includes inhibitors of hydroxy-3-
methyl-glutaryl-CoA reductase (statins), PPARα agonists (fibrates), niacin (nicotinic 
acid), all directly or indirectly inhibiting lipid synthesis in the liver, and selective 
cholesterol absorption inhibitors (e.g. ezetimibe) and bile acid sequestrants (anion 
exchange resins), which work in the intestine by inhibiting the cholesterol absorption 
from food and bile. Next to lipid lowering, statins and fibrates also reduce inflammation 
via inhibition of NF-κB pathways, whereas lowering LDL-C per se also has anti-
inflammatory effects7,37,38. 
Statin therapy may be considered as the ‘standard’ therapy to decrease (V)LDL-C, 
which has been shown to be very effective by lowering LDL-C by almost 30% in 
numerous studies and which may increase HDL-C modestly by a few percents11. 
14
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Together with their pleiotropic effects statins are very potent in reducing CVD 
endpoints11,39,40.  Fibrates potently reduce VLDL-TG (approx. -40%) and mildly increase 
HDL-C (approx. +10%) and seem to have most pronounced effect on CVD in obese and 
diabetic patients18,41,42. Niacin is a very powerful (V)LDL-TG lowering compound 
(approx. -40%) and the strongest HDL-C raising compound currently available (+ 15-
30%)18. However, due to its side-effect, severe flushing, it is not very well tolerated.  
The cholesterol uptake inhibitor ezetimibe mildly lowers LDL-C (approx. -
20%)43, but in combination with a low dose of statin the compounds strongly reduces 
LDL-C levels (approx. -55%).  Bile acid sequestrants also lower LDL-C mildly, which is to 
a similar extent as ezetimibe, however, these compounds tend to increase TG18,44.  
Future therapies aiming at increasing HDL-C are cholesteryl ester transfer 
protein (CETP) inhibitors, GPR109A (‘niacin receptor’) agonists, selective cannabinoid 
type I receptor (CB1) antagonists, ApoAI mimetics and intravenous infusion of HDL18. 
These latter two therapies with a transient increase of HDL aim at an increased 
cholesterol efflux from the vessel wall and additionally a reduced the vessel wall 
inflammation39. 
 
Hypertension 
The RAAS plays an important role in the regulation of blood pressure and body fluid and 
electrolyte homeostasis and may therefore be targeted to treat hypertension. The 
synthesis of angiontensin II, the main regulator molecule of RAAS, or the binding of 
angiotensin II to its receptor can be inhibited by angiotensin converting enzyme (ACE) 
inhibitors or angiotensin II type I receptor blockers (ARBs), respectively both are 
frequently used anti-hypertensive treatments. The RAAS also interacts with 
inflammatory pathways and its inhibition has clear anti-inflammatory effects26,45. 
Vasoconstriction can also be inhibited by blocking the calcium transport into the 
vascular smooth muscle cells by selective calcium channel blockers (CCBs). Other 
regularly used anti-hypertensive drugs are β-blockers and diuretics. Collective data of 
numerous prospective trials showed that anti-hypertensive treatment with any 
commonly-used regimen reduces the risk of total major cardiovascular events, whereby 
larger reductions in blood pressure produce larger reductions in risk 46.   
 
Diabetes and insulin resistance 
The most prescribed and effective insulin sensitizers are the thiazolidinediones, also 
referred to as the glitazones, and metformin. The latter compound has been used 
internationally for decades. Its primary mechanism of action is to suppress 
gluconeogenesis and to increase glucose uptake in the liver47. The glitazones increase 
peripheral utilization of insulin by acting as ligands of the peroxisome proliferator-
activated receptor gamma (PPARγ). This receptor is found in high concentrations in 
adipose tissue and in the vessel wall, and is involved in the regulation of genes that 
15
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control glucose homeostasis, lipid metabolism, and adipose tissue48. In order to increase 
the plasma levels, insulin can be administered, whereas it is also possible to stimulate its 
secretion by the use of sulfonylureas and meglitinides. However, these compounds 
exhibit adverse effects of hypoglycemia and weight gain49. New and future therapies to 
improve insulin sensitivity enclose the endocannabinoid system (CB1 receptor 
antagonists) and gut-hormone regulated routes. 
 
Anti platelet therapies 
The anti-platelet drug acetylsalicylic acid (aspirin) has been proven to prevent 
myocardial infarction and stroke in patients with CVD50. However, the major adverse 
side effect, bleeding, and the large prevalence of aspirin resistance (5-45%) are 
drawbacks of this drug51,52. Another class of anti-platelet agents are the thienopyridines, 
of which clopidogrel is a member, which act by blocking the adenosine diphosphate 
(ADP)-mediated pathway of platelet activation. Clopidogrel is at least as effective as 
aspirin in preventing ischemic stroke, myocardial infarction and vascular death53. 
However, combining the two does not significantly decrease cardiovascular events and 
may even increase major bleedings54. The clinical efficacy of aspirin is based on 
inhibition of the platelet cyclo-oxygenase-1 (COX-1), inhibiting the generation of platelet 
thromboxane A2 (TxA2,), which binds to the thromboxane-prostanoid endoperoxide (TP) 
receptor and thereby activates the platelet55. A third therapeutic route to inhibit platelet 
activation therefore may very well be direct inhibition of TxA2 or its TP-receptor, which 
is present on platelets. No TP-receptor antagonist is currently available; however a new 
compound terutroban (S 18886) has been developed and is currently in phase III of 
development. 
 
This thesis will present and discuss a variety of novel pharmaceutical interventions in 
experimental CVD as new ways to treat elevated lipid levels, blood pressure and 
conditions with increased risk of atherosclerosis. To study the effect of pharmaceutical 
intervention therapies on lipid metabolism, atherosclerosis and CVD we used suitable 
‘humanized’ mouse models for hyperlipidemia and atherosclerosis: APOE*3Leiden and 
APOE*3Leiden.CETP transgenic mice. 
 
 
Experimental model for hyperlipidemia, atherosclerosis and myocardial 
infarction  
Wild-type mice are resistant to atherosclerosis as a result of high levels of anti-
atherosclerotic HDL and low levels of proatherogenic LDL and VLDL, making them not 
useful for atherosclerosis research. All of the current mouse models for atherosclerosis 
are therefore based on modulations of lipoprotein metabolism through dietary or 
genetic manipulations. Among the most widely used mouse models are apolipoprotein 
16
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E–deficient mice (apoE-/- mice), the LDL receptor- deficient mice (LDLr-/- mice) and the 
APOE*3Leiden transgenic mice.  
 
Apolipoprotein E- deficient (apoE-/-) mice 
The targeted deletion of the apoE gene of the homozygous apoE-/- mice results in a 
pronounced increase in the plasma levels of LDL and VLDL attributable to the failure of 
LDLr- and LDLr-related protein (LRP) mediated clearance of these lipoproteins56,57. 
Even on a chow diet they exhibit severe hypercholesterolemia (about 9 mmol/L), which, 
together with the reduced apoe-mediated cholesterol efflux from macrophages, leads to 
spontaneous lesion development especially in the aortic arch58. Over time these lesions 
become quite complex, progressing well beyond the fatty streak and they resemble 
human lesions. This model is suitable to study cellular aspects of lesion development 
and has been used for years to that end. However, one of the major drawbacks of this 
model is the lack of responsiveness to pharmaceutical and/or nutritional lipid lowering 
therapy64. This makes the model less suitable for the evaluation of therapeutic 
interventions in atherosclerosis. The apoE-/- mice may be considered as a severe model 
for atherosclerosis. Additionally hampering the HDL clearance by cross breeding apoE-/- 
mice with HDL receptor scavenger receptor class B, type I deficient mice (generating 
apoE-/-/SR-BI-/-mice), results in extreme hypercholesterolemia and a dramatically 
accelerated atherosclerosis, which even leads to spontaneous lipid- and fibrin-rich 
occlusive coronary arterial lesions, multiple myocardial infarctions, and cardiac 
dysfunction59. These apoE-/-/SR-BI-/- mice die prematurely at about 6 weeks of age and 
can be considered as the most extreme model for CVD.  
 
LDL receptor- deficient (LDLr-/-) mice 
The LDLr-/- mice display a modest hypercholesterolemia on a chow diet (about 5 
mmol/L), with the cholesterol mainly confined to the LDL. Atherosclerosis develops 
slowly and is enhanced when these mice are fed a lipid-rich diet60. Interestingly, LDLr-/- 
mice cross bred with ApoB mRNA editing catalytic polypeptide-1 deficient mice 
(generating LDLr-/-/ApoBEC-/- mice)61 or with human ApoB100 transgenic mice 
(generating LDLr-/-; Tg(ApoB+/+) mice)62 show a large increase in plasma LDL-C and 
develop atherosclerosis on a low-fat diet. The LDLr-/- mouse represents a more 
moderate model than the apoE-/- mouse, mainly because of the lower degree of 
hyperlipidemia. However, their responsiveness to lipid-lowering therapies is not 
optimal or might even be absent64. 
 
APOE*3Leiden transgenic mouse  
A milder model is the APOE*3Leiden transgenic mouse, which develops atherosclerosis 
upon cholesterol feeding, and is more sensitive to lipid-lowering drugs than apoE-/- and 
LDLr-/- mice63,64. Hyperlipidemic APOE*3Leiden transgenic mice were generated by 
17
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introducing a human APOE*3Leiden gene construct, which also contained the APOC1 
gene and a promoter element regulating the expression of APOE and APOC1 genes, into 
wild-type C57Bl/6 mice63,65. Although APOE*3Leiden mice still express endogenous 
apoE protein, the clearance of apoE-containing lipoproteins is impaired, albeit less 
dramatically than in apoE–/– mice. APOE*3Leiden mice show significant elevations of 
plasma cholesterol and TG on a regular chow diet and are, in contrast to wild-type mice, 
highly responsive to fat-, sugar-, and cholesterol-containing diets. This results in a 
lipoprotein profile similar to that of patients with familial dysbetalipoproteinemia in 
whom the elevated plasma cholesterol and TG levels are mainly confined to the 
VLDL/LDL-sized lipoprotein fraction63. Plasma lipid levels can easily be adjusted to a 
desired concentration by titrating the amount of cholesterol and sugar in the diet. As 
compared with other hyperlipidemic mouse models (e.g. apoE–/– and LDL–/– mice), 
APOE*3Leiden mice represent a milder mouse model for hyperlipidemia (cholesterol 
levels on chow are about 2-3 mmol/L and do not exceed 25 mmol/L on a western-type 
high-cholesterol diet). The development of atherosclerosis strongly correlates with the 
plasma cholesterol levels and the duration of cholesterol elevation (figure 3), and 
consists of lesions with all the characteristics of human vascular pathology, varying from 
fatty streak to mild, moderate, and severe lesions66. 
The APOE*3Leiden mice are a 
suitable model to study the (V)LDL 
metabolism and, in contrast to apoE-
/- and ldlr-/- mice, they respond in a 
human-like manner to treatment of 
CVD (e.g. statins, calcium channel 
blockers, fibrates, angiotensin II 
receptor blockers, and cholesterol 
uptake inhibitors 67-73)64. However, 
APOE*3Leiden mice do not respond 
to HDL raising therapies. This is the 
consequence of the lack of CETP 
expression in mice, an important 
factor in the human HDL 
metabolism.  CETP mediates the 
transfer of cholesteryl ester from 
HDL particles to the apoB-
containing lipoproteins ((V)LDL) in 
exchange for triglycerides.  
Therefore, APOE*3Leiden mice were recently cross-bred with mice expressing 
the human CETP gene under control of its natural flanking regions, resulting in 
APOE*3Leiden.CETP mice74. These mice display an elevated basal cholesterol level and 
Figure 3 The strong correlation between 
cholesterol exposure (plasma cholesterol levels in 
mmol/L times the duration in weeks) and the 
atherosclerosis development in APOE*3Leiden 
(black circles) and APOE*3Leiden.CETP (open 
circles)  transgenic mice. Unpublished observations 
of H.M.G. Princen and P.C.N. Rensen. 
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a human-like lipoprotein profile. CETP expression in APOE*3Leiden mice shifts the 
distribution of cholesterol from HDL toward VLDL/LDL, and strongly (7-fold) increases 
atherosclerosis development (figure 3)74. Their responsiveness to lipid modulating 
therapies was even increased, since these mice also respond to the HDL-raising effects 
of fenofibrate75, atorvastatin76, torcetrapib77 and niacin78. 
 
 
Outline of the thesis 
 
This thesis describes a variety of novel pharmaceutical interventions in experimental 
CVD of APOE*3Leiden mice.  
Chapter 2 reviews the effect of current ‘standard’ therapies for the treatment of 
two separate risk factors for CVD, i.e.  hyperlipidemia with atorvastatin and 
hypertension with the calcium channel blocker amplodipine. Additionally, scientific 
evidence is collected to determine the possible advantage of combining these two kinds 
of treatments, potentially leading to additive or synergistic effects in the prevention of 
CVD.  
Although compounds have proven their benefit in the clinic, their exact working 
mechanism is not always clarified. Niacin (vitamin B3) is one of those compounds. In the 
early 1950s it was known that niacin decreases LDL-C and concomitantly increases 
HDL-C. The underlying mechanism however, remained to be elucidated. In Chapter 3 
the mechanism of the HDL-C raising effect of niacin is explored in the 
APOE*3Leiden.CETP transgenic mouse model, which was proven in this study to be a 
very suitable model to investigate HDL-raising therapies.  
 Modulating plasma lipid levels using compounds like niacin, PPARα agonists, or 
cholesterol uptake inhibitors is of significance to obtain an indication about their effect 
on atherosclerosis development. In chapter 4 we evaluate the effect of a new 
cholesterol uptake inhibitor AVE5530 with regard to its VLDL/LDL-C lowering capacity 
as well as its anti-atherosclerotic effects in APOE*3Leiden mice. Ezetimibe, a cholesterol 
uptake inhibitor already used in the clinic, has been used as a reference compound. A 
major difference between AVE550 and ezetimibe is that nearly 100% of ezetimibe is 
absorbed in the intestine whereas AVE5530 is not. 
 As described in chapter 2, combination therapy targeting two risk factors of CVD 
might have synergistic or additive effects in the prevention of CVD and atherosclerosis. 
An example of such a study is presented in chapter 5 where APOE*3Leiden mice are 
treated with either the anti-hypertensive angiotensin receptor blocker olmesartan or 
the antihyperlipidemic drug pravastatin, alone or with the combination of both 
compounds.  
Nowadays compounds are developed in order to target two independent risk 
factors for CVD simultaneously, for instance the dual PPARα/γ agonist tesaglitazar 
19
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treating both hyperlipidemia and insulin resistance/diabetes. In chapter 6 the effect of 
tesaglitazar is investigated in APOE*3Leiden.CETP with pre-existing atherosclerotic 
lesions. Such a study design is of more clinical significance, since in humans lesions have 
already been developed before treatment is started. 
  A similar design is used for the study presented in chapter 7 where 
APOE*3Leiden mice had developed mild lesions before cholesterol-lowering and anti-
platelet therapy with a thromboxane prostanoid (TP) receptor antagonist S18886 was 
started. The effects of thromboxane and its receptor on platelet function and peripheral 
tissue are not fully clarified yet. However, evidence is accumulating that it interacts with 
inflammatory pathways and affects atherosclerosis and CVD endpoints. It has been 
observed that selective cyclooxygenase-2 (COX-2) inhibition by rofecoxib is associated 
with increased risk of cardiovascular events. We hypothesized that this could be due to a 
disrupted local TXA2-PGI2 balance, which could be prevented by concomitant treatment 
with TP-receptor antagonist S18886 that might ameliorate possible negative effects.  
This is investigated in chapter 8 in APOE*3Leiden mice with ischemia reperfusion 
injury of the myocardium.  
The results obtained in these studies and their clinical relevance are discussed in the 
General Discussion.  
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Abstract 
Hypertension and hyperlipidemia are major risk factors for the development of 
atherosclerosis. Calcium channel blockers (CCBs) are used for decades for their 
established antihypertensive effects, as statins are used for a long time for their potent 
lipid lowering properties. Amongst others inflammation and oxidation are involved in 
enhanced progression of atherosclerosis and new lesion development. Therefore 
research has been initiated focusing on e.g. the antioxidant and anti-inflammatory 
properties of CCBs and statins, beyond their primary effect in order to evaluate the 
possible additive effects of combined treatment of CCBs with statins as anti-
atherosclerotic therapy. 
 Clinical studies, amongst others the International Nifedipine Trial on 
Antiatherosclerotic Therapy (INTACT), have demonstrated that the antiatherosclerotic 
action of CCBs is limited to attenuation of the first stage of atherosclerogenesis (fatty 
streak formation or new lesion growth). The lesions that pre-existed the start of CCB 
therapy did not demonstrate progression or regression on angiography.  However, 
because the mechanisms of action of lipid-lowering drugs and CCBs and their role in 
preventing the progression of atherosclerosis differ, it is conceivable that these two 
classes may have an additive or synergic effect, not only on new lesion formation but 
also on inhibiting the progression of established coronary atherosclerosis.  Indeed, this 
combined effect of lipid-lowering therapy and CCBs on human coronary atherosclerosis 
has been reported in the Regression Growth Evaluation Statin Study (REGRESS) trial. 
Researchers observed a significant beneficial effect of CCBs with regard to angiographic 
progression and new lesion formation in patients treated with a statin, but no similar 
antiatherosclerotic effect in those treated with CCB alone (placebo group).  This 
beneficial effect as a result of combining CCBs with statins has now been replicated in 
transgenic atherosclerotic mice, where the combination of amlodipine and atorvastatin 
produced an additional 60% reduction of atherosclerosis compared with that observed 
with the statin alone. Serum markers of atherosclerosis and vascular integrity also 
improved most in the combination group. Recently Mason et al. showed a synergistic 
effect of the combination of atorvastatin and amlodipine on acute NO 
release/endothelial function, whereas Leibovitz et al demonstrated that the 
combination of amlodipine and atorvastatin had an additive effect in improvement of 
arterial compliance in hypertensive hyperlipidemic patients. 
Collectively, these studies support the clinical anti-atherosclerotic advantages of 
combination of CCBs and statins and in particular of atorvastatin with amlodipine 
beyond their established antihyperlipidemic and antihypertensive modes of action. 
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Introduction 
Cardiovascular disease (CVD) is the main cause of death in the Western Society. CVD is 
mostly caused by atherosclerosis. Established risk factors for developing atherosclerosis 
are male gender, age, diabetes mellitus, genetic predisposition, high plasma lipoprotein 
levels, hypertension, obesity and smoking.  
Hypertension is considered a 'traditional' risk factor for developing 
atherosclerosis, which entails a threefold risk over that of normotensive persons of the 
same age 1. However, in the fast majority of cases no single reason can be found for a 
patient causing the hypertension. This indicates that hypertension is a very complex 
multifactorial disease, in which different mechanisms are involved. The last decade 
newer 'nontraditional' risk factors for the development of atherosclerosis are identified 
including inflammation and its markers, like C-reactive protein, homocysteine, oxidative 
stress and endothelial dysfunction, but also activation of the renin-angiotensin-
aldosterone-system (RAAS)2. Evidence is accumulating that hypertension may be just a 
marker and the underlying mechanism is the risk factor for the development of 
atherosclerosis. 
In patients with coronary atherosclerosis, disease progression is one of the main 
factors that determine clinical prognosis. Patients with progression of coronary 
atherosclerosis, do significantly worse with regard to clinical event-free survival than 
patients with attenuated progression3. Thus inhibition of the progression of 
atherosclerosis is almost as important as preventing atherosclerosis development. 
Lipid-lowering therapy has undoubtedly proven to be an effective therapeutic modality 
to retard the progression of coronary atherosclerosis4. Possible beneficial modes of 
action of lipid-lowering therapy include: (1) retardation of progression and induction of 
regression of coronary atherosclerosis4 (2) atherosclerotic lesion-plaque stabilization5,6 
(3) restoration of endothelial dysfunction7, (4) decreased thrombotic tendency8, and 
immune system modulation 9. 
Evidence indicating also that some calcium channel blockers (CCBs), which are 
established anti-hypertensive drugs, inhibit atherosclerosis is accumulating. Many 
investigations support the view that a number of key processes in atherosclerosis may 
be influenced by CCBs. These key processes include: (1) oxidation of circulating 
lipoproteins, such as LDL10, (2) binding of monocytes to and transmigration of 
monocytes through the endothelial cell layer11,(3) formation of macrophage-derived 
foam cells, (4) proliferation and migration of VSCMs12, (5) binding of platelets to the 
endothelial cells layer and subsequent platelet aggregation13, and (6) synthesis of matrix 
components, such as collagen. 
In this review first the development of atherosclerosis and hypertension will be 
briefly described. Secondly mechanisms and effects of lipid-lowering therapy by statins 
and anti-hypertensive therapy by calcium channel blockers will be described. Because 
the mechanisms of action of lipid-lowering drugs and CCBs and their role in preventing 
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the progression of atherosclerosis differ, and it therefore is conceivable that these two 
classes may have an additive or synergic effect, it is interesting to focus on combination 
therapy. Most research with regard to combination therapy of CCBs and statins has been 
performed with amlodipine and atorvastatin and therefore the effects of the 
combination of these compounds on atherosclerosis will be specially highlighted. 
 
 
Hypertension and atherosclerosis 
In 1996 Meyer et al.14 showed the effects of pressure-induced stretch and convection on 
low-density lipoprotein (LDL) and albumin uptake in the rabbit aortic wall. It was 
demonstrated that pressure-induced stretching of the arterial wall is a major 
determinant of arterial mass transport, and that pressure-driven convection accentuates 
LDL accumulation in the inner media, which may explain enhanced atherosclerosis in 
hypertension. Accumulation of atherogenic lipoproteins in the arterial wall is generally 
considered to be the first step in the development of atherosclerosis. Reactions with 
reactive oxygen species (ROS) 15 can oxidatively modify the lipid and apoB components 
of LDL trapped in the subendothelial space. Proinflammatory factors, such as oxidized 
LDL and ROS stimulate release of cytokines. This leads to the accumulation of 
mononuclear cells, migration and proliferation of SMCs and formation of fibrous tissue 
that eventually results in an atherosclerotic plaque.  
Most, if not all, of the risk factors that are related to atherosclerosis and 
cardiovascular morbidity and mortality, were also found to be associated with 
endothelial dysfunction. Many of these risk factors, including hyperlipidemia, 
hypertension, diabetes and smoking are associated with overproduction of ROS or 
increased oxidative stress 16,17. Measurement of endothelial (dys)function gives a proper 
indication about the health/condition of the endothelium. In endothelial dysfunction the 
homeostasis of vasoactive substances is disrupted 18. The bioavailability of NO, which 
promotes vasodilation in response to hemodynamic stress, is decreased due to reduced 
secretion and to interaction with superoxide anion (O2-)19. The level of the 
vasoconstrictor factor angiotensin II, promoting the proliferation and influx of vascular 
cell adhesion molecule-1 (VCAM-1), intercellular adhesion molecule-1 (ICAM-1) and 
cytokines, and the level of the potent vasoconstrictor hormone endothelin-1 (ET-1) are 
increased 20. These changes in homeostasis lead to changes in vascular structure and 
function 19,21. Besides a disturbed balance of vasodilators and vasoconstrictors, 
endothelial dysfunction also comprises a specific state of 'endothelial activation’, which 
is characterized by a proinflammatory, proliferative, and procoagulatory environment 
that favors all stages of atherogenesis16. As a number of these cellular and inflammatory 
processes are mediated by disruption of calcium homeostasis, there has been interest in 
the potential role of calcium channel antagonists (CCBs) as antiatherogenic agents, apart 
from their anti-hypertensive potential 11. 
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Calcium Channel Blockers 
Mechanism 
The mechanisms of the anti-atherosclerotic effect of CCBs, also called calcium 
antagonists, are not fully understood, however many pathways have been studied last 
decade, giving more insight in different mechanisms of CCBs. CCBs are essentially used 
as anti-hypertensive drugs. The primary action of calcium channel blockers is to inhibit 
calcium ion entry through voltage-gated transmembrane L-type channels, thus 
decreasing intracellular calcium concentration and inducing smooth muscle relaxation. 
Several important processes in atherosclerosis may be influenced by CCBs because they 
require calcium-dependent energy. In vitro studies have shown that CCBs can reduce 
lipoprotein oxidation and proliferation and migration of smooth muscle cells. However, 
the anti-atherosclerotic activity of CCBs probably involves many additional properties of 
the compounds because calcium-independent mechanisms, such as binding of 
monocytes to the endothelial cell layer, esterification of cholesterol in macrophages, and 
expression of matrix metalloproteinases in vascular endothelial cells, have also been 
shown to be inhibited by calcium antagonists22. CCB can be separated in two main 
groups i.e. the dihydropyridine (DHP) and the non-dihydropiridine (non-DHP) CCBs. On 
average these different CCBs display different anti-atherosclerotic potential, especially 
some DHP CCBs seem to have anti-atherosclerotic potential.  
CCBs and atherosclerosis 
Anti-atherosclerotic properties of CCB treatment were discovered in the 1980s. It was 
demonstrated that plasma membrane calcium transport in the aortic wall of rabbits with 
experimental atherosclerosis was increased fivefold and that CCBs were able to 
suppress such experimental atherosclerosis23. Since then CCBs have been evaluated for 
their anti-atherosclerotic effect in humans24.  
In Vitro 
Mak et al.10 demonstrated that DHP CCBs had the same protective effect against 
oxidative damage in bovine aortic endothelial cells like vitamin E. Because endothelial 
cells do not have receptors for CCBs (the L-type calcium channels are not involved in 
calcium influx25) the molecular mechanism of the antioxidant effect is less clear. 
Apparently, the cytoprotective effects of the DHP calcium blockers were mediated by a 
membrane 'chain-breaking' antiperoxidative action similar to that provided by vitamin 
E10. DHP CCB amlodipine has been shown to stimulate NO release from canine coronary 
microvessels in a dose dependent manner like the ACE inhibitors analaprilat and 
ramiprilat, whereas DHP CCB nifedipine and diltiazem did not. Amlodipine mediates NO 
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release and hereby may have antioxidative properties, similar to the mechanism of ACE 
inhibitors, by modulation of the actions or formation of kinins26. 
Oxidative-modification of LDL contributes to destructive inflammatory processes 
associated with atherosclerosis. It is characterized by elevations in cholesterol content 
and increased electro negativity, factors that contribute to aggregation and foam cell 
formation. Phillips and Mason27 designed a study to test the effect of the positively 
charged calcium channel blocker (CCB) amlodipine on the aggregation properties of 
oxidized LDL lipids. Amlodipine inhibited binding of the oxidized LDL lipids in a dose-
dependent fashion, in contrast to other drugs lacking a formal positive charge (including 
CCBs).  
Amlodipine also modulates metabolism of collagens within the extracellular 
matrix and thus potentially has plaque stabilizing properties. It was demonstrated that 
CCBs, including amlodipine, specifically increased the proteolytic activity of the 72-kDa 
type IV collagenase and inhibited the transcription of tissue inhibitor of MMP-228. 
Amlodipine, but not nifedipine significantly decreased interleukin-1β induced MMP-1 
expression in human endothelial cells29. Additionally, several studies demonstrated a 
role for amlodipine in the remodeling of SMC membranes and in the inhibition of SMC 
proliferation and migration, which are hallmark features of atheroma development 
11,12,29. 
In vivo 
Amlodipine was tested in hyperlipidemic hamsters for is antiatherogenic properties. 
Male Golden Syrian hamsters were subjected to a hyperlipidemic diet. At intervals 
ranging from 2 to 14 weeks, the animals were examined for changes in serum 
constituents and structural modifications of lesion-prone areas like the cardiac valves, 
coronary arteries and aortic arch. Amlodipine treatment of hyperlipidemic hamsters 
was assessed. Amlodipine exhibited an atheroprotective effect, acting as antioxidant, 
reducing the LDL uptake by the vessel wall and consequently, limiting the size and 
extent of lesion areas30.  Recently Turgan et al.31investigated the interactions of 
amlodipine with major cellular antioxidants in order to elucidate the mechanisms 
underlying its atheroprotective effects. New Zealand white male rabbits were fed 
regular chow with or without 1% cholesterol and with or without amlodipine for 8 
weeks. Total cholesterol, malondialdehyde and vitamin E concentrations and catalase 
and superoxide dismutase activities were determined in blood drawn before and after 
the experimental period. Aortic tissue was examined for atherosclerotic changes and 
aortic total cholesterol, malondialdehyde, catalase and superoxide dismutase were 
determined. Amlodipine seemed to exert atheroprotective effects by reducing aortic 
cholesterol accumulation and blood and aortic lipid peroxidation, enhancing superoxide 
dismutase activity both in blood and aortic tissue and suppressing the consumption of 
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vitamin E. On the other hand, the suppression of catalase activity in blood and the aorta 
interferes with the well-known antioxidant effects of amlodipine. 
Atherosclerosis may result in plaque rupture resulting in a myocardial infarction. 
Calcium dependent factors, including cholesterol-induced changes in membrane calcium 
permeability and calcium deposition into lesions, may contribute to plaque formation 
and stability during the early and late stages of atherogenesis. Hoshida et al. evaluated 
the effect of amlodipine treatment on myocardial infarction size after 30-min coronary 
occlusion/48-h reperfusion in rabbits fed a diet with or without 1% cholesterol. Infarct 
size was significantly larger in cholesterol-fed rabbits (72.0 +/- 3.5%, n = 9, mean +/- 
S.E.M.) than in normal-fed rabbits (47.1 +/- 4.9%, n = 9, P < 0.05). Amlodipine treatment 
effectively reversed the infarct size augmentation in cholesterol-fed rabbits (46.3 +/- 
6.3%, n = 9, P < 0.05), but did not affect infarct size in normal-fed rabbits (51.0 +/- 4.7%, 
n = 8). Calcium content and leukocyte accumulation were markedly elevated in the 
ischemic myocardium of cholesterol-fed rabbits compared with normal-fed rabbits. 
Amlodipine treatment effectively reversed this elevation. Acetylcholine showed a 
marked reduction in endothelium-dependent relaxation in the aorta of cholesterol-fed 
rabbits, which also was reversed by amlodipine treatment32.  
Clinical trails with CCBs, using angiography show different results. The INTACT 
study33 showed that nifedipine had no effect on the progression of existing lesion but 
could reduce the number of new formed lesions in coronary artery diseased patients. 
The PREVENT study34 demonstrated in cardiovascular diseased patients that 
amlodipine treatment was associated with reduction in cardiovascular morbidity, but 
had no effect on the angiographic progression of atherosclerosis or cardiovascular 
mortality. The ELSA study35 compared the progression of atherosclerosis in 
hypertensive patients treated with β-blocker atenolol or DHP CCB lacidipine. Despite a 
smaller ambulatory blood pressure reduction, lacidipine was shown to have a greater 
efficacy on carotid intima-media thickness progression, which predicts cardiovascular 
events, and number of plaques per patient.  Recently, the NICOLE study36 evaluated the 
effect of nisoldipine on atherosclerosis progression in patients who had undergone 
coronary angioplasty. It was found that long acting nisoldipine did not retard the 
angiographic progression of coronary artery disease and did not affect mortality. 
However, it reduced the need for coronary revascularisation.  
Besides the (clinical) antiatherosclerotic effects found in previous described 
studies Ghiadoni et al. 37 found reduced oxidative stress and increased plasma oxidant 
capacity hypertensive patients receiving amlodipine or nifedipine. 
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Statins 
Mechanism 
3-Hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase catalyses the rate-
limiting step in cholesterol biosynthesis. Consequently this has been an important target 
for the development of cholesterol-lowering agents. Inhibition of HMG-CoA reductase 
leads to an upregulation of LDL-receptors in the liver mediated by the activation of 
Sterol Regulatory Element-Binding Proteins (SREBPs) and enhanced clearance of LDL 
from the circulation. HMG-CoA reductase inhibitors, or statins, were first introduced into 
clinical practice in the 1980s. Pravastatin and lovastatin are produced from fungal 
metabolites, simvastatin is semi-synthetic and fluvastatin, atorvastatin and rosuvastatin 
are synthetic statins38. Pravastatin and rosuvastatin are hydrophilic agents; other statins 
are highly lipophillic.  
Statins and atherosclerosis 
Because lipoproteins infiltrated in the vessel wall are the start of the development of 
atherosclerotic lesion and oxidized particles may trigger or enhance atherogenicy, 
statins are relevant in treatment for preventing atherosclerosis. In many clinical trails is 
proven that treatment with statins reduce morbidity and mortality in CVD patients. Best 
known, major trials in the 1990s were 4S (1994) 39, CARE (1996) 40 (1996) and LIPID 
(1998) 41 (1997). The 4S trial was designed to evaluate the effect of cholesterol lowering 
with simvastatin on mortality and morbidity in patients with coronary heart disease. 
4444 Patients with angina pectoris or previous myocardial infarction and serum 
cholesterol 5.5-8.0 mmol/L on a lipid-lowering diet were randomised to double-blind 
treatment with simvastatin or placebo. Over the 5.4 years median follow-up period, 
simvastatin showed a reduction of major coronary events, coronary deaths and overall 
mortality. Other benefits of treatment included a reduction in the risk of undergoing 
myocardial revascularisation procedures. This study showed that long-term treatment 
with simvastatin is safe and improves survival in CVD patients. CARE and LIPID are both 
trails in which the effect of pravastatin on coronary events and death was investigated in 
patients with a history of myocardial infarction of unstable angina pectoris. In the CARE 
study 4159 patients and in the LIPID study 9014 patients participated. The mean follow-
up period was 5 (CARE) and 6 (LIPID) years. In both studies was demonstrated that 
pravastatin reduced the fatal coronary events, myocardial infarction, stoke and overall 
death. 
Statins and inflammation 
Over the last years evidence is accumulating that not only the lipid lowering effect of the 
statins but also their anti-inflammatory properties may be responsible for 
atheroprotective effects. In 1998 Yamamoto et al.42 demonstrated that fluvastatin, more 
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than pravastatin inhibited NAD(P)H dependent lipid peroxidation in liver microsomes. 
In addition fluvastatin scavenged ROS such as hydroxyl radicals and O2-. A reduction of 
fibrinogen and serum amyloid A was seen in ApoE*3-leiden transgenic mice treated 
with atorvastatin, which is a synthetic and lipophilic statin like fluvastatin 43. 
Recently Hernandez-Presa et al.44 investigated whether simvastatin reduced 
inflammation in atherosclerosis beyond its hypolipidemic effects. Rabbits with induced 
femoral injury and on an atherogenic diet were randomized to normolipidemic diet or to 
continue the atherogenic diet while receiving simvastatin or no treatment for 4 weeks. 
As compared with no treatment, the normolipidemic diet significantly reduced lipid 
levels, while simvastatin produced nonsignificant reductions. In spite of this, NF-κB 
binding activity in peripheral mononuclear cells was reduced in the simvastatin group 
as compared with no treatment and normolipidemic groups (electrophoretic mobility 
shift assay). NF-κB activity in the atherosclerotic lesions was also reduced by 
simvastatin as compared to nontreated animals, while the normolipidemic diet induced 
only a nonsignificant diminution (Southwestern histochemistry). Similarly, simvastatin 
decreased macrophage infiltration and the expression of interleukin-8 and MMP-3, 
while the reduction achieved by normolipidemic diet in all these parameters was again 
nonsignificant. 
In APOE*3Leiden transgenic mice, which develop human-like atherosclerosis, 
Kleemann et al.45 demonstrated that rosuvastatin treatment reduced atherosclerosis 
beyond and independent of the reduction achieved by cholesterol lowering alone. In this 
study mice received a high cholesterol diet with or without rosuvastatin or a 
normolipidemic diet. It was also shown by in situ hybridization in the aortic root, that 
the number of TNF-α and MCP-1 positive cells was significant reduced after rosuvastatin 
treatment. A same reduction was found for Serum Amyloid A and fibrinogen levels. 
These findings were all lipid independent, demonstrating anti-inflammatory activities of 
rosuvastatin. 
Atorvastatin and inflammation 
Several studies showed results regarding the interaction of statins and NF-κB signalling. 
Atorvastatin reduces activation of transcription factor NF-κB in cultured VSMCs 46 as 
well as in atherosclerotic lesions in the rabbit47. Dichtl et al.48 aimed to characterize the 
effects of statins on the activation of transcription factors known to regulate 
inflammation and cell proliferation/differentiation. Simvastatin, atorvastatin, and 
lovastatin inhibited the binding of nuclear proteins to both the NF-κB and activator 
protein-1 DNA consensus oligonucleotides in human endothelial cells and VSMCs as 
assessed by electrophoretic mobility shift assay. Furthermore, statins inhibited DNA 
binding of hypoxia-inducible factor-1α. 
Recently Zhao et al.49 demonstrated that atorvastatin can inhibit IL-6 secretion in 
rabbit adipocytes, in a dose-dependent manner, possibly through upregulating 
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peroxisome proliferator-activated receptor (PPAR) gamma. In high cholesterol fed 
rabbits on two week atorvastatin treatment, IL-6 concentrations in plasma and 
adipocytes culture supernatant and PPARgamma mRNA expression were measured. 
Two weeks atorvastatin treatment resulted in significant reduction of circulating IL-6 
concentrations, which was associated with IL-6 secretion in adipocytes. Meanwhile 
mRNA expression of PPARgamma in adipocytes was intimately related to the IL-6 
secretion in adipocytes.   
Thrombin, a serine protease, plays an important role in inflammation and thus 
the progression of atherosclerosis. Haloui et al. 50 demonstrated that atorvastatin could 
limit the pro-inflammatory response to thrombin in cultured rat aortic smooth muscle 
cells. The variations in expression of interleukin-6, heme oxygenase-1, p(22phox) and 
Mox-1 mRNAs were evaluated. Thrombin activated interleukin-6 secretion and mRNA 
expression in smooth muscle cells in a dose-dependent manner. The greatest effect on 
mRNA expression was obtained after 1 h of stimulation. Preincubation of the cells with 
various concentrations of atorvastatin prevented this effect. Thrombin was without 
effect on p(22phox) and heme oxygenase-1 mRNA expression but, after 3 hour of 
stimulation, induced a two-fold increase in that of Mox-1. Preincubation with 
atorvastatin dose-dependently down regulated this Mox-1 mRNA expression. In 
addition, thrombin induced NF-kappaB translocation and membrane translocation of 
RhoA in smooth muscle cells which were both prevented by pre-treatment of the cells by 
atorvastatin.  
 
 
Atorvastatin in humans 
Inflammation 
Adhesion molecules and cytokines are involved in the pathogenesis of intimal injury in 
atherosclerosis. To investigate their relationship with endothelial function Nawai et al. 51 
examined the effects of atorvastatin on soluble adhesion molecules, interleukin-6 (IL-6) 
and brachial artery endothelial-dependent flow mediated dilatation (FMD) in patients 
with familial (FH) and non-familial hypercholesterolemia (NFH).  
A total of 74 patients (27 FH and 47 NFH) were recruited. Fasting lipid profiles, 
soluble intercellular adhesion molecule-1 (sICAM-1), soluble vascular-cellular adhesion 
molecule-1 (sVCAM-1), E-selectin, IL-6 and FMD were measured at baseline, 2 weeks, 3 
and 9 months post-atorvastatin treatment (FH: 80 mg/day, NFH: 10 mg/day). In both 
groups, compared to baseline, sICAM-1 levels were significantly reduced at 2 weeks, 
further reduced at 3 months and maintained at 9 months. The IL-6 levels were 
significantly reduced at 3 months and 9 months compared to baseline for FH and NFH. 
In both groups, the FMD at 2 weeks was higher than baseline, with progressive 
improvement up to 9 months. FMD was negatively correlated with sICAM-1 and IL-6. 
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Thus both low and high doses of atorvastatin lead to early progressive improvement in 
endothelial function in patients with primary hypercholesterolemia. sICAM-1 and IL-6 
levels do reflect endothelial dysfunction in these patients. 
The pleiotropic actions of statins include anti-inflammatory and antioxidant 
actions. To evaluate whether alternative oxidative pathways are suppressed in vivo after 
atorvastatin administration was examined by Shishehbor et al.9. Hypercholesterolemic 
subjects with no known coronary artery disease were evaluated at baseline and after 12 
weeks of atorvastatin therapy (10 mg/d). Plasma levels of protein-bound 
chlorotyrosine, NO2Tyr, dityrosine, and orthotyrosine, specific molecular fingerprints 
for distinct oxidative pathways up regulated in atheroma, were determined by mass 
spectrometry. In parallel, alterations in lipoproteins and C-reactive protein were 
determined. Statin therapy caused significant reductions in chlorotyrosine, NO2Tyr, and 
dityrosine (30%, 25%, and 32%, respectively) that were similar in magnitude to 
reductions in total cholesterol and apolipoprotein B-100 (25% and 29%). Nonsignificant 
decreases in orthotyrosine and C-reactive protein levels were observed (9% and 11%, 
respectively). Statin-induced reductions in oxidation markers were independent of 
decreases in lipids and lipoproteins. Statins promote potent systemic antioxidant effects 
through suppression of distinct oxidation pathways. The major pathways inhibited 
include formation of myeloperoxidase-derived and nitric oxide-derived oxidants, species 
implicated in atherogenesis.  
Plaque stability 
Beside prevention and regression of atherosclerosic plaque formation, prevention of 
plaque rupture is another very important aspect. Coronary plaque stabilization by statin 
therapy in humans was investigated by Takano et al. 6. They evaluated the changes in 
coronary plaque color and morphology by atorvastatin therapy using coronary 
angioscopy. Thirty-one patients with coronary artery disease were divided into either 
the comparison group (n = 16) or the atorvastatin group (n = 15). Before treatment and 
12 months after, the color and complexity of 145 coronary plaques were determined 
according to angioscopic findings. The yellow score of the plaque was defined as 0 
(white), 1 (light yellow), 2 (yellow), or 3 (dark yellow), and its disrupted score was 
defined as 0 (smooth surface) or 1 (irregular surface) and as 0 (without thrombus) or 1 
(with thrombus). In each patient, the mean yellow score and mean disrupted score were 
calculated. Mean LDL cholesterol decreased by 45% in the atorvastatin group, whereas 
an increase of 9% was seen in the comparison group. The mean yellow score decreased 
from 2.03 to 1.13 in the atorvastatin group, whereas it increased from 1.67 to 1.99 in the 
comparison group. There was a good correlation between the change in the mean yellow 
score and the change in LDL cholesterol levels. The change in the mean yellow score and 
mean disrupted score differed significantly between the two groups. This is the first 
report clarifying detailed changes in coronary plaque by statin in humans. This study 
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indicated that lipid-lowering therapy changes plaque colour and morphology possibly 
reflecting a more stable plaque phenotype in vivo. 
 
Revascularisation 
The AVERT study52 was designed to determine whether aggressive lipid-lowering 
therapy with atorvastatin is an alternative to angioplasty or other catheter-based 
revascularization procedures in patients with significant coronary artery disease. 341 
Patients with low-density lipoprotein (LDL) cholesterol ≥ 3 mmol/L and ≥ 1 defined 
narrowing of a major coronary artery were randomized to atorvastatin or the indicated 
catheter-based revascularization and conventional care (including lipid-lowering 
therapy if prescribed). Ischemic events were tracked for 18 months. The primary 
efficacy parameter was the incidence of an ischemic event, defined as 1 of the following: 
cardiovascular death, cardiac arrest, nonfatal myocardial infarction, the need for 
coronary bypass grafting or angioplasty, cerebrovascular accident, and worsening 
angina verified by objective evidence requiring hospitalization (including unstable 
angina). Results of this study favour the use of aggressive lipid lowering over 
percutaneous transluminal coronary angioplasty in patients with mild to moderate 
coronary disease. Treatment with atorvastatin significantly reduced LDL cholesterol 
levels, and was associated with a 36% reduction in ischemic events and a significant 
delay in time to first ischemic event. 
 
 
Combining Statin and Calcium Channel Blocker therapy 
Advances of combination therapy 
It has been demonstrated very often that statins and CCBs both have antiatherosclerotic 
potential via different mechanisms. Gathering their strengths might lead to additive or 
synergistic antiatherosclerotic effects. Important evidence for an additive effect of CCBs 
and statin treatment in retarding progression of coronary atherosclerosis was found in a 
retrospective study on data from the REGRESS-study4. Evaluating the effect of pravastatin 
on progression and regression of coronary artery disease, it was found that the 
combination of pravastatin and a calcium antagonist was more successful in retarding the 
progression of atherosclerosis than pravastatin alone. This seemed to be especially true 
for DHP CCBs, which tended to have stronger antiatherosclerotic properties than non-
DHP CCBs 53 ( Figure 1 ).  
The ENCORE54 investigators examined the effects of a statin and/or a calcium 
antagonist on coronary endothelial function in patients with coronary artery disease. In 
343 patients the endothelial function was investigated. Thereafter, patients were 
randomized in a double-blind manner to a 6 month treatment with placebo, cerivastatin, 
nifedipine, or their combination. In the most constricted segment, nifedipine but not 
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cerivastatin improved endothelial dysfunction. Patients not taking ACE inhibitors showed 
a smaller improvement in the placebo group (6.0%), but nifedipine still had an effect 
(17.0%; P<0.05 versus placebo). 
Analysis of all evaluable coronary segments revealed an improved endothelial 
function in patients receiving nifedipine and cerivastatin (P<0.05 versus placebo). 
Cerivastatin lowered LDL cholesterol by 35%.  The ENCORE II study is designed to detect 
the effects of nifedipine together with a statin on coronary morphology. This may give 
more insights in the role of CCB combined with statin in coronary artery disease. 
 
 
 
 
 
 
 
 
 
Atorvastatin and amlodipine 
The combination therapy of amlodipine and atorvastatin was tested in APOE*3Leiden 
transgenic mice, which develop human-like atherosclerosis, by Delsing et al43.  4 Groups 
of 15 ApoE*3Leiden mice received a high-cholesterol diet. One group received 
amlodipine in the diet, which had no effect on plasma cholesterol levels. Another group 
received atorvastatin, resulting in a decrease of plasma cholesterol by 50% by a 
reduction in very low density lipoprotein production. The combination group received 
both amlodipine and atorvastatin. After 28 weeks, atherosclerosis in the aortic root was 
quantified. Treatment with amlodipine alone had no significant effect on atherosclerotic 
lesion area, whereas atorvastatin markedly reduced atherosclerosis by 77% compared 
with the control group. Atorvastatin also reduced inflammation markers. The 
combination of amlodipine and atorvastatin tended to reduce lesion area by 61% 
compared with the atorvastatin-only group; this effect just did not reach statistical 
significance (Figure 2). However, after subgroup analysis, the combination therapy did 
reach significance in animals that respond relatively modestly to atorvastatin. 
Amlodipine treatment significantly reduced calcification in the lesions, whereas 
Figure 1 Angiographic progression 
(change of minimum obstruction 
diameter) in patients with and without 
CCB cotreatment, stratified with regard 
to type of CCB treatment (no CCB, non-
dihydropyridine (non-DHP) CCB, and 
DHP CCB), in the pravastatin group and 
in the placebo group in the REGRESS 
study4,51. Patients in the pravastatin 
group had significantly less progression 
if cotreated with CCBs as compared with 
no CCB cotreatment (p=0.03), with most 
striking results for the DHP CCBs (hardly 
any progression left; p = 0.008), whereas 
in the placebo (no pravastatin) group no 
significant effect of any type of CCB 
treatment was observed. 
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atorvastatin alone had no effect. The combination of amlodipine and atorvastatin 
resulted in a near absence of calcium deposits in the lesions. Measurement for Serum 
Amyloid A resulted in significant lower levels of both in the group receiving both 
atorvastatin and amlodipine than in the groups receiving no drugs or only one of them. 
Fibrinogen levels were reduced as compared with the control group, and von 
Willebrand Factor, a marker for vessel wall integrity, was reduced in the combination 
group as compared with the group receiving amlodipine alone. Van de Poll et al.55 
examined the effects of amlodipine and atorvastatin on advanced atherosclerosis in 
APOE*3Leiden mice. They showed that the combination treatment of amlodipine and 
atorvastatin not only reduced lesion size compared to the control group but also 
reduced the area of existing lesions.  The lesion areas of the mice receiving treatment 
were compared to the lesion area of mice which were sacrificed at the beginning of the 
experiment. Recently, research by Mason et al.56 demonstrated that the combination of 
amlodipine and atorvastatin had a synergistic effect on nitric oxide release from human 
endothelial cells, which in vivo may lead to an improvement of endothelial function. 
The ASCOT-LLA study57 assessed benefits of cholesterol lowering in the primary 
prevention of coronary heart disease in hypertensive patients who are not 
conventionally deemed dyslipidemic. Of 19342 hypertensive patients (aged 40-79 years 
with at least three other cardiovascular risk factors) randomised to one of two 
antihypertensive regimens in the Anglo-Scandinavian Cardiac Outcomes Trial, 10305 
with non-fasting total cholesterol concentrations 6.5 mmol/L or less were randomly 
assigned additional atorvastatin 10 mg or placebo. These patients, whom at least half 
were additionally treated with amlodipine, formed the lipid-lowering arm of the study. 
The primary endpoint was non-fatal myocardial infarction and fatal coronary heart 
disease. Treatment was stopped after a median follow-up of 3.3 years. A reduction of 
36% (p=0.0005) of primary endpoints was seen in the atorvastatin group. This benefit 
emerged in the first year of follow-up.  A 27% reduction of fatal and non-fatal stroke 
(p=0.024), 21% reduction of total cardiovascular events (p=0.0005), and a 29% 
reduction of total coronary events (p=0.0005) were also observed. Addition of 
amlodipine to the atorvastatin treatment may have accounted for these impressive 
positive effects. 
The effects of amlodipine monotherapy and combination therapy of atorvastatin 
and amlodipine on arterial compliance were investigated on 21 consecutive 
hypertensive hyperlipidemic patients by Leibovitz et al.58. Patients were followed every 
month for 6 months (3 months of amlodipine therapy and 3 months of amlodipine and 
atorvastatin combination). During the 3 months of amlodipine monotherapy, large and 
small arterial compliance were improved by 26% and 38%, respectively, and the 
systemic vascular resistance was reduced by 10%. The addition of atorvastatin during 
the next 3 months improved small arterial compliance by an additional 42% and 
decreased the systemic vascular resistance by another 5%, but large arterial compliance 
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and blood pressure did not change. Thus amlodipine improved large and small arterial 
compliance, and the beneficial effect of atorvastatin on small arterial compliance was 
additive to the effect achieved by amlodipine in hypertensive hyperlipidemic patients. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Conclusion and final remarks 
Previous described studies demonstrate the antiatherosclerotic properties of CCBs, 
especially amlodipine. Of great importance are the anti-oxidative properties10,26 and the 
ability to inhibit the aggregation of oxidized LDL particles56. Amlodipine was also shown 
to stabilize plaques and to reduce the ischemic area after myocardial infarction32. Statins 
are used for years to decreased plasma cholesterol levels and thereby reduce 
atherosclerosis. Huge clinical trails like 4S39, CARE40 and LIPID41 showed that statins 
reduced myocardial infarction and fatal coronary deaths. Over the last years researchers 
demonstrated lipid independent antiatherosclerotic properties of statins e.g. anti-
inflammatory and antioxidative capacities9,46-51. It was also angiographically 
demonstrated that atorvastatin improved plaque stability in humans6. High dose 
treatment of atorvastatin may even be favoured above angioplasty in reducing ischemic 
cardiac events in patients with stable angina pectoris52. 
Because of the verifiable antiatherosclerotic properties of amlodipine and 
atorvastatin, it seems a logical step to combine these two types of drugs. This potent 
combination therapy has now been shown to result in reduced atherosclerosis, by 
inhibiting the progression of atherosclerosis24,43 and even reduce lesion size55, 
improvement of endothelial function56 and arterial compliance58. Capacities for plaque 
stabilization and reduction of infarction size are suggested and should be further tested. 
Outcomes of the ASCOT study59 are of great interest, since a group of approximately 
2500 hypertensive patients is randomised to the combination treatment of atorvastatin 
Figure 2 Lesion area per section in the 
aortic root of APOE*3Leiden mice after 
treatment with amlodipine, atorvastatin 
of the combination of both as described 
by Delsing et al. 42. Atorvastatin reduced 
lesion area with 77% as compared with 
the control group. The combination 
therapy decreased the lesion area with 
91% when compared with the control 
group and 61% (not significant) when 
compared to the atorvastatin 
monotreatment. *** P < 0.005. 
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and amlodipine. The lipid lowering arm of the ASCOT study57 has demonstrated 
impressive effects of atorvastatin treatment.   
These results of obtained from in vitro, mice and clinical studies, in which the 
combination therapy was tested, collectively support the clinical anti-atherosclerotic 
advantages of combination of CCBs and statins and in particular of atorvastatin with 
amlodipine beyond their established antihyperlipedemic and antihypertensive modes of 
action.  
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Abstract 
 
Objective: Niacin (nicotinic acid) potently decreases plasma triglycerides and LDL-
cholesterol. In addition, niacin is also the most potent HDL-cholesterol increasing drug 
used in the clinic. In the present study, we aimed at elucidation of the mechanism 
underlying its HDL-raising effect. 
 
Methods and Results: In APOE*3Leiden transgenic mice expressing the human CETP 
transgene, niacin dose-dependently decreased plasma triglycerides (up to -77%, 
P<0.001) and total cholesterol (up to -66%, P<0.001). At the same time, niacin dose-
dependently increased HDL-cholesterol (up to +87%, P<0.001), plasma apoAI (up to 
+72%, P<0.001), as well as the HDL particle size. In contrast, in APOE*3Leiden mice that 
do not express CETP, niacin also decreased total cholesterol and TG but did not increase 
HDL-cholesterol. In fact, in APOE*3Leiden.CETP mice, niacin dose-dependently 
decreased the hepatic expression of CETP (up to -88%; P<0.01) as well as plasma CETP 
mass (up to -45%, P<0.001) and CETP activity (up to -52%, P<0.001). In addition, niacin 
dose-dependently decreased the clearance of apoAI from plasma and reduced the 
uptake of apoAI by the kidneys (up to -90%, P<0.01).  
 
Conclusion: Niacin markedly increases HDL-cholesterol in APOE*3Leiden.CETP mice by 
reducing the CETP activity, as related to lower hepatic CETP expression and a reduced 
plasma (V)LDL pool, and increases HDL-apoAI by decreasing the clearance of apoAI 
from plasma.  
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Introduction 
Dyslipidemia is an important risk factor for the development of cardiovascular disease 
(CVD). Although lowering of LDL-cholesterol (C) by e.g. statins reduces CVD risk by 
approximately 30%, substantial residual cardiovascular risk remains, even with very 
aggressive reductions in levels of LDL-C.1-3 Due to clinical studies, which have shown 
that HDL-C, independently of LDL-C, is inversely correlated with the risk of CVD,4,5 
attention has shifted toward strategies for targeting HDL composition as adjunctive 
therapy to prevent and treat CVD. Current strategies to mildly increase HDL-C levels 
include aggressive overall lifestyle modification (i.e. exercise, diet, weight loss, and 
smoking cessation), and modest increases in HDL-C levels are achieved with statins6 and 
fibrates (5-10%).7 
Niacin (nicotinic acid, vitamin B3) has been described to exhibit lipid-modifying 
capacities already since the 1950s. Since then various (clinical) studies have shown the 
beneficial effects of niacin on plasma lipid levels. Treatment with niacin alone was 
associated with a 27% reduction in non-fatal myocardial infarction and it reduced all 
cause mortality by 11%.8,9 In combination with colestipol (FATS trial) or simvastatin 
(HATS trial), niacin reduced cardiac events by as much as 80-90%.10,11 These potent 
atherogenic properties of niacin are thought to be due to its marked HDL-elevating 
effect (+20% to +30%), besides it potent effect on reducing plasma TG (-40% to -50%) 
and LDL-C (-20%).7,12 In fact, niacin is currently the most effective therapy for elevating 
HDL-C. 
The mechanism underlying the ability of niacin to reduce the plasma (V)LDL level 
has been well-studied. By selective binding to GPR109A on adipocytes, niacin 
suppresses hormone sensitive triglyceride lipase (HSL) activity, resulting in a decreased 
release of free fatty acids (FFA) from adipose tissue and decreased plasma FFA levels.13 
The resulting reduced supply of FFA towards the liver is believed to bring about a 
decreased hepatic VLDL-TG production, resulting in reduced VLDL-TG and (V)LDL-C 
levels.13,14 In contrast, the mechanism underlying the HDL-C raising effect of niacin has 
not been elucidated as yet. This is probably related to the lack of suitable animal models 
that respond in a human-like manner to HDL-raising drug interventions. In wild-type 
mice and apoE-knockout mice (the classical animal model for hyperlipidemia and 
atherosclerosis), rats and dogs, niacin only transiently reduced plasma levels of TG but 
failed to failed to raise HDL-C.15,16 An HDL-C-elevating effect of niacin has been reported 
in rabbits, but with 30% ethanol as dosing vehicle and only after 12 weeks of 
treatment.17 
Therefore, the aim of this study was to elucidate the mechanism underlying the 
HDL-C raising effect of niacin. To this end, we used our recently developed 
APOE*3Leiden (E3L).CETP transgenic mouse model. We have previously demonstrated 
that E3L mice have a human-like lipoprotein profile in which the elevated plasma 
cholesterol and TG levels are mainly confined to the (V)LDL-sized lipoprotein 
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fractions.18,19 These mice develop atherosclerosis upon dietary cholesterol feeding and 
respond in a human-like manner to drugs used in the treatment of CVD (e.g. statins, 
fibrates, cholesterol uptake inhibitors, calcium channel blockers and angiotensin II 
receptor antagonists20-23), but they did not yet respond to HDL-modulating 
interventions. By cross-breeding E3L mice with mice expressing human CETP under 
control of its natural flanking regions, E3L.CETP were obtained24 that respond to the 
HDL-raising effects of fenofibrate,25 atorvastatin26 and torcetrapib.27 We now fed these 
mice a Western-type diet without or with increasing doses of niacin to reveal the 
mechanism underlying its HDL-C raising effect. 
 
 
Methods 
 
Animals 
Hemizygous human CETP transgenic (CETP) mice, expressing a human CETP minigene 
under the control of its natural flanking sequences28 were purchased from the Jackson 
Laboratory (Bar Harbor, ME) and crossbred with hemizygous E3L mice18 at our 
Institutional Animal Facility to obtain E3L and E3L.CETP littermates.24 In this study, 
female mice were used, housed under standard conditions in conventional cages with 
free access to food and water. At the age of 12 weeks, E3L and E3L.CETP mice were fed a 
semi-synthetic cholesterol-rich diet, containing 15% (w/w) fat and 0.25% (E3L) or 0.1% 
(E3L.CETP) (w/w) cholesterol (Western-type diet; Hope Farms, Woerden, The 
Netherlands) for three weeks to obtain similar total cholesterol levels in both strains 
(about 12-14 mmol/L). After matching based on total plasma cholesterol (TC), 
triglyceride (TG) levels, and age, mice (n=8 per group) received a Western-type diet 
without or with 0.03% (~36 mg/kg/day), 0.1% (~118 mg/kg/day), 0.3% (~360 
mg/kg/day) or 1% (~1180 mg/kg/day) niacin (Sigma, St. Louis, MO, USA) for at least 3 
weeks. These doses correspond well to the doses used in humans, if the 10 times faster 
metabolism of mice as compared to humans is taken into account. Experiments were 
performed after 4 h of fasting at 12:00 pm with food withdrawn at 8:00 am, unless 
indicated otherwise. The institutional Ethical Committee on Animal Care and 
Experimentation has approved all experiments.  
 
Plasma lipid and lipoprotein analysis 
Plasma was obtained via tail vein bleeding as described24 and assayed for TC, TG and 
phospholipids (PL), using the commercially available enzymatic kits 236691 and 
11488872 (Roche Molecular Biochemicals, Indianapolis, IN, USA) and ‘Phospholipids B’ 
(Instruchemie, The Netherlands), respectively. The distribution of lipids over plasma 
lipoproteins was determined by fast-performance liquid chromatography (FPLC) using a 
Superose 6 column as described previously.24 HDL-C was isolated by precipitating the 
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apoB-containing lipoproteins from 20 µL EDTA plasma by adding 10 µL heparin (LEO 
Pharma, The Netherlands; 500 U/mL) and 10 µL 0.2 M MnCl2. Mixtures were incubated 
for 20 min at room temperature and centrifuged for 15 min at 13,000 rpm at 4°C. In the 
supernatant HDL-C was measured using enzymatic kit 236691 (Roche Molecular 
Biochemicals, Indianapolis, IN, USA). 
 
Plasma apoAI concentration 
Plasma apoAI concentrations were determined using a sandwich ELISA. Here to, rabbit 
anti-mouse apoAI polyclonal antibody (ab20453; Abcam plc, Cambridge, UK) was coated 
overnight onto Costar strips (Costar, Inc., New York, NY) (at 3 µg/mL) at 4°C and 
incubated with diluted mouse plasma (dilution 1:400,000) for 90 min at 37°C. 
Subsequently, goat anti-mouse apoAI antibody (600-101-196; Rockland 
Immunochemicals, Inc., Gilbertsville, PA; dilution 1:3000) was added and incubated for 
90 min at 37°C. Finally, horse radish peroxidase (HRP)-conjugated rabbit anti-goat IgG 
antibody (605-4313; Rockland; dilution 1:15000) was added and incubated for 90 min 
at 37°C. HRP was detected by incubation with tetramethylbenzidine (Organon Teknika, 
Boxtel, The Netherlands) for 15 min at room temperature. Purified mouse apoAI 
(A23100m; Biodesign International, Saco, Maine, USA) was used as a standard. 
 
HDL size by native PAGE 
The HDL size was determined essentially as described.29 Total lipoproteins were 
isolated from plasma by ultracentrifugation (5 h at 541,000 g) as the d < 1.21 g/mL 
plasma fraction in a TLA 100.3 rotor (Beckman). Lipoproteins (7.5 µg protein) were 
loaded onto a 4-20% polyacrylamide Tris.HCl gel (BioRad, Hercules, CA, USA) and 
electrophoresis was performed according to the manufacturer’s protocol. Gels were 
stained with Coomassie Brilliant Blue (Merck) and HDL size was compared with 
globular protein standards (HMW native marker kit, GE Healthcare). 
 
Plasma lipolysis 
Post-heparin plasma from overnight fasted mice was collected from the tail vein at 20 
minutes after intraperitoneal injection of heparin (1.0 U/g body weight). Post-heparin 
plasma triacylglycerol hydrolase activity was determined in the presence or absence of 1 
mol/L NaCl to estimate the hepatic lipase (HL) activity, which was calculated as the 
portion of total triacylglycerol hydrolase activity not inhibited by 1 mol/L NaCl.30 
 
Preparation of 125I-apoAI-labeled autologous HDL 
ApoAI was radiolabeled at pH 10 with carrier-free 125I according to the ICl method31, and 
separated from unbound 125I by Sephadex G50 gel filtration. 125I-apoAI (~75 µg) was 
incubated with 1.4 mL of plasma from E3L.CETP mice (3 h at 37°C), and 125I-apoAI-HDL 
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was isolated after density gradient ultracentrifugation. The specific activity was ~15 
cpm /ng HDL protein. 
 
In vivo kinetics of 125I-apoAI-labeled HDL 
E3L.CETP mice were injected via the tail vein with 125I-apoAI-HDL (40 µg protein) in a 
total volume of 200 µL PBS. At the indicated time points after injection, blood was 
collected from the tail vein to determine the plasma decay of 125I-apoAI. The total plasma 
volumes of the mice were calculated from the equation V (mL) = 0.04706 x body weight 
(g), as determined from previous 125I-BSA clearance studies.32 At 6 h after injection, the 
mice were sacrificed and organs were taken and counted for 125I-activity. Values were 
corrected for serum radioactivity present in the liver (84.7 µL/g wet weight), kidneys 
(135.2 µL/g wet weight), skeletal muscle (13.7 µL/g wet weight) and white adipose 
tissue (16.1 µL/g wet weight).33 
 
Hepatic lipid analysis 
Liver tissue samples were homogenized in phosphate-buffered saline (approx. 10% wet 
w/v), and the protein content was measured according to the method of Lowry et al. 
Lipids were extracted, separated by high-performance thin-layer chromatography on 
silica gel plates and analyzed with TINA2.09 software (Raytest Isotopen Messgeräte, 
Straubenhardt, Germany), as described before.34 
 
Hepatic mRNA expression 
Total RNA extraction from liver tissue samples was performed using RNA-Bee (Amsbio, 
Oxon, UK) according to the manufacturer’s instructions. RNA was converted to single-
stranded cDNA by a reverse transcription procedure (Promega) according to the 
manufacturer’s protocol using random primers. cDNA levels were measured by real-
time polymerase chain reaction (PCR) using the ABI Prism 7700 Sequence Detection 
System (Applied Biosystems, Foster City, CA, USA), according to the manufacturer’s 
instructions. PCR master mix from Eurogentec was used. Primers and probes were 
obtained from Biosource (Nivelles, Belgium). The probes were labelled with 3-BHQ1 and 
5-FAM or 5-TET. The mRNA levels were normalized to mRNA levels of three 
housekeeping genes (i.e., cyclophilin, HPRT and GAPDH). Primers and probes used for 
this study were described previously.25 The level of mRNA expression for each gene of 
interest was calculated according to the manufacturer’s instructions (Applied 
Biosystems) as described previously.35  
 
CETP mass and activity in plasma 
Plasma CETP mass was analyzed by ELISA using kit ’CETP ELISA Daiichi’ (Daiichi Pure 
Chemicals Co, Ltd, Tokyo, Japan). Plasma CETP activity was measured as the transfer of 
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[3H]cholesteryl oleate ([3H]CO) from exogenous LDL to HDL as described.36 CETP 
activity was calculated as µmol CE transfer per mL plasma per hour.  
 
Biliary lipid secretion 
The common bile duct of anesthetized mice was ligated, the gall bladder was cannulated, 
and bile was collected during 90 minutes.30 Cholesterol, PL and total bile acids in bile 
were determined using kits ‘236691’ (Roche Molecular Biochemicals, Indianapolis, IN, 
USA), ‘Phospholipids B’ (Instruchemie, The Netherlands) and ‘Total bile acids assay’ 
(Bio-Stat, UK), respectively. 
 
Fecal excretion of bile acids and neutral sterols 
The mice were housed at 3 mice per cage. Feces produced during 2 subsequent periods 
(48 h each) were separated from the wood shavings by sieving. Aliquots of lyophilized 
feces were used for determination of neutral and acidic sterol content by gas-liquid-
chromatography procedures as described.30 
 
Statistical analysis 
All data are presented as means ± SD unless indicated otherwise. Data were analyzed 
parametrically by one-way ANOVA followed by Dunnett to correct for multiple testing.  
P-values less than 0.05 were considered statistically significant. SPSS 14.0 was used for 
statistical analysis. 
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Figure 1. Effect of niacin on lipoprotein profiles. E3L (A) and E3L.CETP (B) mice received a Western-
type diet without (open circles) or with (closed circles) niacin (118 mg/kg/day) for 3 weeks. Plasma 
was pooled per group and the distribution of cholesterol over the individual lipoproteins was 
determined after separation by FPLC. 
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Niacin decreases plasma lipids in both E3L 
and E3L.CETP mice, but increases HDL 
only in E3L.CETP mice 
No adverse clinical signs were observed 
with increasing dosages of niacin as 
indicated by absence of differences in 
weight gain and plasma ALT levels 
between treatment groups and the 
control. Treatment of E3L mice with 
niacin (118 mg/kg/day) caused a 
sustained reduction in plasma TG by -
26% (1.4±0.6 mM vs 1.9±0.6 mM; 
P<0.05) and in plasma TC by -35% 
(9.2±3.4 mM vs 14.2±4.5 mM; P<0.05). 
Lipoprotein fractionation by FPLC 
showed that the reduction in cholesterol 
was confined to the apoB-containing 
lipoproteins (V)LDL, whereas HDL-C was 
not affected (figure 1A). An equal dose of 
niacin even more potently reduced 
plasma TG (-57%, P<0.05) and TC (-44%, 
P<0.01) in E3L.CETP mice. As in E3L 
mice, the TC-decreasing effect of niacin in 
E3L.CETP mice was caused by a 
reduction of (V)LDL-C. However, whereas 
niacin did not affect HDL levels in E3L 
mice, it increased HDL-C in E3L.CETP 
mice (figure 1B). In E3L.CETP mice, the 
effects of niacin on plasma TG and TC levels were dose-dependent as shown in figure 2. 
At the highest dose of 1180 mg/kg/day, niacin reduced TG levels by -77% (P<0.001) 
(figure 2A) and TC levels by -66% (P<0.001) (figure 2B). 
 
The HDL-increasing effect of niacin in E3L.CETP mice is dose-dependent 
To investigate whether the HDL-increasing effect of niacin in E3L.CETP mice was also 
dose-dependent, we determined HDL-C concentrations in whole plasma after 
precipitation of apoB-containing lipoproteins by heparin/ MnCl2. Indeed, niacin 
appeared to decrease (V)LDL-C levels up to -79% (P<0.001) (figure 3A), and to increase 
HDL-C up to +87% (P<0.001) (figure 3B), both in a dose-dependent fashion. We next 
evaluated whether niacin also affects apoAI, the main apolipoprotein constituent of HDL.  
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Figure 2. Dose-dependent effect of niacin on 
plasma triglycerides and total cholesterol. 
E3L.CETP mice received a Western-type diet 
without or supplemented with incremental doses 
of niacin for 3 weeks. Plasma triglycerides (A) 
and total cholesterol (B) were determined. Values 
are means ± SD (n=8 per group). *P<0.05, 
**P<0.01, ***P<0.001. 
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Indeed, niacin dose-dependently increased apoAI up to +72% (P<0.001) (figure 3C). 
Whereas niacin thus increases both HDL-C and apoAI, the effects on HDL-C at the 
various doses are somewhat more pronounced than on apoAI, suggesting that niacin 
increases the lipidation of apoAI. This was reflected by a modest increase of the HDL 
particle size as determined by native PAGE (figure 4). Further analyses of the pooled 
HDL fractions showed a decrease in triglycerides (-45%) and an increase in cholesteryl 
ester (+56%) and phospholipids (+66%) (data not shown). Niacin did not seem to affect 
the hepatic synthesis or clearance of HDL, at least judged from unchanged hepatic mRNA 
expression of genes involved in HDL synthesis (apoa1, abca1) or clearance (sr-b1) (data 
not shown). Hepatic pltp mRNA expression was slightly increased upon niacin treatment 
(data not shown). In plasma niacin did decrease the HL activity, albeit that the effect was 
not dose-dependent (maximal reduction of -47% at 118 mg/kg/day; P<0.05).  
                   
Niacin increases the residence time of apoAI in plasma  
To evaluate whether the dose- dependently increased plasma apoAI level as induced by 
niacin-treatment was caused by decreased clearance of apoAI from plasma, we 
determined the effect of niacin on the plasma kinetics of intravenously injected 125I-
apoAI-labeled HDL (figure 5). Indeed, niacin dose-dependently increased the residence 
of 125I-apoAI in plasma (figure 5A). From the mono-exponential decay curves it was 
calculated that the plasma half-life of 125I-apoAI (3.5±0.1 h) was increased by niacin at 
118 mg/kg/day (5.5±1.3 h; P<0.01) and 1180 mg/kg/day (6.6±1.3 h; P<0.01). This was 
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Figure 3. Dose-dependent effect of niacin on 
(V)LDL-cholesterol, HDL-cholesterol and 
apoAI levels. E3L.CETP mice received a 
Western-type diet without or supplemented 
with incremental doses of niacin for 3 weeks. 
Plasma (V)LDL-C (A), HDL-C (B) and apoAI 
(C) were determined. n=8 per group. 
*P<0.05, **P<0.01, ***P<0.001. 
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accompanied by a dose-dependent 
reduction in the uptake of 125I-activity by 
the liver (up to -50%; P<0.05) and the 
kidneys (up to -90%; P<0.01) (figure 
5B). For comparison, the uptake of 
[3H]cholesteryl oleoyl ether-labeled HDL 
by the liver was much larger (approx. 
40% of dose/g wet weight), whereas the 
uptake by the kidneys was undetectable 
(data not shown). 
 
Niacin reduces the hepatic lipid content  
The effects of niacin on plasma lipid 
metabolism in E3L.CETP mice are 
consistent with a niacin-induced 
reduction in CETP activity. Since CETP 
expression is regulated by the hepatic 
cholesterol content,28 we first examined effects of niacin on liver lipids (figure 6A). 
Niacin decreased the hepatic TG content (-38%, P<0.05). This is consistent with the 
inhibitory effects of niacin on HSL in adipose tissue,13 thereby reducing the trafficking of 
FFA to the liver for TG synthesis. Niacin also decreased the hepatic TC content (-21%, 
P<0.01), which was mainly attributed to a reduction in hepatic cholesteryl esters (-22%, 
P<0.05). This effect was in line with a compensatory increase in hepatic Hmgcoared 
mRNA expression (+232%, P<0.05) (not shown).  
0
20
40
60
80
100
0 60 120 180 240 300 360
Time after injection (min)
1
2
5
I-
a
p
o
A
I-
H
D
L
 (
%
 o
f 
d
o
se
) control
118 mg/kg/day
1180 mg/kg/day
A
**
**
    
control
118 mg/kg/day
1180 mg/kg/day
0
1
2
3
4
liver kidneys muscle WAT
1
2
5
I-
a
p
o
A
I-
H
D
L
(%
 o
f 
d
o
se
 /
 g
 w
e
t 
w
e
ig
h
t)
B
**
*
**
 
 
Figure 5. Dose-dependent effect of niacin on plasma apoAI kinetics. E3L.CETP mice were injected with 
125I-apoAI-HDL, and plasma 125I activity was determined at the indicated time points (A). After the last 
time point, mice were sacrificed and 125I activity was determined in the liver, kidneys, skeletal 
(hindlimb) muscle and white adipose tissue (WAT) (B). n=5 per group. *P<0.05, **P<0.01. 
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Figure 4. Dose-dependent effect of niacin on the 
HDL particle size. Total lipoproteins from pooled 
plasma were subjected to native 4-20% PAGE, 
and the resulting gel was stained with Coomassie 
Brilliant Blue. 
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Niacin decreases hepatic CETP mRNA 
expression and plasma CETP levels 
The decrease in hepatic cholesterol was 
indeed accompanied by a dose-dependent 
reduction in hepatic CETP mRNA up to -
88% (P<0.01) at 1180 mg/kg/day (figure 
6B). To evaluate whether the niacin-
induced decreased hepatic CETP mRNA 
expression was reflected by reduced CETP 
levels in plasma, we determined both 
CETP mass (figure 7A) and activity 
(figure 7B). Indeed, niacin dose-
dependently decreased plasma CETP mass 
and CETP activity to a similar extent (up 
to -45% and -52%; P<0.001).  
 
Niacin does not affect biliary and fecal 
cholesterol output 
To evaluate the consequences of the 
niacin-induced alterations in lipid 
metabolism on lipid excretion into bile 
and feces, we determined bile flow, biliary 
lipids and sterols in stool. Niacin did not 
affect bile flow or the bile composition 
(cholesterol, phospholipids and bile 
acids). The highest dose of niacin (1180 
mg/kg/day) did affect the composition of 
the fecal sterols to some extent, as 
reflected by a slight non-significant 
increase in neutral sterols and a decrease 
in bile acids (-22%; P<0.05). However, like 
the dietary input, total fecal sterol output 
was not affected by niacin (table 1).  
 
 
Discussion 
In this study, we investigated the mechanism(s) underlying the HDL-raising effect of 
niacin. We demonstrated that CETP plays a crucial role in the niacin-induced increase in 
plasma HDL-C and apoAI levels in E3L.CETP mice. Niacin reduced CETP dependent 
transfer of cholesterol from HDL to (V)LDL as related to lower hepatic CETP expression 
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Figure 6. Effect of niacin on hepatic lipid content 
and CETP mRNA expression. E3L.CETP mice 
received a Western-type diet without (open bars) 
or with (closed bars) niacin for 3 weeks, and 
livers were excised. Total lipids were extracted, 
and triglycerides (TG), total cholesterol (TC), free 
cholesterol (FC) and cholesteryl esters (CE) were 
separated by high-performance thin-layer 
chromatography and quantified (A). Total RNA 
was extracted, and CETP mRNA expression was 
measured by RT-PCR (B). Values are means ± SD 
(n=7 per group). *P<0.05, **P<0.01. 
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and a reduced plasma (V)LDL pool. This resulted in an increased lipidation of apoAI, as 
reflected by an increased HDL particle size, and a reduced uptake of apoAI by the 
kidneys. 
We previously showed that E3L mice are highly susceptible to dietary 
interventions with respect to modulating plasma lipid levels and that these mice show a 
human-like response to drug interventions aimed at treatment of CVD (e.g. statins, 
fibrates, cholesterol uptake inhibitors, calcium channel blockers and angiotensin II 
receptor antagonists20-23) with respect to alterations in the lipoprotein profile and/or 
atherosclerosis development. This is in sheer contrast with wild-type C57Bl/6 mice and 
conventional hyperlipidemic mice, such as apoE-deficient or LDL receptor-deficient 
mice, which show either an adverse response or no response to such interventions.37 In 
 
Niacin Niacin
Control 118 mg/kg/d 1180 mg/kg/d
Bile
Bile flow (µL/min/100g bw) 2.0 ± 0.5 2.0 ± 0.4 2.3 ± 0.7
Bile acid output (nmol/min/100g bw) 50 ± 14 67 ± 18 65 ± 25
Cholesterol output (nmol/min/100g bw) 1.1 ± 0.3 1.1 ± 0.2 1.1 ± 0.2
Phospholipid output (nmol/min/100g bw) 14 ± 3 14 ± 3 16 ± 5
Feces
Neutral sterols (µmol/100g bw/d) 32.7 ± 2.2 34.8 ± 4.6 36.1 ± 4.5
Bile acids (µmol/100g bw/d) 8.6 ± 1.5 8.4 ± 1.6 6.7 ± 0.9*
Total sterols (µmol/100g bw/d) 41.3 ± 3.1 43.2 ± 5.1 42.7 ± 4.7  
 
Table I. Effect of niacin on biliary and fecal lipid output. E3L.CETP mice received a Western-type diet 
without or supplemented with niacin for 3 weeks. The bile bladder was cannulated, and bile flow and 
composition were measured during 90 minutes (n=6-7). Feces were collected per cage (3 mice per 
cage) in two subsequent periods of 48 h each (n=8). Fecal composition was measured by gas-liquid-
chromatography and fecal sterol output was calculated. Data are presented as mean ± SD, *P<0.05. 
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Figure 7. Dose-dependent effect of niacin on plasma CETP mass and activity. E3L.CETP mice received a 
Western-type diet without or supplemented with incremental doses of niacin for 3 weeks. Plasma 
CETP mass (A) and CETP activity (B) were determined. Values are means ± SD (n=8 per group). 
*P<0.05, ***P<0.001. 
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particular, administration of niacin to wild-type mice or apoE-deficient mice did show a 
transient decrease in plasma TG and FFA levels, but failed to increase plasma HDL-C in 
these mice.13,16 Likewise, we now showed that niacin lowered TG and cholesterol within 
apoB-containing lipoproteins in E3L mice, but did not affect HDL-C levels. 
Recently, we showed that introduction of the human CETP gene in E3L mice 
results in a mouse model which also shows a human-like response with regard to raising 
HDL-C after treatment with fenofibrate,25 atorvastatin26 and torcetrapib.27 Since the 
introduction of CETP permits cross-talk between (V)LDL and HDL metabolism via the 
exchange of neutral lipids, we reasoned that the E3L.CETP mouse would also be an 
excellent mouse model to study the effects of niacin on HDL metabolism. 
 First, we observed that niacin dose-dependently reduced VLDL-TG and (V)LDL-C 
levels. The primary action of niacin is inhibition of HSL activity in adipose tissue after 
binding to the GPR109A receptor that is selectively expressed by adipocytes. This 
results in a decreased liberation of FFA from adipose tissue, and a decreased flux of 
albumin-bound FA to the liver, which is required for substrate-driven hepatic TG 
synthesis and VLDL production.13 As a consequence we thus observed a concentration-
dependent drop in VLDL-TG and (V)LDL-C levels. In addition, we observed that niacin 
reduced the hepatic cholesterol content. This may be caused by reduced input of 
cholesterol from plasma into the liver, since plasma (V)LDL-C concentrations are 
reduced and cholesterol-enriched HDL is formed from which cholesteryl esters are 
presumably not being delivered efficiently to the liver. The decreased hepatic 
cholesterol content cannot be explained by differences in biliary sterol output, since the 
excretion of bile acids and cholesterol remained unchanged. Alternatively, niacin may 
reduce the endogenous hepatic synthesis of cholesterol.  
Second, we showed that niacin dose-dependently raised HDL-C levels in 
E3L.CETP mice, but not in E3L mice, as paralleled by a less pronounced raise in apoAI. 
The presence of CETP thus plays a crucial role in the HDL-raising effect of niacin, and we 
reasoned that niacin may dose-dependently inhibit CETP activity. It is well-known that 
VLDL-TG is a driving force for CETP activity, and the relative proportions of VLDL and 
HDL have been shown to play a determinant role in CETP activity. It has been 
demonstrated that the capacity of apoB-containing lipoproteins to accept CE from HDL is 
closely correlated with the relative TG content of the lipoprotein acceptor particles.38-41 
By decreasing VLDL levels, niacin may thus reduce CETP activity simply by decreasing 
the availability of VLDL-TG as substrate for CETP.  
Our data corroborate recent observations from Hernandez et al.15,42 who showed 
that niacin increased HDL-C levels in CETP mice and APOB.CETP mice, but not their 
CETP-deficient wild-type littermates. In fact, they speculated the reduced VLDL levels to 
be the main mechanism underlying the HDL-raising effect of niacin. However, we 
observed that niacin not only reduced plasma CETP activity, but also dose-dependently 
reduced plasma CETP mass to a similar extent, suggesting that niacin reduces the 
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synthesis of CETP leading to less CETP  protein being released in plasma as reflected by 
similar reductions in CETP mass and activity. Indeed, niacin dose-dependently reduced 
hepatic CETP mRNA expression. It has been reported that hepatic cholesterol 
determines the hepatic CETP mRNA expression in CETP transgenic mice,28 presumably 
via an LXR responsive element in the CETP promoter.43
 
Therefore, it is likely that niacin 
decreases the hepatic CETP mRNA expression as a result of the observed decreased 
cholesterol content of the liver upon niacin treatment. 
Besides increasing HDL-C, niacin also dose-dependently increased plasma apoAI 
levels. Niacin has been shown to inhibit the uptake of HDL-apoAI (but not HDL-CE) by 
cultured hepatocytes,44 which we now confirmed in vivo. This may partly contribute to 
the increased apoAI levels. Such a potential effect of niacin should be independent of 
GPR109A, since expression of this receptor has not been detected in hepatocytes.13,45,46 
Together with our observations that hepatic mRNA expression of genes involved in HDL 
synthesis (apoa1, acba1) and clearance (sr-b1) were not affected by niacin, and an 
increase of PLTP would rather lead to a decrease in HDL-C levels 30,47,  it is most likely 
that the raise in apoAI is explained directly by the niacin-induced decreased CETP 
activity, which prevents cholesteryl ester transfer from HDL to (V)LDL. This leads to 
increased lipidation of apoAI, resulting in larger and cholesteryl ester-enriched HDL 
particles, and thus decreased glomerular filtration and excretion of lipid-poor apoAI via 
the cubulin/megalin receptor complex.48 Indeed, we demonstrated a clear dose-
dependent reduction in the uptake of 125I-apoAI by the kidney. 
Based on our collective data, we thus propose the following mechanism by which 
niacin reduces TG and (V)LDL-C and concomitantly raises HDL-C, as summarized in 
figure 8. By inhibiting HSL in adipose tissue upon binding of the niacin receptor 
GPR109A, niacin decreases TG lipolysis and thereby the supply of FFA to the liver, 
required for lipid synthesis. The consequently reduced hepatic lipid content results in a 
lower VLDL production and thus lower (V)LDL levels. In addition, reduction in hepatic 
cholesterol results in reduced hepatic expression of CETP, as well as diminished release 
of CETP into the plasma. Additionally, HL activity is reduced which may contribute to 
reduced remodelling of HDL in plasma, resulting in decreased clearance of HDL. The 
HDL particles become CE enriched, and less lipid-poor apoAI is cleared by the kidney. 
Niacin thus increases HDL-C and apoAI levels by 1) reducing levels of (V)LDL, the 
acceptor of CETP-mediated HDL-CE transfer, 2) decreasing CETP expression, 3) 
decreasing HL activity, and 4) decreasing the clearance of apoAI.  
As concluded from a many clinical trials using statins, lowering LDL-C alone is not 
longer regarded to be sufficient to treat CVD. Therefore, comprehensive lipid 
management, in which raising HDL-C is an important target, is becoming a new 
standard.4,7 Niacin (at dosages of 2-4 g/day) is unsurpassed in raising HDL-C. We show 
that niacin (in a clinical relevant range if we take into account the 5-10 times faster 
metabolism of mice) significantly improves the plasma lipid levels in E3L.CETP mice, e.g. 
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reduces TG and 
(V)LDL-C and 
increases HDL-C, 
albeit that total fecal 
sterol output is 
unaffected. Whether 
this will lead to 
improved HDL 
function and HDL-
related reductions in 
CVD in the clinic still 
remains to be 
investigated. 
Niacin has not 
been a very 
successful drug thus 
far because of its 
side-effect: severe 
flushing. Niacin is 
nowadays produced 
as an extended 
release (ER) 
compound, which 
enhances the 
tolerability. Clinical 
trails AIM-HIGH49 and 
ARBITER-6 (HALTS)50 evaluating the secondary prevention of CVD by ER niacin 
treatment are currently running. Post-hoc analysis of a subgroup of ARBITER-2, a 
randomized, placebo-controlled trial, showed increases in HDL-C upon daily intake of ER 
niacin (+20%), which were related to reduced progression of carotid intima-media 
thickness in the setting of both normal glycemic status and diabetes mellitus.51,52 Since 
the flushing effects of niacin appeared to be prostaglandin D2 (PGD2) receptor 
mediated,53 a combination therapy is currently being evaluated combining ER niacin and 
PGD2 receptor antagonist laropiprant, which is better tolerated than ER niacin alone.54 
Currently one trail evaluating effects of this combination drug on hard clinical 
endpoints, as myocardial infarction, stroke or revascularisation (HPS2-THRIVE) is 
underway. 
In conclusion, our results show that niacin increases HDL-C by reducing the 
hepatic CETP expression and plasma CETP protein and CE transfer activity in E3L.CETP 
mice. Therefore, we postulate that reduction of CETP expression contributes to the 
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Figure 8. Proposed mechanism underlying the HDL-raising effect of 
niacin. For explanation see text. CE, cholesteryl ester; FA, fatty acids; HSL, 
hormone sensitive lipase; TC, total cholesterol; TG, triglycerides. 
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increase in HDL that is found in human subjects treated with niacin, which should be 
subject of further investigation. 
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Abstract 
 
Objectives The cholesterol uptake inhibitor ezetimibe is currently used as a cholesterol 
lowering drug mainly in combination with statin therapy. Ezetimibe is nearly 100% 
absorbed in the intestine and is active on cholesterol transport in macrophages. The 
consequence of this systemic activity is unclear. The novel cholesterol absorption 
inhibitor AVE5530 which is being developed for the treatment of dyslipidemia is poorly 
absorbed in the intestine. The aim of this study was to compare the anti-atherosclerotic 
activities of AVE5530 and ezetimibe.  
 
Methods and Results APOE*3Leiden mice were fed a cholesterol-raising diet alone or 
either supplied with AVE5530 or ezetimibe (both 0.3 mg/kg bw/day). Effects on plasma 
lipids, levels of pro-inflammatory biomarkers and atherosclerosis were assessed after 
20 weeks of treatment. AVE5530 and ezetimibe lowered plasma cholesterol as 
compared to control (-64% and -33%, respectively; p<0.001) and both had favorable 
effects on inflammation markers, as indicated by reduced plasma levels of SAA (by 70% 
and 69%), MCP-1 (by 38 % and 31%), E-selectin (by 30% and 29%), VCAM-1 (by 24% 
and 16%, all P<0.01, respectively). Additionally, AVE5530 also reduced fibrinogen (by 
32%) levels and reduced hepatic cholesterol content (by 69%, P<0.05). Ezetimibe did 
not affect fibrinogen levels and reduced hepatic cholesterol content to a less extent. 
AVE5530 strongly inhibited atherosclerosis development: it decreased lesion size (by 
93%), the number of lesion (by 61%), and additionally improved the quality of lesions. 
The percentage of severe lesions was also decreased (by 58%) and the undiseased 
segments were 7-fold increased (all P<0.001). Ezetimibe only reduced the quantity of 
atherosclerosis by decreasing the lesion size by 59% (P<0.001), but did not have 
significant effects on the other three parameters. AVE5530 differed significantly from 
ezetimibe in all atherosclerosis parameters.  
 
Conclusions We showed that AVE5530 markedly reduced plasma cholesterol levels and 
therewith decreased the systemic and local vessel wall inflammation. Together these 
effects resulted in a more potent prevention of atherosclerosis development than 
ezetimibe.  
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Introduction 
Dyslipidemia is an important risk factor for the development of cardiovascular disease 
(CVD). Therefore current guidelines to treat CVD emphasize targeting primarily Low-
Density Lipoprotein- cholesterol (LDL-C)1. Since the introduction of statins, which 
became the gold standard of cholesterol lowering therapy, a large reduction of plasma 
LDL-C levels can be achieved2. However, there is still an important percentage of 
patients who do not reach their treatment goals or are statin intolerant3. Therefore, 
other lipid lowering drugs, used alone or in combination, are of great clinical 
significance.  
Ezetimibe is the first of a new class of selective cholesterol absorption inhibitors4. 
Ezetimibe or rather its phenolic glucuronide selectively inhibit cholesterol absorption in 
the intestine at the brush border membranes of small intestine enterocytes, confining 
the cholesterol to the intestinal lumen for subsequent excretion5,6. The working 
mechanism of ezetimibe has been investigated extensively, and both Niemann–Pick 1 
like 1 protein (NPC1L1) as well as aminopeptidase N (or CD13), both expressed in a.o. 
the intestine and macrophage, were suggested to be its molecular targets6,7. Ezetimibe is 
rapidly and completely absorbed and metabolized in the intestine and liver to its 
phenolic glucuronide, then it is excreted into the bile and delivered back to its site of 
action8.  The compound has been shown to reduce atherosclerosis development in apoE 
knock-out mice9. Clinical trials have demonstrated the lipid-lowering properties of 
ezetimibe as a single agent and its additive cholesterol-lowering effects when combined 
with a statin10,11. However, unexpected and still unexplained were the results of the 
recently published ENHANCE trial, in which patients with familial hyperlipidemia were 
treated with simvastatin alone or in combination with ezetimibe. Despite lower levels of 
LDL-C and C reactive protein with the combination therapy, no additional protective 
effects in retarding on intima-media thickness were measured12.  
AVE5530 is a new cholesterol absorption inhibitor, which, in contrast to 
ezetimibe, is very poorly absorbed13. AVE5530 has similar targets as ezetimibe7, and 
lowers LDL cholesterol in a similar manner, however, it is not systemically available13.  
The aim of the present study was to compare AVE5530 with ezetimibe regarding 
their effects on plasma lipid levels and atherosclerosis development. To this end, we 
used female APOE*3Leiden transgenic mice, which are a well-established mouse model 
for hyperlipidemia and atherosclerosis14. These mice have a lipoprotein profile similar 
to the profile of patients with familial dysbetalipoproteinemia in which the elevated 
plasma cholesterol and triglyceride levels are mainly confined to the VLDL/LDL-sized 
lipoprotein fraction. In addition, in contrast to other mouse models for dyslipidemia 
and/or atherosclerosis15, these mice respond in a human-like manner to treatment of 
CVD (e.g. statins, cholesterol uptake inhibitors, calcium channel blockers, fibrates and, 
angiotensin II receptor antagonists16-23). 
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Methods 
 
Mice and treatments 
Female heterozygous APOE*3Leiden transgenic mice (11 to 16 weeks of age), 
characterized by ELISA for human apoE14, were used. During a 3 week run-in period, all 
animals received a semi-synthetic western-type diet (WTD) containing 40.5% sucrose, 
15% cacao butter and 0.75% (w/w) cholesterol. After matching into 3 groups, based on 
age, plasma cholesterol and triglyceride levels, the mice received WTD diet either alone 
(control group) or supplemented with either ezetimibe (0.3 mg/kg bw/day) or with 
AVE5530 (0.3 mg/kg bw/day). Both compounds were provided by Sanofi Aventis 
Deutschland GmbH. EDTA blood was drawn at week 2, 4, 9, 12, 16 and 20 of the study, 
and was assayed for lipids. After 20 weeks, mice were sacrificed and the hearts and 
livers were isolated to assess atherosclerosis and hepatic cholesterol content. The 
animals received food and water ad libitum. Body weight and food intake were 
monitored during the study. Animal experiments were approved by the Institutional 
Animal Care and Use Committee of The Netherlands Organization for Applied Scientific 
Research (TNO). Animals were bred by TNO. 
 
Lipid and lipoprotein analysis and plasma inflammation markers 
After a 4-hour fasting period from 9 a.m. to 1 p.m., EDTA plasma was collected (Sarstedt, 
Nümbrecht, Germany) and lipoproteins were separated by FPLC24. Total hepatic 
cholesterol content was determined after homogenization of the liver tissue25. Total 
cholesterol (TC) (No-1489437, Roche Diagnostics, USA) and triglyceride (TG) (1488872, 
Roche Diagnostics, USA), levels were measured. Alanine aminotransferase (ALT) and 
aspartate aminotransferase (AST) were determined spectrophotometrically using a 
Reflotron system (Roche Diagnostics, USA). Fibrinogen (FBG) (as described before 18), 
serum amyloid A (SAA) (Biosource International, Belgium), monocyte chemoattractant 
protein (MCP)-1, endothelial (E) -selectin, vascular cell adhesion molecule (VCAM)-1 (all 
R&D systems Inc, USA), were determined by ELISA.  
 
Histological assessment of atherosclerosis 
After the 20-week treatment period, the mice were sacrificed. The hearts with aortic 
root were dissected, formalin fixed and embedded in paraffin. Serial cross sections (5 
μm thick, spaced 50 μm apart) throughout the entire aortic valve area were used for 
histological analysis. Sections were stained with haematoxylin-phloxine-saffron (HPS). 
Per mouse, 4 sections with intervals of 50 μm were used for quantification and 
qualification of the atherosclerotic lesions. For determination of severity of 
atherosclerosis, the lesions were classified into 5 categories as described before17,18,20 I) 
early fatty streak, II) regular fatty streak, III) mild lesion, IV) moderate lesion, V) severe 
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lesion. Per mouse the percentages of all lesions found in the respective categories were 
calculated. The total lesion area was calculated per cross-section. In each segment used 
for lesion qualification the number of monocytes adhering to the endothelium was 
counted and the macrophage area was measured after immunostaining with AIA31240 
(1:3000, Accurate Chemical and Scientific, USA). Smooth muscle cells (SMCs) were 
immunostained with mouse anti-human actin (DAKO, Denmark), which cross reacts 
with mouse actin. The collagen was stained by a Sirius Red staining. The lesion content 
of the different compounds was quantified morphometrically. All analyses were 
performed by the same operator, who was blinded for experimental group allocation. 
 
Statistical analysis 
Data are presented as means ± SD unless indicated otherwise. Statistical differences 
were assessed using the non-parametrical Kruskal-Wallis test followed by Mann 
Whitney U test. P<0.05 was considered significant. In tables and figures: *p<0.05, 
**p<0.01, ***p<0.001. 
 
 
Results  
 
Effect of AVE5530 and ezetimibe on plasma lipid levels 
Treatment with AVE5530 or ezetimibe did not affect food intake or body weight gain. As 
presented in figure 1 feeding the Western type-diet induced hyperlipidemia in the mice, 
giving plasma cholesterol levels of 17.5 ± 4.1 mmol/L and triglyceride levels of 3.0 ± 0.9 
mmol/L at the start of treatment (week 0). Inhibiting the cholesterol uptake by 
AVE5530 resulted in a strong reduction of plasma cholesterol after two weeks and a 
64% (p<0.001) reduction at the end of the study and decreased plasma triglycerides by 
20% (p<0.05) at the later time points in the study. Ezetimibe was less potent as 
compared to AVE5530 treatment resulting in a 33% (p<0.001) reduction of plasma 
cholesterol levels without affecting the triglycerides. The reductions in plasma 
cholesterol upon AVE5530 and ezetimibe treatment were confined to apoB-containing 
lipoproteins as measured after plasma separation by FPLC (figure 1C).  
Control AVE reduction EZE reduction
FBG mg/ml 2.9 ± 1.1 2.0 ± 0.6 -32%*   2.4 ± 0.8
SAA µg/ml 9.2 ± 5.3 2.8 ± 2.6 -70%*** 2.8 ± 1.8 -69%***
MCP-1 pg/ml 162.8 ± 51.8 100.8 ± 36.4 -38%** 111.9 ± 44.4 -31%**
E-Selectin ng/ml 64.0 ± 13.9 44.9 ± 4.2 -30%*** 45.1 ± 13.2 -29%**
V-CAM µg/ml 3.1 ± 0.4 2.4 ± 0.3 -24%*** 2.6 ± 0.6 -16%**
 
Table 1. The effect of AVE5530 and ezetimibe (EZE) on plasma inflammation markers. The parameters 
were measured at the end of the study after a 20 week treatment period. Values are means ± SD (n=15-
16 per group). *p<0.05,**p<0.01 ***p<0.001 as compared to control. 
70
CHAPTER 4_________________________________________________________________________________________    
 
 70 
 
Effect of AVE5530 and ezetimibe on liver 
and inflammatory parameters 
As elevated cholesterol has an important 
impact on liver condition and plays a 
major role in enhancing 
inflammation17,26, we measured hepatic 
cholesterol content and also plasma 
markers for systemic and vessel wall 
inflammation (table 1). The relative 
liver weights (as percentage of body 
weight) tended to be reduced in the 
animals treated with AVE5530 (5.6 ± 
1.1% vs 6.2 ± 0.9% in the control group, 
P=0.1 Kruskall-Wallis followed by 
P=0.03 Mann-Whitney), which was not 
observed in the ezetimibe treated group 
(5.9 ± 1.1%, N.S.).  Concomitantly 
AVE5530 significantly reduced the 
cholesterol content of the liver by 69% 
(17.7 ± 5.5 vs 57.6 ± 5.5 mg/ g liver in 
the control group, P<0.001). Ezetimibe 
decreased liver cholesterol content by 
only 35% (to 37.2 ± 12.8 mg/ g liver, 
P<0.001), which was significantly less 
than the reduction observed after 
AVE5530 treatment (P<0.001). Plasma 
ALT and AST levels were not affected by 
both treatments. Additionally, treatment 
with AVE5530 resulted in reduced levels 
of liver derived acute phase proteins SAA 
(by 70%, P<0.001) and FBG (by 32%, 
P<0.05), chemokine MCP-1 (by 38%, 
P<0.01), and vessel wall inflammation 
markers E-selectin and VCAM-1 (by 30% 
and 24%, both P<0.01, respectively) as 
compared to control. Treatment with ezetimibe brought about similar reduction of 
inflammation markers as AVE5530, however, without affecting FBG as compared to 
control.  
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Figure 1. The effect of AVE5530 (AVE) and 
ezetimibe (EZE) on plasma lipid levels. The plasma 
cholesterol (A) and triglyceride levels (B) were 
measured throughout the study. After 16 weeks of 
treatment the lipoproteins were separated by FPLC 
and the cholesterol was measured in the fractions 
(C). *P<0.05, ***P<0.001 as compared to control 
and †P<0.05, †††P<0.001 as compared to 
ezetimibe. 
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Effect AVE5530 and ezetimibe on atherosclerosis development  
To determine the effect of AVE5530 and ezetimibe treatment on atherosclerosis 
development we measured the amount of lesions, the lesion area and we qualified the 
severity of these lesions in the aortic root (figure 2). The control group had on average 
4.1 ± 1.0 lesions per cross section in the aortic root with a total area of 196 ± 59 *1000 
µm2; 64 ± 17% of these lesions were severe type IV-V lesions. AVE5530 strongly 
reduced lesion number by 61% (1.6 ± 1.1, P<0.001), the lesion area by 93% (14 ± 19 
*1000 µm2, P<0.001) and the percentage of severe lesions (down to 27 ± 23%, P<0.001) 
as compared to control. AVE5530 at the same dosage was more potent in preventing 
atherosclerosis development than ezetimibe. This was reflected by an absence in 
reduction of the amount of lesions in the ezetimibe group, whereas the decrease in total 
lesion area was less as compared to the AVE5530 (to -59%, 80 ± 58 *1000 µm2, 
P<0.001). Also the lesion severity was not affected by ezetimibe treatment. For all 
atherosclerosis parameters AVE5530 had significantly stronger effects than ezetimibe 
treatment. Representative pictures of the lesions are shown in figure 3. In line with 
these latter results we observed relatively more undiseased segments after either 
treatment, whereby again AVE5530 was more potent than ezetimibe (from 7 ± 15% in 
the control up to 54 ± 23%  in the AVE5530  group and to 21 ± 25% in the ezetimibe 
group, P<0.001, figure 4). 
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Figure 2. The effect of AVE5530 (AVE) and 
ezetimibe (EZE) on atherosclerosis development. 
APOE*3Leiden mice received a western-type diet 
(0.75% w/w cholesterol) for 20 weeks alone 
(control) or were additionally treated with either 
EZE (0.3 mg/kg/d) or AVE (0.3 mg/kg/d). In the 
aortic root the lesions were counted (A), the total 
lesion area was measured (B) and the severity of 
lesions was analyzed (C). ***P<0.001 as 
compared to control and †P<0.05, †††P<0.001 as 
compared to ezetimibe. 
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  To assess the vulnerability to rupture of the lesions we measured the amount of 
collagen and SMCs, which can be considered to stabilize the lesions, and the amount of 
macrophages, known to be a destabilizing factor, in the lesions (figure 5A). 40 ± 13% of 
the lesion content in the control group was collagen. Treatment with AVE5530 or 
ezetimibe resulted in an equal increase in the collagen content to 65 ± 20% and 68 ± 
11%, respectively  (P<0.001). No change in the amount of SMCs was found (control 1.2 ± 
1%). The macrophage content of the lesions in the control group was 30 ± 11%. 
Treatment with AVE5530 reduced this amount to 14 ± 14% (P<0.01). Ezetimibe was 
comparably effective and decreased it to 21 ± 9% (P<0.05). AVE5530 thereby tended to 
be more potent in reducing the macrophage content than ezetimibe (P=0.077). 
 As both the macrophage content of the lesions and the plasma markers for vessel 
wall inflammation were reduced by both the treatments, we also investigated the 
amount of monocytes adhering to the 
activated endothelium of the aortic root, 
which is considered as the first step in 
lesion development and a functional 
parameter for the extent of vessel wall 
inflammation. In the control group on 
average 7.9 ± 4.1 monocytes per cross 
section adhered to the activated 
endothelium (figure 5B). This was 75% 
reduced upon AVE5530 treatment (to 2.0 ± 
1.1, P<0.001), while ezetimibe inhibited 
adhesion of monocytes less effectively, but 
still noteworthy by 35% (to 5.1 ± 2.8, 
P<0.05). Also for this parameter AVE5530 
had significantly more effect than ezetimibe 
(P<0.001).  
 
 
A     Control  B       AVE  C       EZE 
   
Figure 3. After 20 weeks of intervention the amount of atherosclerosis in the aortic root was 
measured. Representative pictures of atherosclerotic lesions of the control group (A), AVE5530 (AVE) 
(B) and ezetimibe (EZE) (C) are presented. 
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Figure 4. The effect of AVE5530 (AVE) and 
ezetimibe (EZE) on the percentage of undiseased 
(healthy) segments in the aortic root. *P<0.05, *** 
P<0.001 as compared to control and †††P<0.001 
as compared to ezetimibe. 
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Discussion 
In this study we showed that the new low-absorbable, non-systemically acting 
cholesterol absorption inhibitor AVE5530 is more potent in cholesterol lowering than 
ezetimibe, resulting in less hepatic and vascular inflammation and in a stronger 
prevention of atherosclerosis development in APOE*3Leiden transgenic mice. 
The present study was designed to investigate the efficacy of AVE5530 to reduce 
plasma lipid levels and to inhibit the development of atherosclerosis as compared to 
ezetimibe. To this end we used APOE*3Leiden transgenic mice, which are highly 
susceptible to dietary and pharmacological interventions with respect to modulating 
plasma lipid levels. Moreover, APOE*3Leiden mice show a human-like response to 
interventions aimed at treatment of CVD (e.g. statins, cholesterol uptake inhibitors, 
fibrates, calcium channel blockers and angiotensin II receptor antagonists 17-23) with 
respect to alterations in the lipoprotein profile and/or atherosclerosis development at 
clinically relevant dosages. AVE5530 and ezetimibe both reduced plasma cholesterol; 
however, at an equal dose AVE5530 was markedly more effective than ezetimibe. 
Inhibition of cholesterol absorption with AVE5530 also resulted in reduced plasma 
triglycerides at the later time points, which was not observed in the ezetimibe treated 
animals. The reductions in cholesterol were mainly confined to the apoB-containing 
lipoproteins, similarly as observed previously in APOE*3Leiden mice on a low 
cholesterol diet and after treatment with statin, fibrates and ACAT inhibitors17,20,21,26.  
There is ample evidence that hypercholesterolemia (i.e. elevated plasma levels of 
(V)LDL) is a major causative factor in atherogenesis, but that an inflammatory 
component, thought to drive the initiation and progression of the disease, is also 
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Figure 5. The effect of AVE5530 (AVE) and ezetimibe (EZE) the vessel wall. The lesion composition 
was analyzed by measuring the collagen content and the macrophage content (A). In the aortic root the 
number of adhering monocytes was counted per cross section (B). *P<0.05, ** P<0.01, *** P<0.001 as 
compared to control and †††P<0.001 as compared to ezetimibe. 
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required27,28. It has been shown that hypercholesterolemia and inflammation are not 
separate factors in diet induced hypercholesterolemia in APOE*3Leiden mice, but 
closely related features of the same trigger, hepatic cholesterol content26. We showed 
that inhibition of cholesterol absorption with either AVE5530 or ezetimibe reduced 
circulating inflammation markers mostly to the same extent. Difference was found for 
the liver derived acute phase protein fibrinogen, which was only reduced after AVE5530 
treatment. Additionally AVE5530 strongly reduced the cholesterol content of the liver 
and was therewith significantly more potent than ezetimibe. Both hepatic cholesterol 
content and inflammation are considered as indirect measures for the amount of 
cholesterol absorption26,29. Therefore, it is likely that the strong anti-inflammatory 
effects of the two cholesterol absorption inhibitors are secondary to their cholesterol 
lowering properties. Similar anti-inflammatory and liver protective effects were 
observed previously in APOE*3Leiden mice treated with sphingolipids, which protect 
the liver from fat- and cholesterol induced steatosis22.  Cholesterol and inflammation 
activate the endothelium of the vessel wall, which in turn expresses adhesion molecules 
facilitating the adherence and infiltration of monocytes, which is considered to be the 
first step in lesion development27. Therefore we investigated the effect of both 
treatments on a functional parameter of vessel wall inflammation: monocyte adherence. 
Whereas we did not observe differences in circulating levels of vessel wall derived 
inflammation markers (i.e. E-selectin and VCAM-1), we found less monocyte adherence 
to and macrophage accumulation in the arterial wall, both indicative for reduced local 
inflammation in the vessel wall.  
Atherosclerosis development was strongly prevented by both AVE5530 and 
ezetimibe treatment, in line with previous reports on the anti-atherosclerotic effects of 
ezetimibe in apoE knock-out and apoE/eNOS double knock-out mice9,30. However, while 
AVE5530 reduced lesion area very potently (-93%, P<0.001) and additionally reduced 
the lesion number and prevented the progression of lesion severity, the effect of 
ezetimibe was restricted to a reduction of the lesion area (-59%, P<0.001) as compared 
to control. At an equal dose ezetimibe was markedly less efficacious as compared to 
AVE5530 for most atherosclerosis related read-out parameters. The reason for this 
marked difference in atherosclerosis development between AVE5530 and ezetimibe is 
likely related to the difference in potency to lower plasma cholesterol levels. However, 
an additional explanation may be provided by recent reports showing that NPC1L1 is 
not only present in the intestinal epithelial cells, but also in the liver and in monocytes 
and macrophages31-33. Herein is the protein involved in transport of cholesterol and 
modified lipoproteins. In macrophages in cell culture ezetimibe blocked the uptake of 
oxidized LDL and repressed the induction of cholesterol transporter genes ABCA1, 
ABCG1 and apoE31.  Moreover, the drug has been reported to interfere with raft 
assembly in monocytes and to reduce the surface expression of raft-associated proteins 
involved in the cellular uptake of modified lipoproteins or phagocytosis32. What this 
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consequently means for the macrophage function in vivo remains unanswered, however, 
it can be hypothesized that macrophage activation, differentiation and efflux capacity 
are at least influenced. 
Since its approval by the FDA in October 2002 many studies have confirmed the 
effective cholesterol lowering capacity of ezetimibe, especially when being co-
administered with other lipid lowering drugs34. Surprisingly, the results of the 
ENHANCE trial35 showed no benefit of ezetimibe/statin treatment over statin alone on 
intima media thickening, a surrogate endpoint for CVD, in patients with familial 
hypercholesterolemia, despite of a stronger decrease in LDL-cholesterol in the co-
treated group. In fact, a worsening of intima media thickening in the group treated with 
the combination of drugs was found. Whether this also translates into differences in 
hard clinical endpoints, need to be investigated, e.g. in the currently ongoing larger 
IMPROVE-IT trial36. Also long-term safety data for ezetimibe have not been established 
yet. Generally ezetimibe is well tolerated, demonstrating a favorable safety profile 37. 
Side effects have been infrequently reported, mainly in combination treatment with 
statins, concerning myopathy, liver damage and pancreatitis38. This might hypothetically 
be a consequence of the similar metabolism of the two compounds, as both statins and 
ezetimibe are glucuronidated by the uridine 5’-diphosphate glucuronosyltransferase 
isoenzymes39,40. However, more research is required to elucidate the consequence of the 
systemic availability and metabolism of ezetimibe, e.g. also whether this drug is active 
on cholesterol transport in macrophages in vivo31,32. Since AVE5530, in contrast to 
ezetimibe, is barely systemically available, it may have less adverse side effects in 
clinical use. This, however, remains to be investigated in clinical studies. 
In conclusion, we showed that the new low-absorbable, non-systemically acting 
cholesterol absorption inhibitor AVE5530 is more effective in lowering plasma lipid 
levels and development of atherosclerosis than ezetimibe in APOE*3Leiden mice. 
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Abstract 
 
Objective This study was designed to investigate the effect of the angiotensin II receptor 
blocker olmesartan alone, or in combination with standard treatment with a statin, 
pravastatin, on atherosclerosis development in APOE*3Leiden transgenic mice.  
 
Methods and Results Four groups of 15 mice received an atherogenic diet alone (plasma 
cholesterol 17.4 ±2.7 mM) or supplemented with either 0.008% (w/w) olmesartan (9.3 
mg/kg/d) (plasma cholesterol 16.4 ±3.9 mM), 0.03% (w/w) pravastatin (35 mg/kg/d) 
(plasma cholesterol 14.6 ±2.6 mM), or the combination of both (plasma cholesterol 14.5 
±2.9 mM) for six months. Treatment with olmesartan or pravastatin reduced the 
development of atherosclerosis as compared to the control group (-46% and -39%, 
respectively). Pravastatin also reduced the severity of the lesions. As compared to 
control the combination of both treatments almost fully prevented atherosclerosis (-
91%, p<0.001) and strongly reduced lesion number (-69%), lesion severity (-79%), 
number of macrophages (-89%) and T lymphocytes (-86%) per cross-section. 
Treatment with olmesartan alone and in combination with pravastatin inhibited the 
adhesion of monocytes to the vessel wall (-22%; p<0.05 and -25%; p<0.01, respectively), 
and reduced the relative quantity of macrophages in the lesions (-38%; p<0.05 and -
26%; N.S., respectively) as compared to control. 
 
Conclusion Olmesartan reduced atherosclerosis development mainly by decreasing 
monocyte adhesion and the relative amount of macrophages, whereas pravastatin 
inhibited the progression of atherosclerosis to more advanced lesions, reflecting 
different anti-atherosclerotic modes of action of the two drugs. Combination therapy 
with olmesartan and pravastatin additively reduced atherosclerosis development, 
resulting in less and less severe lesions. 
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Introduction 
Atherosclerosis is a complex disease in which foam cell formation and vascular 
remodeling, next to oxidation and inflammation, play an important role1. Since 
atherosclerosis is considered to be a multifactorial disease, there is broad consensus 
that medical treatment should have different approaches. Cholesterol accumulation in 
macrophages, which leads to foam cell formation, is a crucial stage in the development of 
atherosclerotic lesions. Therefore, reduction of high plasma cholesterol appears to be 
the first choice approach for medical treatment in preventing atherosclerosis 
development. Reduction of plasma cholesterol levels by 3-hydroxy-3-methylglutaryl 
coenzyme A (HMG-CoA) reductase inhibitors, or statins, is a widely used therapy in 
primary and secondary prevention of cardiovascular disease2. Angiographic clinical 
trials, like REGRESS3 and MAAS4, clearly demonstrate that statins significantly reduce 
progression of coronary atherosclerosis and decrease the occurrence of new 
cardiovascular events in patients with coronary artery disease. Large clinical trials like 
CARE5, WOSCOPS6, LIPID7 have shown significant benefit from pravastatin in both 
primary and secondary prevention of coronary events. There is growing evidence that 
statins, independent of their cholesterol lowering capacities, have anti-inflammatory 
activity as well8-10. 
Angiotensin II, the major effector molecule in the Renin-Angiotensin-System 
(RAS), is known to play a pivotal role in the regulation of blood pressure and electrolyte 
homeostasis.  Besides its vasoconstrictive effect by binding to the angiotensin II type I 
receptors (AT1) on vascular smooth muscle cells (VSMCs), angiotensin II has 
proinflammatory actions by stimulating the production of cytokines and of reactive 
oxygen species. These can activate nuclear factor-κB (NF-κB) resulting in its 
translocation into the nucleus where it regulates the transcription of genes encoding for 
cytokines, chemokines and adhesion molecules, which are all involved in the 
recruitment of monocytes/macrophages and leukocytes to sites of inflammation in the 
vascular wall11,12. It is known that angiotensin II plays an important role in the 
development of atherosclerosis13,14. Strong links between hypercholesterolemia and the 
production and expression of angiotensin II and AT1 have been described15,16. Clinical 
intervention studies like SAVE17 and SOLVD18 with angiotensin-converting enzyme 
(ACE) inhibitors and ELITE19 with an angiotensin II receptor blocker (ARB), showed a 
reduction in myocardial infarction and sudden cardiac death. In clinical studies it was 
observed that olmesartan is a very potent anti-hypertensive drug with minimal adverse 
effects20. Olmesartan also significantly reduced vascular microinflammation in patients 
with essential hypertension21.  
The purpose of this study was to investigate whether the angiotensin II receptor 
blocker (ARB) olmesartan has additional or synergistic anti-atherosclerotic effects, 
when it is used together with the HMG-CoA reductase inhibitor pravastatin in 
APOE*3Leiden transgenic mice. APOE*3Leiden mice are a well-established model for 
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hyperlipidemia and atherosclerosis9,22,23. The mice have a human-like lipoprotein profile 
in which, upon feeding a cholesterol-containing diet, elevated plasma cholesterol and 
triglyceride levels are mainly confined to the VLDL/LDL-sized lipoprotein fraction. In 
contrast to other mouse models for hyperlipidemia, i.e. LDL receptor deficient24 and 
ApoE deficient mice25, APOE*3Leiden mice have relatively mildly increased plasma 
cholesterol levels, and respond well to statin treatment by reduction of both the apoB-
containing lipoproteins and atherosclerosis. In this mouse model the human 
atherosclerotic situation can be mimicked both with regard to the development of 
atherosclerosis as well as to the response on therapy9,22,26-28.  
 
 
Methods 
 
Mice 
Female heterozygous APOE*3Leiden transgenic mice (16 to 18 weeks of age), 
characterized by ELISA for human apoE23, were used. Animal experiments were 
approved by the Institutional Animal Care and Use Committee of The Netherlands 
Organization for Applied Scientific Research (TNO). Animals were bred by TNO. 
 
Diets 
During a 3 week run-in period, all animals received a semi-synthetic high fat cholesterol 
diet (HFC) containing 40.5% sucrose, 15% cacao butter and 0.5% (w/w) cholesterol. 
After randomization into 4 groups on the basis of age, body weight, plasma cholesterol 
and triglyceride levels, the mice received HFC diet alone (control group) or 
supplemented with either 0.008% (w/w) olmesartan (9.3 mg/kg/d), with 0.03% (w/w) 
pravastatin (35 mg/kg/d), or 0.008% (w/w) olmesartan plus 0.03% (w/w) pravastatin. 
The mice receiving olmesartan in the diet showed a small reduction in food intake, 
probably causing the slight decrease in plasma cholesterol levels. After 18 weeks of 
treatment, both diets containing olmesartan were adjusted to 0.005% (w/w) (5.8 
mg/kg/d) to reduce the hypotensive effect and increase the food intake. The pravastatin 
concentration was raised to 0.04% (w/w) (47 mg/kg/d) to obtain equal cholesterol 
exposures (i.e. plasma cholesterol levels x total time in weeks) between the control and 
olmesartan groups and between the pravastatin and combination groups. Since the 
olmesartan group had a significant lower total cholesterol exposure after 24 weeks of 
treatment, this group was sacrificed 2 weeks later. Olmesartan and pravastatin were 
provided by Sankyo Company, Ltd. The animals received food and water ad libitum. 
Body weight and food intake were monitored during the study. 
 
Lipid and lipoprotein analysis and plasma SAA 
After a 4-hour fasting period from 9 a.m. to 1 p.m., EDTA plasma was collected (Sarstedt, 
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Nümbrecht, Germany). Total plasma cholesterol (Roche Diagnostics, No-1489437) and 
triglyceride (Roche Diagnostics, No-1488872) levels were measured. Lipoprotein 
profiles were obtained by FPLC23. Serum amyloid A was determined by ELISA 
(Biosource International, Nivelles, Belgium)9,28.  
 
Systolic blood pressure 
To evaluate the effect of olmesartan, the systolic blood pressure was measured in all 
groups after 4, 13 and 20 weeks of treatment using the Blood Pressure System for Rats 
and Mice (RTBP1001, Harvard Apparatus, Holliston, MA, USA). The mice were trained 
every day, seven days before measurement. For each mouse the blood pressure was 
measured three times during one session27. 
 
Histological assessment of atherosclerosis 
After the six-months treatment period, the mice were sacrificed after anesthetizing and 
blood collection23. Formalin fixed and paraffin embedded sections of the entire aortic 
root area were haematoxylin-phloxine-saffron stained for atherosclerosis 
measurement29. For determination of severity of atherosclerosis, the lesions were 
classified into 5 categories9,27,28: I) early fatty streak, II) regular fatty streak, III) mild 
plaque, IV) moderate plaque, V) severe plaque. Per mouse the percentages of all lesions 
found in the respective categories were calculated. The total lesion area was calculated 
per cross-section.  
In each segment used for lesion qualification, the number of monocytes adhering 
to the endothelium was counted. Mouse monocytes were immunostained with 
AIA31240 (1:3000, Accurate Chemical and Scientific, New York, USA). Macrophage area 
was measured after immunostaining with anti mouse CD68 (1:100, Serotec Ltd, UK). The 
number of T lymphocytes was counted after immunostaining with mouse anti human 
CD3 (Serotec Ltd, UK), cross reacting with mouse CD3, a marker for all T cell subtypes. 
Collagen content of the plaque was quantified morphmetrically after Sirius Red staining. 
Mouse smooth muscle cells were immunostained with mouse anti-human alpha actin 
(1:800, DAKO, Denmark), which cross reacts with mouse alpha actin. smooth muscle 
cells were counted in the superficial part of the lesions (e.g. the cap) in the type III, IV 
and V lesions. Proliferating smooth muscle cells in the cap were immunostained with 
anti PCNA (1:180, Calbiochem, Merck, Germany). All analyses were performed by the 
same operator, who was blinded for experimental group allocation. 
 
Statistical analysis 
Significance of differences was calculated by using the non-parametric Mann-Whitney U 
test. Each group was compared to control and the combination group was additionally 
compared to the pravastatin group. Differences in lesion area were corrected for 
differences in blood pressure, using analysis of variance and analysis of covariance. To 
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ensure normality, lesion area was transformed using a square-root transformation, 
which was used as dependent variable. The treatment group was used as the 
independent variable and difference in blood pressure was the covariate. P<0.05 was 
considered significant. All data are presented as mean ± SD. 
 
 
Results 
 
Plasma lipids and blood pressure 
As presented in table 1 the control group had a cholesterol exposure of 420 ± 34 
mM*weeks, which was equal to the olmesartan group. Cholesterol exposure was 
decreased by 18% (p<0.001) in the pravastatin group and by 17% (p<0.001) in the 
combination group, as compared to the control group. Average plasma cholesterol levels 
were 17.5 ± 2.7 mmol/L for the control group. Although at any time point the 
olmesartan group did not differ from the control group, the average overall cholesterol 
level was slightly decreased (p<0.05). In the pravastatin and the combination group a 
17% (p<0.001) reduction of the plasma cholesterol level was observed. The average 
plasma triglyceride level for the control group was 1.47 ± 0.47 mmol/L. Olmesartan 
lowered plasma triglyceride levels by 13% (p=0.001) and pravastatin by 37% 
(p<0.001). In the combination group triglyceride levels were decreased by 39% 
(p<0.001). Average systolic blood pressure, measured after 4 and 13 weeks of 
treatment, the blood pressures were 101 ± 6 mmHg for the control group, 83 ± 6 mmHg 
for olmesartan group (-18%, p<0.001), 104 ± 7 mmHg for the pravastatin group and 89 
± 4 mmHg for the combination group (-11%, p<0.001). After diet adjustment (at t=18 
weeks), the blood pressures were measured again after 20 weeks of treatment (shown 
in table 1). Olmesartan alone or in combination with pravastatin decreased systolic 
blood pressure by 14% as compared to control and pravastatin treatment. 
Total 
cholesterol 
exposure 
(mM *weeks)
Average 
plasma 
cholesterol 
(mmol/L)
Average 
plasma 
triglyceride 
(mmol/L)
Systolic blood 
pressure 
(mmHg)
C ontrol 420 ± 34 17.5 ±2.7 1. 47 ±0.47 104 ± 4
Olmesartan 415 ± 74  16.4 ± 3.9*  1.27 ± 0.48*   90 ± 2*#
Pravastatin   346 ± 48*†  14.6 ± 2.6*  0.93 ± 0.42* 105 ± 4
Olmesartan + Pravastatin   348 ± 49*†  14.5 ± 2.9*  0.89 ± 0.45*   89 ± 3*#
 
Table 1 The effect of olmesartan, pravastatin and the combination of both on plasma lipids and 
systolic blood pressure after twenty weeks of treatment. (*p<0.05 compared to control; †p<0.05 
compared to olmesartan; #p<0.05 compared to pravastatin) 
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Atherosclerosis evaluation: Lesion number, lesion area and lesion severity 
Representative photomicrographs of atherosclerotic lesions found in the different 
groups are shown in figure 1. The number of lesions per cross-section in the control 
group was 5.9 ± 1.1 (figure 2A). A significant decrease of 31% was found in the 
olmesartan group (P<0.005) and of 34% in the pravastatin group (P<0.001). 
Combination treatment reduced lesion number by 69% (P<0.001), which was also 
significantly different from the olmesartan group (-56%; P=0.001) and pravastatin 
group (-54%; P<0.001). The total lesion area per section for the individual groups is 
shown in figure 2B. For the control group the total lesion area was 164.4 ± 68.8 
μm2*1000. Olmesartan significantly reduced lesion area by 46% (P<0.05) and 
pravastatin by 39% (P<0.05). The combination therapy further inhibited the 
development of atherosclerosis by 91% which was highly significant compared to the 
control (P<0.001), the olmesartan (-83%; P=0.001) and pravastatin (-85%; P<0.001) 
group. For each animal the lesion severity was analyzed and the percentages of lesions 
belonging to the respective lesion categories were calculated. Figure 2C shows the 
percentages of type 0-III lesions (no lesions, fatty streaks and mild plaques) and type IV-
V lesions (moderate and severe plaques).  About 70% of lesions in the control group 
were type IV or type V lesions, which was 47% (N.S.) in the olmesartan group,  38% 
(P<0.01) in the pravastatin, and only 15% (P<0.001) in the combination group. This 
finding indicates that treatment with olmesartan, alone or in combination with 
pravastatin, interferes with the progression of lesion development, resulting in less 
advanced lesions. 
Control              Olmesartan 
   
Pravastatin            Olmesartan + Pravastatin 
   
 
Figure 1 Representative 
photomicrographs of 
atherosclerotic lesions found 
in the different groups 
(haematoxylin-phloxine-
saffron staining). The control 
example shows a severe 
lesion (type V). For both the 
olmesartan and pravastatin 
group mild and moderate 
lesions (type II, III and IV) 
are presented. The example 
for the combination group 
shows a small fatty streak 
(type I). 
 
 
86
CHAPTER  5__________________________________________  _______________________________________________ 
 86 
We also analyzed whether 
olmesartan had anti-atherosclerotic 
properties beyond its blood pressure 
lowering qualities. We calculated, using a 
univariate analysis of variance (with blood 
pressure as covariate), that the differences 
in lesion area remained significant after 
statistical correction for differences in 
blood pressure (P<0.01). This shows that 
olmesartan had an additional beneficial 
effect independent of its blood pressure 
lowering effect. The nature of these effects 
was explored in more detail below. 
 
Systemic inflammation: plasma serum 
amyloid A 
The liver-derived plasma inflammation 
marker serum amyloid A (SAA), which 
reflects the overall systemic inflammatory 
state, was measured at the beginning of the 
study and at sacrifice (figure 3). Levels at 
sacrifice were 32.2 ± 19.2 μg/mL in the 
control group, which was significantly 
higher (P=0.01) when compared to the 
levels at the start of the treatment (11.6 ± 
3.5 μg/mL). As compared to control, SAA 
was reduced by 68% (p<0.001) in the 
olmesartan group, by 72% (p<0.001) in 
the pravastatin group, and by 64% 
(P<0.001) in the combination group. The 
pravastatin group showed a significant 22% reduction (p<0.05) in SAA levels as 
compared to the levels at the beginning of the study. These data emphasize the anti-
inflammatory properties of both drugs. 
 
Inflammatory cells: Monocyte adhesion and macrophage and T lymphocyte abundance 
As inflammation is an important process in atherogenesis, the presence of pro-
inflammatory cells was measured. In the same four sections of the aortic root used for 
measurement of lesion number, size and severity, the monocytes adhering to the 
activated endothelium were counted. In the control group on average 18.1 ± 3.2 
adhering monocytes per cross-section were present (figure 4A). A significant reduction 
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Figure 2 Effect of olmesartan, pravastatin and 
the combination of both on atherosclerosis. The 
number of lesions (A) and lesion area per cross-
section (B). Severity of the atherosclerotic lesions 
(C) as determined by the percentages of lesions 
classified as mild (absence of lesions + type I-III 
lesions) and severe (type IV-V lesions). P<0.05 
compared to control; †P<0.05 compared to 
olmesartan; #P<0.05 compared to pravastatin. 
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of 22% (p<0.05) was observed in the 
olmesartan group, whereas the 
pravastatin group had an equal number 
of adhering monocytes as compared to 
the control group. The combination 
group showed a similar reduction as the 
olmesartan group, which was 
significantly different from the control 
group (-25%; P<0.01) and the pravastatin 
group (-27%; P<0.01). A resembling 
pattern was seen for the relative amount 
of macrophages in the total lesion area 
(figure 4B), in which a 38% (P<0.05) 
decrease was observed in the olmesartan group. No reduction was observed in the 
pravastatin group and there was a 26% (N.S.) decrease in the combination group. The 
total number of macrophages in the lesions showed a pattern comparable to the lesion 
area (compare figure 4C with figure 2B). In the control group on average 209 ± 67 
macrophages were present per cross-section. Significant decreases of 46% (P<0.05) and 
of 51% (102 ± 113, P<0.01) were found in the olmesartan group and pravastatin group, 
respectively. An 89% (P<0.001) reduction was observed in the combination group, 
which was significantly lower than the olmesartan (P<0.01) and pravastatin group 
(p<0.001).  
In the control group on average 2.1 ± 0.4 T-lymphocytes were present per cross-
section (figure 4D). This number was lowered by 62% (P<0.05) in the olmesartan 
group, by 76% (P<0.01) in the pravastatin group, and by 86% (P<0.001) in the 
combination group. Taken figures 4A to 4C together, our data indicate that treatment 
with olmesartan decreases activation of the endothelium and results in less foam cell 
rich plaques as compared with pravastatin treatment.  
 
Lesion composition: Collagen and smooth muscle cell content 
To obtain an indication of plaque stability, the collagen content of the lesions and 
smooth muscle cell area in the cap of the lesions were measured. The average collagen 
content was 30.8 ± 10.9% in the control group. A 30% increase (39.8 ± 14.0%; N.S.) was 
seen in the olmesartan group, 40% (43.3 ± 10.7%; P<0.01) in the pravastatin group and 
48% (45.6 ± 22.2%; N.S.) in the combination group. Smooth muscle cell area in the cap 
was measured and expressed as percentage of the lesion area, in those lesions that 
contained fibrous caps (type III, IV en V) (figure 4E). It was found that 1.7 ± 1.2% of the 
lesion area was smooth muscle cell area in the control group. A 2.6-fold (P<0.01) 
increase was measured in the olmesartan group. Pravastatin treatment resulted in a 3.1-
fold increase (P<0.001) and a 5-fold (P<0.01) increase was observed in the combination 
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Figure 3 Effect of olmesartan, pravastatin and 
the combination of both on plasma levels of 
serum amyloid A (SAA). *P<0.05 compared to 
control; #P<0.05 compared to start of treatment. 
 
88
CHAPTER  5__________________________________________  _______________________________________________ 
 88 
group. To obtain an indication about the state of differentiation of these smooth muscle 
cells the sections were stained for alpha-SMactin, as a marker of the differentiated, 
contractile phenotype and for PCNA as marker of proliferation. In all groups hardly any 
proliferation of smooth muscle cells was found in the cap area (data not shown). This 
suggests that the smooth muscle cells in the cap area are differentiated contractile 
smooth muscle cells, which hardly proliferate. The enhanced smooth muscle cell area 
per lesion area suggests an increased stability of the plaques.  
 
0
5
10
15
20
25
Con Olme Prava Olme +
Prava
M
o
n
o
c
y
te
s
* #
* #
0
100
200
300
M
a
c
ro
p
h
a
g
e
s
* #
*
*
†
0
5
10
15
20
25
30
M
a
c
ro
p
h
a
g
e
a
re
a
(%
)
* #
0
4
8
12
16
S
M
C
 a
re
a
(%
)
* *
*
Con Olme Prava Olme +
Prava
0
1
2
3
T
-l
y
m
p
h
o
cy
te
s
*
*
*
Con Olme Prava Olme +
Prava
Con Olme Prava Olme +
Prava
Con Olme Prava Olme +
Prava
A B
C D
E
 
 
Figure 4 Effect of olmesartan, pravastatin and 
the combination of both on lesion composition. 
A) The number of adhering monocytes to the 
endothelium per cross-section. B) Relative 
amount of macrophage area per lesion area. C) 
The number of macrophages in the lesions per 
cross-section. D) The number of T lymphocytes 
per cross-section. E) Relative amount of smooth 
muscle cell area in the cap per lesion area. 
*P<0.05 compared to control; †P<0.05 compared 
to olmesartan; #P<0.05 compared to pravastatin 
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Discussion 
The present study was designed to evaluate and characterize the nature of the effect of 
the ARB olmesartan alone or in combination with statin treatment, the latter of which 
can be considered as standard therapy for patients suffering from cardiovascular 
disease, on the development of atherosclerosis. To create a human-like condition 
APOE*3Leiden transgenic mice were used, since these mice respond to statins with 
cholesterol-lowering just as humans9,22,26-28 and develop atherosclerotic lesions akin to 
their human counterparts with respect to morphological, histological and 
immunohistochemical characteristics23. In this study treatment with olmesartan 
resulted in an 11 to 18% reduction in blood pressure, resembling the human response (-
10 to -17%) to ARB treatment30. Pravastatin reduced plasma cholesterol levels by 17%, 
which is also comparable to the about 20% decrease achieved in clinical trials31.  
Mono treatment with olmesartan inhibited atherosclerosis development, beyond 
and independent of the reduction achieved by its antihypertensive action alone. This 
finding is in line with previous studies in monkeys32 and in apoE deficient mice33, in 
which olmesartan reduced atherosclerosis but did not affect blood pressure. We 
investigated whether olmesartan exerts this additional anti-atherosclerotic effect via an 
anti-inflammatory activity by measuring plasma levels of the liver-derived inflammation 
marker SAA. SAA is a risk factor for cardiovascular disease, which reflects the overall 
inflammatory state34. Treatment with olmesartan reduced SAA levels to initial levels of 
healthy control animals (i.e. before the atherogenic diet was started). The decrease was 
observed even under conditions of increased plasma cholesterol levels, which are 
known to increase SAA levels9,28,29. In addition, histological analysis of the lesions 
showed anti-inflammatory features of olmesartan as characterized by reductions in the 
number of pro-inflammatory adhering monocytes, macrophages, and T-cells per cross-
section and by a decrease in total macrophage area in the lesions. Since lesion formation 
starts by monocyte adherence to the activated endothelium, the above data indicate that 
olmesartan has an inhibiting effect on the early phase of lesion formation. The reduction 
in the ‘soft’ macrophage area, known to be prone to plaque rupture, together with the 
increased smooth muscle cell area of the contractile phenotype covering the lesions, 
suggests that olmesartan has plaque stabilizing effects.  
Besides blood pressure and inflammation, elevated plasma triglyceride levels are 
an independent risk factor for cardiovascular disease35. In this study it was observed 
that olmesartan slightly but significantly decreased plasma triglyceride levels. A similar 
effect combined with an improved insulin sensitivity was observed in olmesartan-
treated, fructose-fed rats36. Another angiotensin II receptor blocker, telmisartan, was 
recently shown to reduce triglyceride levels and to improve insulin sensitivity in insulin 
resistant rats and humans37. These effects were attributed to its peroxisome 
proliferator-activated receptor-γ (PPAR-γ) modulating abilities. PPAR-α and PPAR-γ are 
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expressed in the cells of the cardiovascular system and have been shown to participate 
in the regulation of cell growth and migration, and oxidative stress and inflammation38. 
For olmesartan no PPAR-γ activating capacity has been detected39 until now and it 
needs to be investigated whether the effect on triglyceride levels and the anti-
inflammatory effects of olmesartan are due to modulation of PPAR-α activity. 
Mono treatment with pravastatin inhibited the progression of atherosclerosis 
resulting in less severe and less advanced lesions. This can not solely be attributed to the 
reduction in plasma lipid levels by pravastatin treatment, but also to its anti-
inflammatory properties. These were exhibited in the liver as was visible by reduced 
plasma SAA levels to even lower concentrations than at the start of the study and 
histologically in the vessel wall by a reduced number of macrophages and T-cells. SAA, 
macrophages and T cells are considered to participate in pro-atherogenic processes of 
early lesion evolution and promote lesion development40,41. The reductions in these 
parameters were all comparable to the decreases achieved by olmesartan mono therapy. 
Pravastatin did not affect the number of adhering monocytes and the macrophage 
containing area in the plaques. However, it may stabilize the lesions by increasing the 
amount of differentiated contractile alpha-SMactin positive smooth muscle cells in the 
fibrotic cap like olmesartan does. 
 
When olmesartan was combined with pravastatin the anti-atherosclerotic and anti-
inflammatory activities of both drugs appeared to be additive, resulting in a significant 
reduction of 85% when compared to the pravastatin mono treatment. Combination 
treatment lowered the number of adhering monocytes and T-cells like olmesartan mono 
therapy, but further reduced the lesion severity and the number of macrophages. No 
further reduction by combination treatment was found for plasma SAA, which already 
was decreased by olmesartan or pravastatin alone to levels found at the start of 
treatment. In agreement with the present data combination treatment with 
candesartan/rosuvastatin42, or valsartan/fluvastatin43 reduced atherosclerosis to a 
greater extent than treatment with each drug alone in ApoE-/- mice. However, treatment 
with telmisartan plus atorvastatin did not show any additional effects on atherosclerotic 
progression and stability in this mouse model44. Our data in APOE*3Leiden transgenic 
mice are in line with a recent report on the effect of combination treatment in rabbits45 
and extend the latter observation of reduced atherosclerosis development by providing 
a more mechanistic explanations for the additive effect of both drugs.  
In conclusion, the current data show that olmesartan interferes with the initiation 
of lesion formation, whereas pravastatin inhibits lesion progression, and both drugs 
have vascular and hepatic anti-inflammatory properties. The clinical study EUTOPIA21 
also points to anti-inflammatory activity of olmesartan in humans by reducing the 
plasma levels of C-reactive protein, interleukin-6 and tumor necrosis factor-α in patients 
91
_________________________ _____OLMESARTAN AND PRAVASTATIN ADDITIVELY REDUCE ATHEROSCLEROSIS 
 91 
with essential hypertension and microinflammation. Co-treatment with pravastatin 
resulted in further reductions of these levels, whereas pravastatin alone did not affect 
these inflammatory factors. SAA levels were not measured in the latter study.  
The effect of combination treatment of olmesartan with pravastatin on 
cardiovascular endpoints in humans has not yet been studied. However, combination 
therapy of atorvastatin with an ACE inhibitor was shown to be more effective in 
reducing cardiovascular events than statin treatment alone in a post-hoc analysis of the 
patients of the GREASE46 study47. Similar synergistic effects of atorvastatin and anti-
hypertensive treatment with the calcium channel blocker amlodipine and ACE inhibitor 
perindopril were recently reported in the ASCOT study48. The present study and the 
results of the mentioned clinical trails provide evidence that combination treatment of 
olmesartan and pravastatin may be more effective in the prevention of atherosclerosis 
than treatment with statins alone.  
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Abstract 
 
Objective  To evaluate the effect of the PPARα/γ agonist tesaglitazar on the progression 
of pre-existing atherosclerotic lesions in APOE*3Leiden.CETP (E3L.CETP) transgenic 
mice. 
 
Methods and Results After feeding E3L.CETP mice a high cholesterol (HC) diet for 11 
weeks to induce atherosclerosis, mice were fed a low cholesterol (LC) diet for 4 weeks to 
obtain a human-like plasma total cholesterol level of ~10 mmol/L. Thereafter, Mice 
were subdivided into three groups. Then, one group was  sacrificed  (“baseline group”) 
and two groups were continued to feed for another eight weeks with LC diet, one group 
without (“control group”) and one group with 10 µg/kg/day tesaglitazar (“tesaglitazar 
group”).  Atherosclerosis development was assessed in the aortic root. Tesaglitazar 
significantly reduced plasma triglycerides (-71%), total cholesterol (-55%; mainly by 
reducing (V)LDL-C), CETP mass (-42%) and CETP activity (-56%), and increased HDL-C 
(+38%). In the baseline group, substantial atherosclerosis had developed (lesion area 
~136,000 µm2) as reflected by mainly moderate and severe lesions. During the 8 weeks 
LC diet period, atherosclerosis had progressed in the control group with respect to 
lesion area (+54%) and severity, whereas tesaglitazar inhibited lesion progression 
during this period. In fact, tesaglitazar reduced local inflammation in the vessel wall as 
reflected by decreased monocyte adhesion (-48%) and macrophage area (-85%) and 
introduced lesions with more stabilized phenotype , as evident from an increased 
smooth muscle cell content in the cap (+64%) and collagen content (+97%). 
 
Conclusion Dual PPARα/γ agonism with tesaglitazar markedly reduced (V)LDL-C and 
increased HDL-C and turned down cholesterol-induced vessel wall activation. These 
combined actions resulted in complete inhibition of progression and even stabilization 
of pre-existing atherosclerotic lesions in E3L.CETP transgenic mice.  
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Introduction 
A doubling of the global burden of diabetes within 25 years from now has been 
predicted1. Patients with obesity, insulin resistance, or type 2 diabetes (T2D) are prone 
to develop the atherogenic triad, as characterized by raised plasma triglycerides (TG), 
reduced high-density lipoprotein cholesterol (HDL-C) and a predominance of small 
dense low-density lipoprotein (sdLDL)2. Besides insulin resistance (IR) and high glucose 
levels, these lipid abnormalities are all associated with an increased risk of 
cardiovascular diseases (CVD)3. HMGCoA-reductase inhibitors (statins) effectively lower 
plasma LDL cholesterol (LDL-C) but do not optimize the other lipid abnormalities 
associated with increased CVD risk. Therefore, additional therapies are required to 
further improve the atherogenic dyslipidemia typically associated with insulin 
resistance. 
Peroxisome proliferator–activated receptors (PPARs) are nuclear hormone 
receptors that control the expression of genes involved in both carbohydrate and lipid 
metabolism, and could be valuable as additional drug targets. Stimulation of PPARα by 
fibrates 1) inhibits hepatic TG production, 2) increases lipoprotein lipase (LPL)-
mediated TG lipolysis 3) provides a higher affinity of remnants for the LDL receptor 
(LDLr), 4) enhances human apoAI and apoAII synthesis4, and 5) reduces the expression 
of the cholesteryl ester transfer protein (CETP)5. These concomitant effects of fibrates 
result in a significant on average 36% decrease in TG and a 10% increase of HDL-C in 
humans6. Fibrates reduce atherosclerosis in mice independent of their cholesterol-
lowering effect7, which may be related to their anti-inflammatory capacities8. They also 
reduce cardiovascular events in humans, which is most evident in obese and insulin 
resistant patients9,10. Thus, PPARα agonism is beneficial by its effect on the lipoprotein 
profile and its inflammation-reducing properties. On the other hand, PPARγ agonists 
(glitazones) improve insulin sensitivity and induce glycemic control in diabetic animals 
as well as in patients with T2D11. Independent of their metabolic action, they also reduce 
inflammatory markers such as C-reactive protein (CRP), matrix metalloproteinase-9 
(MMP-9), serum amyloid A (SAA), soluble CD40 ligand (sCD40L), monocyte 
chemoattractant protein-1 (MCP-1), and tumor necrosis factor α (TNFα), which may 
contribute to their anti-atherogenic properties8,12.  
Because of their additive modes of action, dual PPARα/γ agonists (glitazars) 
improve both lipid and glucose abnormalities in animal models and human subjects with 
insulin resistance and/or T2D. For example, in patients with T2D, tesaglitazar treatment 
reduced TG, apoB, total cholesterol (TC), nonHDL-C and VLDL-C, and increased HDL-C13. 
In obese dyslipidemic patients, tesaglitazar improved dyslipidemia on top of 
atorvastatin, and was more effective in glucose modulation than the PPARγ agonist 
pioglitazone14. However, its clinical development was discontinued in May 2006 
following phase III clinical trial results as its benefit-risk profile did not provide a 
significant advantage over existing anti-diabetic therapies.  End point studies using 
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tesaglitazar or other dual PPARα/γ agonists in humans have thusfar not been 
performed. 
We have previously shown that tesaglitazar improved the HOMA-IR index, 
lowered plasma TC and TG levels and lowered inflammation markers in APOE*3Leiden 
(E3L) mice15. These mice display a lipoprotein profile comparable to that of patients 
with dysbetalipoproteinemia (with plasma TC and TG are mainly confined to (V)LDL16) 
and do respond to various hypolipidemic drugs in a similar way as humans17. 
Tesaglitazar did not increase HDL in E3L mice, probably by the fact that mice naturally 
lack expression of CETP, which is an important factor for human HDL metabolism. In 
these mice, tesaglitazar reduced atherosclerosis development in a prevention design, in 
which pharmacological treatment was started before the onset of atherosclerosis15. 
The aim of the present study was to evaluate the effect of tesaglitazar on 
atherosclerosis development in a more clinically relevant design, in which 
pharmacological treatment with tesaglitazar was started after atherosclerosis had been 
developed. To this end, we used our recently developed E3L.CETP transgenic mouse 
model18, a more humanized animal model that has been shown to respond to both lipid-
lowering interventions17 and HDL-raising interventions5 19,20. 
  
 
Methods 
 
Mice and diets 
Human CETP transgenic mice which express CETP under control of its natural flanking 
regions (strain 5203)21 were obtained from Jackson laboratories (Bar Harbor, MC) and 
crossbred with E3L mice22 in our local animal facility at TNO to obtain heterozygous 
E3L.CETP mice18. Forty-seven female E3L.CETP mice (on average 18 weeks of age) 
received a semi-synthetic high cholesterol (HC) western-type diet, containing 40.5% 
sucrose and 15% cacao butter, supplemented with 0.3% (w/w) cholesterol for 11 weeks 
to induce hypercholesterolemia and atherosclerosis development. After 11 weeks, the 
diet was replaced by a low cholesterol (LC) western-type diet containing 0.1% (w/w) 
cholesterol for another four weeks to reduce total cholesterol (TC) towards a more 
‘human-like’ level (approx. 10 mmol/L). Thereafter, the animals were divided into three 
groups, after matching based on age, body weight and plasma TC and TG levels. 
Subsequently, the mice were fed the LC diet without tesaglitazar (‘control group’; n=16) 
or with tesaglitazar (‘tesaglitazar group’, 0.25 µmol / kg diet ~ 10 µg/kg body weight/ 
day; n=16) to reduce TC levels by about 50% (dose determined in a pilot study). To 
quantify the extent of atherosclerosis at the start of the drug intervention, a third group 
of mice was sacrificed immediately after matching, which was considered a reference for 
the baseline atherosclerosis level (‘baseline group’, n=15). The animals received food 
and water ad libitum. Body weight and food intake were monitored during the study. 
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Animal experiments were approved by the Institutional Animal Care and Use Committee 
of The Netherlands Organization for Applied Scientific Research (TNO). 
 
Plasma lipids and apolipoproteins 
After a 4-hour fasting period from 9 a.m. to 1 p.m., blood was collected from the tail vein 
into EDTA-coated tubes (Sarstedt, Nümbrecht, Germany). Plasma was assayed for TC 
(No-236691, Roche Diagnostics, USA) and TG (No-1488872, Roche Diagnostics, USA), 
and for apoAI and (human) apoE using sandwich ELISAs as described previously18. The 
distribution of cholesterol of the various lipoproteins was determined after separation 
of lipoproteins by fast-performance liquid chromatography (FPLC) using a Superose 6 
column18. HDL-C was also quantified in plasma after precipitation of apoB-containing 
lipoproteins. Hereto, 10 µL heparin (LEO Pharma, The Netherlands) and 10 µL 0.2 M 
MnCl2 were added to 20 µL plasma and mixtures were incubated for 20 min at room 
temperature and centrifuged for 15 min at 13,000 rpm at 4°C. 
 
Plasma CETP mass and CET activity 
CETP mass was determined using the DAIICHI CETP ELISA kit (Daiichi Pure Chemicals 
Co, Japan) according to manufacturer’s instructions. Cholesteryl Ester Tranfer (CET) 
activity was measured exactly as described, and calculated as nmol/mL/h5.  
 
Plasma inflammation markers 
SAA (Biosource International, Belgium), adiponectin, E-selectin, MCP-1, and vascular 
cellular adhesion molecule-1 (VCAM-1) (all R&D Systems Inc, USA) were determined by 
ELISA according to the manufacturers’ instructions. Fibrinogen was measured with an 
in-house procedure as described previously23. 
 
Histological assessment of atherosclerosis 
The various mouse groups were sacrificed either at the start of LC treatment (“baseline 
group”) or after the 8-week treatment period with LC diet (“control group”) or LC diet 
supplemented with tesaglitazar (“tesaglitazar group”). The hearts were dissected, 
formalin-fixed and embedded in paraffin. Serial cross sections (5 μm) throughout the 
entire aortic valve area were used for histological analysis. Per mouse, 4 sections with 
intervals of 50 μm were used for quantification and qualification of the atherosclerotic 
lesions after staining with hematoxylin-phloxin-saffron (HPS). For determination of the 
severity of atherosclerosis, the lesions were classified into 5 categories as described24: I) 
early fatty streak, II) regular fatty streak, III) mild lesion, IV) moderate lesion, and V) 
severe lesion. Per mouse the percentages of all lesions found in the respective categories 
were calculated. The total lesion area was calculated per cross section. In each segment 
used for lesion qualification, monocytes were immunostained with AIA31240 (1:3000, 
Accurate Chemical and Scientific, USA) and the number of monocytes adhering to the 
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endothelium was counted25. Macrophage area was measured after immunostaining with 
anti-mouse Mac-3 (BD Pharmingen, the Netherlands). Smooth muscle cell (SMC) area 
was measured after immunostaining with mouse anti-human actin (DAKO, Denmark) 
that cross-reacts with murine actin. The collagen content of the lesions was quantified 
morphometrically after Sirius Red staining. SMC area in the cap was measured and 
calculated as percentage of the total lesion area. All analyses were performed by the 
same operator, who was blinded for experimental group allocation. 
 
Statistical analysis 
Data are presented as means ± SD unless indicated otherwise. Statistical differences 
were assessed using the non-parametrical Kruskal-Wallis test followed by Mann 
Whitney U test. P<0.05 was considered statistically significant.  
 
 
Results 
 
Tesaglitazar decreases (V)LDL-C 
and increases HDL-C 
To induce the development of 
atherosclerosis, E3L.CETP mice 
were fed a HC diet for 11 weeks, 
resulting a relatively high plasma 
TC level (19.9 ± 4.9 mmol/L) and 
a moderate TG level (2.3 ± 1.3 
mmol/L) (figure 1). Thereafter, 
the mice were fed a LC diet for 4 
weeks to obtain more ‘human-
like’ TC levels (10.8 ± 4.9 
mmol/L) without reducing TG 
levels (2.2 ± 0.9 mmol/L) at the 
start of the intervention period. 
One mouse group was 
subsequently sacrificed 
(“baseline group”), and the other 
groups were treated with either 
LC diet (“control group”) or the 
LC diet supplemented with 
tesaglitazar (“tesaglitazar 
group”) for 8 weeks. As 
compared to the control group, 
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Figure 1. Effect of dietary cholesterol reduction and 
tesaglitazar on plasma cholesterol and triglyceride levels. 
E3L.CETP mice received a high cholesterol diet for 11 weeks 
followed by a low cholesterol diet for 4 weeks. Subsequently, 
the mice were matched and either sacrificed (“baseline”; 
squares) or continued to be fed the LC diet without 
tesaglitazar (“control”; white circles) or with tesaglitazar 
(“tesaglitazar”; black circles) for 8 weeks. Blood samples 
were taken and plasma was analyzed for total cholesterol (A) 
or triglycerides (B). ***P<0.001 compared to the control 
group.  
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tesaglitazar reduced TC by -55% (4.1 ± 1.4 mmol/L vs 9.1 ± 3.2 mmol/L; P<0.001) 
(figure 1A) and TG by -71% (0.5 ± 0.3 mmol/L vs 1.9 ± 0.6 mmol/L; P<0.001) (figure 
1B). Lipoprotein fractionation by FPLC showed that the TC-lowering effect of 
tesaglitazar was accounted for by a large reduction in (V)LDL-C (~-80%), whereas 
tesaglitazar increased HDL-C (~+45%) (figure 2A). The increase in HDL-C was 
confirmed by direct measurement of HDL-C in plasma after precipitation of apoB-
containing lipoproteins (+38%; P<0.01) (figure 2B). No differences were observed in 
plasma concentrations of apoAI (1.4 ± 0.4 mg/mL vs 1.5 ± 0.5 mg/mL) and human apoE 
(0.22 ± 0.08 mg/mL vs 0.21 ± 0.08 mg/mL). 
 
Tesaglitazar decreases CETP mass and CET activity 
Since the HDL-raising effect of tesaglitazar may have resulted from decreased CETP 
expression, plasma CETP mass and CETP activity were determined after the 8 weeks LC 
treatment (figure 3). As compared to the control group, tesaglitazar lowered CETP mass 
by -42% (8.2 ± 4.5 vs 14.1 ± 4.4 µg/mL; P<0.001) and reduced CETP activity by -56% 
(21.2 ± 13.8 vs 48.5 ± 18.6 nmol/mL/h, P<0.001). 
 
Tesaglitazar blocks progression of atherosclerosis development 
Eleven weeks of feeding the HC diet followed by 4 weeks on the LC diet, resulted in a 
lesion area per cross section of 136 ± 87 x103 µm2 as determined in the baseline group 
(figure 4A). Prolonged feeding of the mice with the LC diet without tesaglitazar for 
another 8 weeks increased the lesion area by +54% (210 ± 84 x103 µm2; P<0.05). This 
diet-induced increase in lesion area was fully blocked by tesaglitazar (140 ± 97 x103 
µm2; NS vs baseline). These changes in lesion area were also reflected by changes in 
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Figure 2. Effect of tesaglitazar on plasma lipoproteins. After matching, E3L.CETP mice were fed the LC 
diet without (white symbols) or with (black symbols) tesaglitazar for 8 weeks. The distribution of 
cholesterol over the individual lipoproteins in pooled plasma was determined after separation of 
lipoproteins by FPLC (A). Plasma HDL-C levels were also measured individually after precipitation of 
apoB-containing lipoproteins (B). **P<0.01 as compared to the control group. 
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lesion severity. Whereas prolonged 
feeding the LC diet without tesaglitazar 
increased the percentage of severe lesions 
(type IV-V, 69 ± 17% vs 47 ± 23% at 
baseline; P<0.01) at the expense of mild 
(type I-II) and moderate (type III) lesions, 
the LC diet with tesaglitazar did not result 
in an increase in type IV-V lesions (59 ± 
24%) or reduction in type III lesions (40 ± 
24% vs 43 ± 23% at baseline, NS) as 
compared to baseline (figure 4B).  
 
Tesaglitazar reduces inflammation in the 
arterial wall 
To investigate the contribution of 
inflammation to the observed effects of 
tesaglitazar, we measured inflammation 
markers. At baseline, plasma markers for 
systemic inflammation such as 
adiponectin (5.0 ± 0.9 μg/mL), SAA (1.0 ± 
0.6 μg/mL), and fibrinogen (1.8 ± 0.3 
mg/mL) were in the physiological range, 
as were the vascular inflammation 
markers E-selectin (43.5 ± 7.2 ng/mL), 
VCAM-1 (1.1 ± 0.3 μg/mL) and 
macrophage-derived chemokine MCP-1 
(75.0 ± 20.1 pg/mL). These markers in 
plasma were not differentially changed in 
the control group and the tesaglitazar 
group as compared to baseline levels, 
albeit that we observed a slight increase in E-selectin levels upon tesaglitazar treatment 
(51.0 ± 7.2 ng/mL; P<0.05). 
Local inflammation in the vessel wall was histologically assessed by measuring 
the adhesion of monocytes to the endothelium (figure 5A) and the macrophage content 
of the lesions (figure 5B). As compared to baseline, the number of monocytes adhering 
to the endothelium (3.1 ± 2.2 vs 3.2 ± 2.2 per cross section) and the macrophage content 
of the lesions (6.4 ± 3.3% vs 5.2 ± 3.7%) were not affected in the control group. 
Tesaglitazar, however, potently reduced inflammation in the vessel wall as compared to 
baseline, as reflected by a 48% decrease in adhesion of monocytes (1.6 ± 1.7 vs 3.2 ± 2.2; 
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Figure 3. Effect of tesaglitazar on CETP mass and 
CET activity. After matching, E3L.CETP mice were 
fed the LC diet without (white bars) or with 
(black bars) tesaglitazar for 8 weeks. Plasma 
CETP mass (A) and CET activity (B) were 
determined. Values are means ± SD (n=16 per 
group). ***P<0.001 as compared to the control 
group. 
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P<0.05) and a strong -85% reduction in 
macrophage content of the lesions (0.8 ± 
1.2% vs 5.2 ± 3.7%; P<0.001). 
 
Tesaglitazar increases the SMC and 
collagen content of the atherosclerotic 
lesions 
To evaluate the effect of tesaglitazar on 
parameters reflecting lesion stability, we 
measured the collagen content (figure 
5C) and SMC area in the cap (figure 5D). 
As compared to baseline, the lesions in the 
control group were more severe and 
contained therefore more collagen (54 ± 
10% vs 33 ± 11%, p<0.001), but had a 
similar amount of SMCs in the cap per 
lesion area (4.8 ± 1.9% vs 3.4 ± 2.6%). 
Tesaglitazar not only blocked lesion 
development (figure 4A), but also 
enhanced the induction of a more stable 
lesion phenotype as compared to control, 
reflected by a further increase in collagen 
content (to 65 ± 9%, P<0.001 vs baseline, 
P<0.05 vs control). The increase in SMC 
area in the cap was +64% increased as 
compared to the baseline (to 5.6 ± 1.9%, 
P<0.05), which was not different from the 
control group.  
 
 
Discussion 
In this study we showed that tesaglitazar, but not dietary cholesterol lowering, fully 
prevented the progression of pre-existing atherosclerosis in E3L.CETP transgenic mice. 
Tesaglitazar also reduced inflammation in the vessel wall as reflected by less monocyte 
adherence and less macrophage area in the lesions, and induced a more stable lesion 
phenotype as indicated by an increased collagen content and SMC area in the cap.  
We previously showed that E3L mice are highly susceptible to dietary 
interventions with respect to modulating plasma lipid levels. Moreover, E3L mice show a 
human-like response to drug interventions aimed at treatment of CVD (e.g. statins, 
fibrates, cholesterol uptake inhibitors, calcium channel blockers and angiotensin II 
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Figure 4. Effect of tesaglitazar on atherosclerosis 
development. Mice were sacrificed at baseline 
(grey bars) or after 8 week intervention with LC 
diet without (white bars) or with (black bars) 
tesaglitazar. In the aortic root the lesion area was 
measured per cross section (A) and the severity 
of lesions was analyzed (B). #P<0.05, ##P<0.01 
as compared to the baseline group. 
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receptor antagonists7,23,25-27) with respect to alterations in the lipoprotein profile and/or 
atherosclerosis development. This is in sheer contrast with wild-type C57Bl/6 mice and 
conventional hyperlipidemic mice, such as apoE-deficient or LDLr-deficient mice, which 
show either an adverse response or no response to such interventions17. In particular, 
administration of tesaglitazar to LDLr-deficient mice did not affect plasma lipid levels28, 
while we demonstrated that tesaglitazar lowered TG and cholesterol within apoB-
containing lipoproteins in E3L mice 15 similarly as in humans13,14. 
Recently, we showed that introduction of the human CETP gene in E3L mice 
results in a mouse model which also displays a human-like response with regard to 
raising HDL-C after administration of fenofibrate5, atorvastatin19, niacin (Van der Hoorn 
et al, unpublished) and torcetrapib20. In the present study, we confirm that treatment of 
E3L.CETP mice with tesaglitazar reduced (V)LDL-C and strongly reduced TG similarly as 
observed previously in E3L mice. In addition, we now demonstrate that tesaglitazar also 
raised HDL-C levels in E3L.CETP mice similarly as reported in clinical intervention trials 
13,14. The presence of CETP thus plays a crucial role in the HDL-C-raising effect of 
tesaglitazar. In fact, tesaglitazar markedly decreased CETP mass in plasma. This is most 
probably due to the PPARα-agonistic effect of tesaglitazar, since we have recently 
observed that treatment of E3L.CETP mice with the PPARα agonist fenofibrate reduced 
hepatic CETP expression as well as the plasma CETP mass and CETP activity5. The 
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Figure 5. Effect of 
tesaglitazar on lesion 
composition. The 
number of monocytes 
adhering to the 
endothelium was 
counted (A). The 
macrophage content 
(B), the collagen 
content (C), the 
smooth muscle cell 
(SMC) content in the 
cap (D) of the lesions 
were measured. 
#P<0.05, ##P<0.01, 
###P<0.001 as 
compared to the 
baseline group; 
*P<0.05, ***P<0.001 as 
compared to the 
control group. 
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observation that plasma CETP activity is reduced to a larger extent than CETP mass may 
relate to the large reduction in plasma TG, as the capacity of apoB-containing 
lipoproteins to accept CE from HDL is closely correlated to its plasma level29-32. The 
tesaglitazar-induced increase in HDL-C was not accompanied by a raise in apoAI, 
suggesting that tesaglitazar increases the particle size of HDL rather than the amount of 
HDL particles, which was indeed confirmed by FPLC profiling. 
To establish the effect of tesaglitazar on atherosclerosis in a setting mimicking 
the clinical situation, we first induced atherosclerosis in E3L.CETP mice by feeding a 
high cholesterol-containing western-type diet. Then, plasma cholesterol was lowered by 
limiting the dietary cholesterol before treatment with tesaglitazar was started. 
Interestingly, lowering cholesterol alone did not prevent further atherosclerosis 
development.  More specifically, vessel wall inflammation was not attenuated by just 
cholesterol lowering and the atherosclerosis had even progressed with respect to total 
lesion area and lesion severity. In contrast, tesaglitazar inhibited further atherosclerosis 
development and stabilized lesions. This can be ascribed to a further reduction of 
atherogenic (V)LDL-C, an increase in HDL-C as well as to local anti-inflammatory effects 
of tesaglitazar in the vessel wall, since atherosclerosis is a dynamic lipid- and 
inflammation-driven process.  
As evidenced by the largely reduced adherence of monocytes and macrophage 
content of the lesion, we demonstrated that tesaglitazar turned down the local vessel 
wall inflammation induced by the high cholesterol diet, whereas cholesterol lowering 
alone did not, These observations confirm our previous observations in E3L mice, which 
showed that tesaglitazar reduced NF-κB-positive areas in the atherosclerotic lesions, 
indicating reduced local inflammation. This was accompanied by less ICAM-1 and MCP-1 
positive areas15, which explains decreased monocyte adherence and transmigration, and 
thus decreased macrophage content of the lesions. Similar anti-inflammatory effects 
regarding endothelium activation have been shown for both single PPARα and PPARγ 
agonists8,33. It has recently been shown that PPARγ activation may program 
mononuclear precursor cells toward an M2 phenotype in vivo, leading to generation of a 
macrophage population with enhanced anti-inflammatory properties34,35. The anti-
inflammatory effect of tesaglitazar is local and not systemic, since tesaglitazar did not 
decrease the (physiologic) plasma levels of inflammation markers in either E3L or 
E3L.CETP mice.  
Furthermore, we observed that tesaglitazar stabilized the lesions by increasing 
the SMC content of the lesion cap as well as the collagen content of the lesion. It has been 
shown that inflammation not only enhances lesion development and progression, but 
also destabilizes lesions by stimulating the release of metalloproteinases (MMPs) from 
macrophages, which are able to degrade collagen. Contrary, tesaglitazar may thus 
increase the collagen content secondarily to the reduction in macrophage accumulation 
in the lesion. In fact, stimulation of PPARγ by rosiglitazone in humans stabilized lesions 
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in the carotid artery, which was ascribed to a reduced expression of MMP-3, MMP-8 and 
MMP-936. These observations indicate that, in established atherosclerotic lesions, the 
anti-inflammatory actions of dual PPARα/γ activation not only inhibit lesion progression 
but also induce a more stable lesion phenotype. 
To date,  all dual PPAR a/g agonists  including tesaglitazar, have been 
discontinued either at a preclinical stage or during clinical development and thus no 
dual PPARα/γ agonist has yet been approved for clinical use37. Long term clinical effects 
can therefore only be extracted from clinical studies using either single PPARα or PPARγ 
agonists. The effect of PPARα-agonistic fibrates on cardiovascular morbidity and 
mortality was studied in primary (HHS38 and FIELD39) and secondary (BIP40, VA-HIT41 
and FIELD39) cardiovascular prevention studies. The results from these trials suggest 
that fibrate therapy reduces CVD and is most efficacious in overweight individuals with 
insulin resistance and chronic inflammation. Whereas PPARγ agonists have been 
demonstrated to be efficient in the management of insulin resistance and T2D in a 
number of prospective clinical trials, their effects on CVD are still under debate42-44. 
While pioglitazone reduced the incidence of myocardial infarction and acute coronary 
syndrome in patients with T2D (PROactive study45), rosiglitazone has been noted to 
increase the CVD risk (ADOPT46 and DREAM47 study). The contradicting results of these 
clinical trials using different compounds to agonize PPARγ might just reflect the complex 
and meticulous balance in PPAR pathways and mechanisms involved in either their 
beneficial or detrimental effects. Likewise, whereas the dual PPARα/γ agonist 
tesaglitazar has atheroprotective effects in E3L.CETP mice, as shown in the present 
study, and in other mouse models for hyperlipidemia and atherosclerosis15,28, the dual 
PPARα/γ agonist ‘compound q’ aggravated inflammation and atherosclerosis in apoE-
deficient mice48. 
In conclusion, we showed that the dual PPARα/γ agonist tesaglitazar halted 
progression of pre-existing atherosclerosis and stabilized lesions in E3L.CETP mice, as 
related to reduction of (V)LDL-C, increase of HDL-C, and of local anti-inflammatory 
properties in the vessel wall. Despite the clinical failure of tesaglitazar, these data clearly 
demonstrate a potential therapeutic window for PPARα/γ agonists for treatment of 
diabetic cardiovascular complications. 
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Abstract 
Objective To evaluate the effect of Thromboxane Prostanoid (TP) receptor inhibition 
by increasing doses of the antagonist S18886 (terutroban) in combination with 
dietary cholesterol-lowering on existing atherosclerotic lesions in APOE*3Leiden 
transgenic mice.  
 
Methods and Results APOE*3Leiden mice were fed an atherogenic diet resulting in 
plasma cholesterol levels of 27.6 mM to develop atherosclerosis. At 10 weeks, 15 
mice were sacrificed to assess atherosclerosis development. Then cholesterol in the 
diet was reduced to reach plasma cholesterol levels of 5-6 mM and the remaining 
mice were treated with: vehicle (control), S18886 (10, 30 or 60 mg/kg bw/d) or 
ADP-receptor antagonist clopidogrel (3.8 mg/kg bw/d). After 12 weeks all groups 
were sacrificed and atherosclerosis was measured.Cholesterol-lowering alone 
decreased levels of inflammation markers SAA (-95%), MCP-1 (-70%) and E-selectin 
(-36%;all p<0.001), lessened the number of lesions (-20%;p<0.05) and improved 
the lesion stability. The latter was revealed by a reduced macrophage content (-95% 
p<0.001) and by a 7-fold increase of smooth muscle cells and collagen areas as 
compared to baseline. Supplementary treatment with S18886 reduced additionally 
and dose-dependently the lesion area (up to -55%), the progression of lesion 
severity (up to -43%) and the monocyte adherence (up to -70%) when compared to 
control (all P<0.01). Clopidogrel did not add to the effect of cholesterol-lowering on 
atheroclerosis development. 
 
Conclusion In APOE*3Leiden mice dietary cholesterol-lowering decreased the 
systemic and vascular inflammatory status and improved lesion stability. S18886 
demonstrated additional atheroprotective effects indicated by a dose-dependently 
reduced lesion size and severity and endothelial monocyte adherence.  
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Introduction 
Atherothrombosis is a multifactorial disease responsible for most cardiovascular 
events. The reduction of high plasma cholesterol by nutritional and/or 
pharmaceutical intervention is the first choice approach for treatment in preventing 
atherosclerosis development. However, different studies have shown that 
substantial residual cardiovascular risk remains, even with very aggressive 
reductions in levels of LDL cholesterol1. More recently, it has been evidenced that 
circulating platelets, when activated, are not only involved in thrombus formation 
leading to clinical complications, but are also able to activate vascular cells. 
Accumulating evidence has shown that they are involved in the initiation and the 
progression of atherosclerosis2, and inhibition of platelet adhesion reduces 
leukocyte infiltration and atherosclerosis in hypercholesterolemic mice3. Therefore, 
platelet inhibition not only leads to a significant decrease in cardiovascular events 
but could also result in a slower progression of atherosclerosis. 
The most widely prescribed anti-platelet treatment is aspirin, which clinical 
efficacy is based on inhibition of the platelet cyclo-oxygenase-1 (COX-1), thus 
inhibiting the generation of platelet thromboxane A2 (TxA2,), which binds to the 
thromboxane-prostanoid endoperoxide (TP) receptor4 and triggers platelet 
aggregation. TP receptors are widely expressed by vascular cells (smooth muscle 
cells, endothelial cells) and by circulating leucocytes, and their activation leads to 
vasoconstriction, inflammation and cell proliferation, phenomena widely involved in 
atherosclerosis initiation and progression. Aspirin treatment has clearly shown a 
beneficial effect in the secondary prevention of cardiovascular diseases (CVD), but is 
less accepted for the primary prevention. This is mainly caused by the increased 
incidence of bleeding and the very modest non-significant CVD risk reduction in 
individuals at low risk5-7. Additionally, aspirin has controversial effects on 
vasoconstriction, endothelial dysfunction or vascular wall proliferation8,9 known to 
be of major importance in the atherosclerotic process. 
Platelet inhibition can also be achieved by blocking TP receptors with specific 
antagonists which have advantages over aspirin. These compounds not only block 
the effects of TxA2, but also inhibit the binding of non specific TP receptor ligands, 
mostly isoprostanes and HETEs, formed in response to oxidative stress and able to 
exert deleterious effects10,11. Furthermore, in contrast to aspirin, TP receptor 
antagonists do not affect the synthesis of prostacyclin (PGI2) by the endothelial cells, 
which is a endogenous antiplatelet and vasodilatory prostanoid[10].  
S18886 (terutroban) is a selective TP receptor antagonist developed for the 
secondary prevention of atherothrombotic complications in patients12,13. It has been 
shown to be a well-tolerated and powerful antiplatelet agent, able to inhibit 
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thrombus formation more efficiently than aspirin 14,15. Previous studies in animal 
models have shown that S18886 displays anti-inflammatory properties combined 
with a decreased expression of adhesion molecules and a reduced recruitment of 
monocytes/macrophages within the arterial wall, resulting in the inhibition of 
atherogenesis 16. 
A third approach to inhibit platelet activation is antagonizing the adenosine 
diphosphate  (ADP) receptor on the platelet with compounds like clopidogrel, 
which, like aspirin, is a generally applied treatment in the clinic. Clopidogrel has 
been shown to be at least as effective as aspirin in preventing ischemic stroke, 
myocardial infarction and vascular death in patients suffering from CVD17.  
The purpose of this study was to evaluate the effects of inhibition of TP 
receptors by incremental doses of S18886 on existing atherosclerotic lesions in 
combination with dietary cholesterol intake lowering. For this study APOE*3Leiden 
transgenic mice were used, which is a well-established model for hyperlipidemia 
and atherosclerosis18,19. These mice become hyperlipidemic upon dietary 
cholesterol and respond to various hypolipidemic drugs in a similar way as 
humans20 As a control for anti-platelet therapy an additional group of mice was 
treated with the ADP receptor antagonist clopidogrel.  
 
 
Methods 
 
Mice 
Eighty-three female heterozygous APOE*3Leiden transgenic mice (16 to 18 weeks 
of age), characterized for human apoE18, were used. Animal experiments were 
approved by the Institutional Animal Care and Use Committee of The Netherlands 
Organization for Applied Scientific Research (TNO). Animals were bred by TNO. 
 
Diets 
To induce atherosclerosis development, all animals received a semi-synthetic 
western type diet (WD)18  supplemented with 0.75% (w/w) cholesterol and 0.05% 
(w/w) cholate for ten weeks. Thereafter (on t=0 weeks) on the basis of age, body 
weight and plasma cholesterol and triglyceride levels, the mice were matched into 
five groups (n=13-14): The control group, fed WD + 0.025% (w/w) cholesterol only 
and four treatment groups, fed the same diet as the control group supplemented 
with either clopidogrel (3.8 mg/kg bw/d) or S18886 (10, 30 or 60 mg/kg bw/d) for 
12 weeks (compounds provided by Institut de Recherches Internationales Servier, 
France). To determine the amount of atherosclerosis at the start of treatment 15 
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mice were sacrificed after matching at t=0 weeks and were considered the reference 
for baseline levels. The animals received food and water ad libitum.  
 
Lipid and lipoprotein analysis and plasma SAA, MCP-1, E-selectin and VCAM-1 
After a 4-hour fasting period, EDTA plasma was collected (Sarstedt, Germany). Total 
plasma cholesterol and triglyceride levels were measured (Roche Diagnostics, No-
1489437 and No-1488872). Lipoprotein profiles were obtained by FPLC. Serum 
amyloid A (SAA) (Biosource International, Belgium), MCP-1, E-selectin and VCAM-1 
(all R&D systems Inc, Minneapolis, USA) were determined by ELISA19,21.  
 
Histological assessment of atherosclerosis 
After the 10-week induction and the 12-week treatment period the mice were 
sacrificed the hearts were dissected, formalin-fixed and embedded in paraffin. Per 
mouse, 4 serial aortic root sections (5µm, 50µm spaced) were used for 
quantification and qualification of the atherosclerotic lesions after staining with 
hematoxylin-phloxin-saffron (HPS). For determination of severity of atherosclerosis, 
the lesions were classified into 5 categories as described before19,21: I) early fatty 
streak, II) regular fatty streak, III) mild lesion, IV) moderate lesion, V) severe lesion. 
Per mouse the percentages of all lesions found in the respective categories were 
calculated. The total lesion area was calculated per cross-section. Collagen content 
of the lesion after Sirius Red staining, macrophage area after immunostaining with 
anti-mouse Mac-3 (BD Pharmingen, the Netherlands) and smooth muscle cells 
(SMCs) area after immunostaining with mouse anti-human actin (DAKO, Denmark), 
cross reacting with mouse actin, were quantified morphometrically. Also the 
number of monocytes adhering to the endothelium was counted after 
immunostaining with AIA31240 (Accurate Chemical and Scientific, New York, USA). 
All analyses were performed by the same operator, who was blinded for 
experimental group allocation. 
 
Statistical analysis 
Significance of differences was calculated by using parametric t-test for comparison 
of baseline levels at the start of the study with the control group. ANOVA tests, 
followed by Dunnett test were applied for comparison of the intervention treatment 
groups with the control group. A parametric Pearson’s correlation was calculated 
for dose dependency. The Extreme Studentized Deviate method was used to identify 
and exclude outliers. P<0.05 was considered significant. All data are presented as 
mean ± SD. 
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Results 
 
Plasma lipid levels  
During the first 10 weeks of study, 
when the mice were fed the high 
cholesterol diet prior to intervention, 
average plasma cholesterol and 
triglyceride levels were 27.6 ± 7.3 mM 
and 2.3 ± 0.6 mM, respectively. As 
aimed for, these values decreased 
significantly to 5.3 ± 1.0 mM and 
1.5 ± 0.3 mM (p<0.001) when the 
dietary cholesterol intake was 
reduced during the 12-week 
intervention period. The reduction 
was confined to the apoB-containing 
lipoproteins (data not shown). The 
total cholesterol exposure (plasma cholesterol level x duration of study) did not 
differ between all treatment groups and the control group. Figure 1 represents the 
plasma cholesterol levels. 
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Figure 1 Mean plasma cholesterol levels over 
time. APOE*3Leiden mice were fed an 
atherogenic diet for 10 weeks to induce 
atherosclerosis development. Thereafter dietary 
cholesterol was lowered and supplementary 
intervention was started. *P=0.014; 60 mg/kg 
S18886 vs control.   
SAA MCP-1 E-Selectin VCAM-1
(µg/mL) (pg/mL) (µg/mL) (µg/mL)
Baseline 13.3± 7.3 81 ± 34 188 ± 26 2.5 ± 0.3
Control 2.5 ± 0.8
◊
24 ± 7
◊
120 ± 10
◊ 2.3 ± 0.2
S18886 (10 mg/kg) 2.6 ± 1.0 26 ± 12 124 ± 16 2.5 ± 0.5
S18886 (30 mg/kg) 2.7 ± 0.7 21 ± 5 133 ±15 2.4 ± 0.4
S18886 (60 mg/kg) 3.4 ± 1.7 19 ± 8 127 ± 15 2.6 ± 0.4
Clopidogrel 3.0 ± 1.1 14 ± 5* 115 ± 19 2.5 ± 0.4
 
 
Table 1. Plasma levels of systemic inflammation marker Serum Amyoid A (SAA) and vascular 
inflammation markers MCP-1, E-selectin and VCAM-1 at baseline (t=0) and after 12 weeks of 
intervention. Cholesterol-lowering with or without additional treatment resulted in a significant 
decrease of SAA, MCP-1 and E-selectin levels. ◊P<0.001 compared to baseline, ٭P<0.001 compared to 
control group. 
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Cholesterol-lowering reduces inflammation markers 
Inflammation plays a major role in the development of atherosclerosis and is 
described to be influenced by lipid lowering22-24. Therefore we investigated the 
effect of dietary cholesterol-lowering and the additional treatments on plasma levels 
of the liver-derived plasma inflammation marker serum amyloid A (SAA), which 
reflects the overall systemic 
inflammatory state, and VCAM-1, 
MCP-1 and E-selectin, as markers for 
endothelial activation. Cholesterol-
lowering from 27.6 to 5.3 mM by itself 
had clear anti-inflammatory effects as 
demonstrated by decreased plasma 
levels of inflammation markers SAA 
(from 13.3 ± 7.3 to 2.5 ± 0.8 µg/mL; 
p<0.001), MCP-1 (from 81 ± 34 to 
24 ± 7 pg/mL; p<0.0001) and E-
selectin (from 188 ± 26 to 
120 ± 10 µg/mL; p<0.0001) (table 1). 
Additional treatment with S18886 did 
not add to this effect, while 
clopidogrel significantly decreased 
MCP-1 levels (14 ± 5 pg/mL; 
P<0.001). Plasma VCAM-1 levels were 
not affected by cholesterol-lowering 
or supplementary treatments. 
 
Treatment with S18886 in 
combination with cholesterol-lowering 
inhibits progression of pre-existing 
atherosclerosis 
Ten weeks of high cholesterol diet 
resulted in the development of a 
moderate amount of atherosclerosis 
in the aortic root, as measured in the 
mice sacrificed at t=0 weeks 
(baseline: 5.1 ± 1.1 lesions and 
67.6 ± 56.0*1000 µm2 lesion area per 
cross section; figure 2A and 2B). The 
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Figure 2. Effect of S18886 and clopidogrel (Clop) 
on the number of lesions per cross sections (A), 
the lesion area per cross section (B, † Ptrend 
=0.006) and the lesion severity (C). Per lesion 
type the percentage of all lesions was calculated. 
◊p<0.05 compared to baseline (Base) and 
*P<0.0001 compared to control (Con). † Ptrend 
=0.011 type III and Ptrend =0.007 type IV & V 
(compared to control). 
◊ 
◊ 
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lesions were mainly foam cell rich lesions. As 
presented in figure 2C, 54 ± 19 % of the lesions 
were fatty streaks, consisting of only foam cells 
(type I and II), 37 ± 20 % were mild lesions, made 
up of foam cells covered by a fibrous cap (type III) 
and the remaining 9 ± 10% were severe lesions, 
which are infiltrated into the media and contain 
necrosis and cholesterol clefts (type IV and V). 
Despite a significant reduction in the number of 
lesions per cross section (from 5.1 ± 1.1 to 
4.1 ± 0.8; p<0.05), lowering of plasma cholesterol 
alone during 12 weeks failed to inhibit the 
progression of atherosclerosis, as reflected by the 
progression of lesion area (87.5 ± 53.8 *1000 µm2 
in the control group vs 67.6 ± 56.0*1000 µm2 at 
baseline, NS). Furthermore, a major shift in the 
distribution of lesion types as compared to 
baseline was observed. Almost all fatty streaks 
(type I and type II) had disappeared (1% ± 3 %; 
p<0.0001) and both mild type III lesions 
(52 ± 16 %; p<0.05) and severe type IV-V lesions 
(47 ± 16 %; p<0.0001) were present, reflecting a 
progression of atherosclerosis severity. 
Additional treatment with increasing doses 
of S18886 showed a dose-dependent reduction of 
the amount of atherosclerosis as compared to the 
control group (p=0.006 for Pearson’s correlation 
coefficient) as reflected by the decreased lesion 
area. Whereas the doses of 10 and 30 mg/kg bw/d 
tended to reduce the lesion area by 37 % and 36 % 
respectively (NS), the highest dose of 
60 mg/kg bw/d resulted in a significant decrease 
of 55 % (p=0.001). Moreover, the progression of the lesions towards more severe 
lesions as observed in the control group was partly prevented with increasing doses 
of S18886 (p=0.011 and 0.007 for Pearson’s correlation coefficient for the increase 
in type III lesions and the decrease in type IV-V lesions, respectively). The highest 
dose of 60 mg/kg bw/d S18886 displayed 42% less severe type IV-V lesions as 
compared to the control group (27 ± 16 % vs 47 ± 16 %). Treatment with 
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Figure 3 Effect of dietary 
cholesterol lowering and S18886 
on lesion composition. The collagen 
content of the lesions as percentage 
of lesion area (A). The SMC area as 
percentage of total lesion area (B). 
The macrophage area as 
percentage of total lesion area per 
group (C). ◊P<0.001 compared to 
baseline. Base = baseline, Con = 
control. 
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clopidogrel failed to reach a statistically significant effect, either in lesion size, 
number or severity, when compared to control group. 
 
Cholesterol-lowering stabilizes lesions 
To assess whether platelet inhibition with S18886 together with cholesterol-
lowering had additional effects next to the reduction of lesion size and severity, the 
lesion composition was analyzed. To this end the amounts of collagen, SMCs (both 
assumed to stabilize lesions) and macrophages (considered as an instable 
component) of the lesions were measured (figure 3A-C). At baseline only 
6.3 ± 5.9% of the total lesion area was filled with collagen, and SMCs were nearly 
absent with a presence of 0.5 ± 0.3% of the total lesion area. The major component 
of these lesions was macrophage foam cells (40.3 ± 14.9% of the total lesion area). 
Dietary cholesterol-lowering increased both the collagen and SMC content of the 
lesions about a 7-fold (46.4 ± 18.0%, p<0.001 and 3.1 ± 1.7%, p<0.005 respectively), 
and concomitantly dramatically decreased the amount of macrophages by 95% 
(p<0.001), resulting in more stable lesions. Supplementary treatment with S18886 
did not add to this improved lesion composition induced by dietary cholesterol-
lowering. 
 
S18886 combined with cholesterol-lowering reduces monocyte adhesion 
The onset of lesion development is considered to be the adhesion of monocytes to 
the activated endothelium followed by infiltration into the media and maturation to 
macrophages and foam cells. Feeding a high cholesterol diet resulted in 4.4 ± 2.9 
adhering monocytes per cross section at baseline (figure 4). Cholesterol-lowering 
did not prevent monocyte adhesion 
(3.7 ± 2.8 monocytes per cross section). 
As compared to the control, treatment 
with S18886 also reduced the adherence 
of monocytes to the endothelium in a 
dose-dependent manner (p=0.007 for 
Pearson’s correlation coefficient) with 
only 1.1 ± 0.9 adhering monocytes per 
cross section in animals receiving the 
highest dose of S18886 (p<0.05). 
Treatment with clopidogrel tended to 
decrease the number to 1.7 ± 2.0 
monocytes per cross section, but not 
significantly. 
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Figure 4. Effect of S18886  and clopidogrel (Clop) 
on the number of monocytes adhering to the 
endothelium per cross-section. ٭P<0.05 
compared to control. †Ptrend =0.007 (compared to 
control). Base = baseline, Con = control. 
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Discussion 
This study shows that in a relevant model of advanced atherosclerosis in 
APOE*3Leiden mice the TP receptor antagonist S18886 together with cholesterol 
lowering in the diet reduced additionally and dose-dependently the atherosclerotic 
lesion area, the progression of lesion severity and the amount of adhering 
monocytes as compared to control.  
In patients with increased risk for cardiovascular diseases, cholesterol-
lowering by treatment with mainly statins is the first choice approach to reduce or 
prevent the progression of atherosclerosis or to even regress it. In the present study, 
dietary cholesterol was reduced and this resulted in lowering of plasma cholesterol 
to human-like levels of 5-6 mM within 4-8 weeks. Positive effects of cholesterol-
lowering on atherogenesis were reflected by a strong decrease in systemic and 
vascular inflammation markers (SAA, MCP-1 and E-selectin) and by a reduction in 
lesion number (-20%). A decrease in macrophage content (-95%) and a 7-fold 
increase in SMC and collagen content of the lesions indicated a shift toward more 
stable lesions. Nevertheless, despite the strong decrease of plasma cholesterol levels 
in the intervention phase, the development of atherosclerosis continued. Albeit that 
a decreased number of lesions was observed, lesions kept on growing as 
demonstrated by an increase in lesion size (NS) and, more strikingly, by a massive 
progression from mild towards severe advanced lesions (when comparing control 
group to baseline levels). These observations revealed that in the present model, 
dietary cholesterol-lowering was unable to fully inhibit atherosclerosis progression 
and are in accordance with previous studies in APOE*3Leiden mice in which dietary 
cholesterol reduction was less efficient than drug-induced reduction by 
hypolipidemics19,21. 
A second line of defence in treatment of clinical atherosclerosis 
complications is platelet inhibition. Although not all physiological functions of 
platelets are fully clear yet, there is accumulating evidence that they go beyond 
aggregation and actively participate in atherosclerotic processes25,26. It has been 
described that platelets can oxidize LDL particles and stimulate their accumulation 
in monocytes and even stimulate CD34+ cells to differentiate into foam cells27,28. 
Moreover, activated platelets have been reported to increase the adhesive 
properties of monocytes29 via the expression of adhesion molecules and the release 
of thromboxane A2, a prostanoid that acts as a pro-inflammatory and chemotactic 
agent. This contention is supported by the observation of atheroprotection in 
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animals in which platelet inhibition was achieved16,30,31 and of aggravating 
atherosclerosis after platelet activation32 . 
In the present study, platelet inhibition by S18886 was in part responsible 
for the decreased progression of atherosclerosis and reduced vascular 
inflammation. Treatment of the APOE*3Leiden mice with incremental doses of the 
selective TP-receptor antagonist S18886 resulted in dose-dependent beneficial 
effects on important parameters of the development of atherosclerosis. S18886 
inhibited lesion progression, as represented by a reduction in lesion size (up to -
55%) and lesion severity with a reduced progression towards more complicated 
lesions. This observation is of critical importance as complicated lesions are more 
prone to trigger clinical events after rupture. The adhesion of monocytes to the 
endothelium, a primary step in the formation of atherosclerotic lesions, was dose-
dependently decreased by S18886 (up to -70%) as compared to the control group. 
To our knowledge this is the first study that demonstrates that S18886 has 
additional atheroprotective effects on top of cholesterol-lowering. In different 
studies in apoE-/- mice16, apobec1/LDLR DKO mice33 and rabbits34, it was shown 
that S18886 reduced the progression of atherosclerosis in a prevention design, in 
which the animals were treated during progression of atherosclerosis. Regarding 
the effect of S18886 on pre-existing atherosclerotic lesions, which is of more 
therapeutic relevance, inconsistent data were found. Without concomitant 
cholesterol lowering S18886 showed no beneficial effect in apobec1/LDLR DKO 
mice33. In rabbits the compound induced regression of pre-existing lesions as 
observed by MRI analysis in the absence of cholesterol-lowering35 and showed no 
effect when cholesterol levels were lowered concomitantly34. In agreement with our 
data, S18886 was also shown to increase the stability of lesions as reflected by a 
decreased content in pro-inflammatory macrophages and lytic enzymes such as 
MMP34,35. 
Limited and ambiguous data on the effects of the platelet inhibitor 
clopidogrel on progression of atherosclerosis in animal models have been reported. 
In rabbits the compound showed atheroprotective and anti-inflammatory effects31 
at a similar dose as used in the present study, whereas it did not hamper 
atherosclerosis development in apoE deficient mice36 at a higher dose. In 
accordance with the latter report, no atheroprotective effects of clopidogrel in 
combination with cholesterol-lowering on pre-existent atherosclerosis was 
observed.  
Other positive effects of platelet inhibition on atherosclerosis were recently 
reported with the novel dual TP-receptor antagonist and thromboxane synthase 
inhibitor BM-573, by hampering the progression of pre-exisiting lesions in LDLr-/- 
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mice37. No effect on inflammation markers was described in the latter study. In 
contrast, anti-inflammatory properties of S18886 were reported in vitro as well as in 
vivo in mice and rabbits16,34. It is possible that these anti-inflammatory effects of 
S18886 on plasma parameters are not visible in the present study, since they may 
be overshadowed by the strong effect of dietary cholesterol-lowering. However, 
S18886 demonstrated clear anti-inflammatory activity as evidenced by a marked 
reduction in monocyte adhesion, which is considered as a functional marker of 
activation of the endothelium in vivo. In conclusion, the present and reported data 
provide evidence for an anti-inflammatory capacity of S18886, ultimately resulting 
in inhibition of lesion progression. 
In humans, the anti-platelet drug aspirin is widely accepted to reduce the risk 
of CVD. However, the major adverse side effect bleeding and the large prevalence of 
aspirin resistance (5-45%) are drawbacks of this drug7,38. In the large CAPRIE trial17 
clopidogrel was shown to be at least as effective as aspirin in preventing ischemic 
stroke, myocardial infarction and vascular death. Combining the two in the 
MATCH39 and CHARISMA40 study did, however, not significantly decrease 
cardiovascular events and may even increase major bleedings. Besides their proven 
benefit in patients with CVD, the variety in response to these anti-platelet 
compounds is considerable, this might be called ‘resistance’, possibly reflecting the 
unravelled complexity of mechanisms affected by these treatments41. Analysis of 
urine samples of aspirin treated patients of the HOPE study demonstrated that 
thromboxane B2 levels were predictive for the risk of myocardial infarction and 
vascular death, providing evidence that inhibition of thromboxane production or 
activity might be protective for cardiovascular death42. This hypothesis was 
confirmed in the DAVID study43, in which picotamide, a dual inhibitor of 
thromboxane A2 synthase and receptor, was shown to be more effective in reducing 
all cause mortality in diabetic patients as compared to aspirin. Previously 
picotamide was shown to inhibit the progression of plaque growth in the carotid 
artery in diabetic patients44. These data suggest that antagonizing the TP-receptor 
may indeed have clinical benefits. 
In conclusion, this study demonstrates that the TP-receptor antagonist 
S18886 combined with dietary cholesterol-lowering prevents the progression of 
established atherosclerosis lesions towards more advanced lesions. The 
atheroprotective effect of S18886 is suggested to stem from the combination of 
platelet inhibition and its additional effects resulting from TP antagonism in 
vascular and inflammatory cells, as reflected by a dose-dependent reduction in 
adhesion of activated monocytes. Data from ongoing clinical trials will indicate 
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whether treatment with the TP receptor antagonist S18886 in humans is also 
successful in the secondary prevention of atherosclerosis and its complications. 
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Abstract 
 
Objective Selective COX-2 inhibition by rofecoxib was associated with increased risk of 
cardiovascular events. We hypothesized that concomitant treatment with thromboxane 
prostanoid receptor antagonist S18886 might ameliorate possible negative effects. We 
evaluated the effects of S18886, rofecoxib, and the interaction of both compounds in a 
combined treatment on myocardial infarct (MI) size and cardiac function after 
experimental ischemia/reperfusion injury in hyperlipidemic APOE*3Leiden transgenic 
mice. 
 
Methods and Results After four weeks of feeding an atherogenic diet, MI was induced by 
a 30-min ligation of the left anterior descending coronary artery, followed by 
reperfusion. Oral compound treatment was initiated 90 minutes prior to MI, and 
continued daily by gavage for seven days. Four treatment groups (n=12, each) were 
studied: solvent (Control), S18886, rofecoxib, and S18886 plus rofecoxib. One week after 
MI, the mice were anesthetized and cardiac function was quantified by left ventricular 
(LV) pressure-volume relationships obtained by miniature pressure-conductance 
catheters. No significant differences in infarct size were found between groups as 
measured by morphometry. Compared to Control, treatment with S18886 did not affect 
heart function whereas the rofecoxib group had significantly lower cardiac output 
(4.5±0.8 vs. 3.2±1.1 mL/min, p<0.01), lower ejection fraction (40±8 vs. 27±11%, 
p<0.005), and increased end-systolic volume (18.6±5.7 vs. 28.6±9.0 µL, p<0.05). The 
group with combined (S18886+rofecoxib) treatment was not different from Control. 
Statistical analysis showed significant interactive effects between S18886 and rofecoxib 
indicating that negative effects of rofecoxib on cardiac function were prevented by 
S18886 treatment. 
 
Conclusion Rofecoxib treatment reduced global and systolic LV function after ischemia-
reperfusion injury in APOE*3Leiden mice. These negative effects are prevented by 
combined treatment with thromboxane prostanoid-receptor antagonist S18886. 
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Introduction 
Cyclooxygenases are the rate-limiting enzymes in prostaglandin (PG) synthesis. They 
metabolize arachidonic acid to PGH2, which is followed by cell-specific synthase and 
isomerase enzymes (figure 1). Two cyclooxygenase iso-enzymes are characterized: 
COX-1 and COX-2. COX-1 is constitutively expressed in most cells to mediate 
physiological responses and regulate homeostasis. COX-2 is expressed in a few organs 
including the central nervous system, kidneys and the gonads in a constitutive manner 
similar to COX-11, but shows increased expression in pathological conditions such as 
inflammation and ischemia and acts as an inflammatory mediator2. Based upon these 
findings, a subclass of nonsteroidal anti-inflammatory drugs, designed to selectively 
inhibit COX-2 has been developed for the treatment of chronic inflammatory diseases. 
However, their use has been under debate since an increased risk of cardiovascular 
events with the COX-2 inhibitor rofecoxib was noted in the Vioxx Gastrointestinal 
Outcomes Research study (VIGOR)3 and was also observed in subsequent studies4,5. The 
Adenomatous Polyp 
Prevention on Vioxx 
(APPROVe)6 study also showed 
a significant increase in the 
risk of myocardial infarction 
and atherothrombotic events, 
leading to the market 
withdrawal of rofecoxib. Two 
other large randomized 
controlled trials assessing the 
safety of celecoxib 7 and 
valdecoxib found the same side 
effects8. A recently published 
meta-analysis based on nine 
case-control studies and two 
cohort studies showed an 
relative risk of 1.35 for serious 
cardiovascular events with 
rofecoxib treatment9. To 
explain these observations, the 
hypothesis has been advanced 
that COX-2-selective inhibitors 
shift the balance in the 
vascular system between the 
prostanoid thromboxane A2 
(TXA2) and prostaglandin I2 
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Figure 1. Schematic overview of the production arachidonic 
acid metabolites. The COX-derived PGs are mediators of 
inflammation, whereas TXA2 and the LTs are mainly pro-
inflammatory. LXs have anti-inflammatory effects. COX = 
cyclooxygenase, LT = Leukotriene, LX = lypoxin,PG = 
prostaglandin, xP receptor = prostanoid receptor, TXA2 = 
Thromboxane A2. 
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(PGI2) by suppressing the synthesis of (endothelial) COX-2-derived PGI2, without 
changing the (platelet) COX-1-derived TxA2 synthesis10. Increased TXA2 release has been 
shown during myocardial ischemia, possibly not only derived from aggregating platelets 
but also from macrophages and other immunologically reactive cells11. Since TXA2 is 
responsible for platelet aggregation, vasoconstriction of coronary arteries, and has pro-
inflammatory and cytotoxic effects12, it can be speculated that TXA2 exerts a deleterious 
effect during ischemia and reperfusion. 
S18886 is a potent and selective antagonist of the thromboxane-prostanoid (TP) 
endoperoxide receptor13. The compound is being developed for the secondary 
prevention of ischemic events in patients with atherosclerosis. S18886 inhibits platelet 
aggregation and vasoconstriction induced by the agonists of the TP receptor, without 
affecting the production of prostacyclin by endothelial cells and other vessel wall cells14. 
We thus hypothesized that concomitant treatment with S18886 might ameliorate 
negative effects (if any) of COX-2 inhibition on the cardiovascular system, by redressing 
the functional balance between inflammatory mediator PGI2 and the pro-inflammatory 
TXA2. 
The goal of the present study was to further investigate the previously reported 
negative effects of the COX-2-selective inhibitor rofecoxib on myocardial infarct size and 
on heart function and to test the hypothesis that concomitant treatment with 
thromboxane prostanoid receptor antagonist S18886 might ameliorate the anticipated 
negative effects. We used APOE*3Leiden transgenic mice on a standardized Western 
type diet - an established mouse model for hyperlipidemia  and pharmaceutical 
interventions15,16 - and induced myocardial injury by ischemia-reperfusion in order to 
mimic the human situation with regards to elevated plasma lipid levels and relatively 
limited infarct size due to early reperfusion by PTCA or thrombolysis. 
 
 
 Methods 
 
Animals 
Twelve-week-old male heterozygous APOE*3Leiden transgenic mice backcrossed into a 
C57BL6/J background and characterized by an ELISA for human apoE15, were used. The 
mice were housed in a clean-conventional animal room at the Gaubius Laboratory TNO. 
Housing conditions were: relative humidity 50-60%, temperature ~21˚C, light cycle 6 
am to 6 pm. Mice were housed in macrolon cages. Food and water were supplied ad 
libitum. Animal experiments were approved by the Institutional Animal Care and Use 
Committee of The Netherlands Organization for Applied Scientific Research TNO, and 
conformed to the rules and regulations set forth by The Netherlands Animal 
Experiments Act. 
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Study design  
Fifty APOE*3Leiden mice were fed a standardized Western type diet, containing 15% 
(w/w) cacao butter, 1.0% (w/w) cholesterol and 0.05% (w/w) cholate17. After three 
weeks, mice were randomized into four groups of 12 or 13 mice each, matched for body 
weight and plasma cholesterol level. One week later, myocardial ischemia and 
reperfusion was induced, essentially as described by Michael et al.18. One hour prior to 
the induction of anesthesia (approximately 90 min before the ischemic period), mice 
were treated orally (100 µL/10 gram bw) with vehicle (1.0% hydroxyethylcellulose) for 
the control group, 10 mg S18886/kg bw, for the S18886 group, or 10 mg rofecoxib/kg 
bw for the rofecoxib group. The S18886 plus rofecoxib combination group received 10 
mg S18886/kg plus 10 mg rofecoxib/kg (given separately, each in 50 µL/10 gram body 
weight). Subsequently, drugs or solvent were administered daily by gavage until 
sacrifice seven days later. The S18886 dose was based on previous studies13,19,20 
showing effective TP receptor antagonism with 5-10 mg/kg/day. Likewise rofecoxib 
dose was chosen in line with previous studies21-23 mimicking human use and taking into 
account approximately 10x higher metabolism in the mouse. 
Body weight was determined weekly. Seven days after ischemia-reperfusion, heart 
function was assessed by LV pressure-volume relationships (as described in detail 
below), and the hearts were harvested to measure the infarct size. Before excision of the 
heart, intracardiac blood was drawn and serum was prepared (30 min 37ºC, 30 min 4ºC, 
2000 x g for 15 min) and stored at -70ºC. 
 
Induction of myocardial ischemia.  
The mice were anesthetized by intraperitoneal injection of a mixture of fentanyl (0.8 
mg/kg bw), fluanison (25 µg/kg bw) and midazolam (12.5 µg/kg bw) (FFM). An 
intratracheal tube was inserted, and the animals were artificially ventilated, using a 
dedicated mouse ventilator (UNO, Zevenaar, The Netherlands). After left lateral 
thoracotomy, the left anterior descending coronary artery (LAD) was ligated just distal 
to the left atrial appendix. After thirty minutes of ischemia (evidenced by blanching in 
the LV), reperfusion was initiated by removing the ligature. The thorax was closed, and 
the mouse was allowed to recover on a heating pad18. Oxygen support and an analgesic 
(Nubaine) were given as required. 
 
Hemodynamic measurements  
Seven days after myocardial ischemia-reperfusion, the mice were re-anesthetized with 
FFM, intubated, ventilated, and instrumented to assess LV function by pressure-volume 
loop analysis. The jugular vein was cannulated for infusion of hypertonic saline to 
determine parallel conductance. Via the carotid artery a miniaturized pressure-
conductance catheter (SPR-839, Millar Instruments, Houston, TX) was positioned into 
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the LV. The abdomen was opened just below the diaphragm to enable temporary 
preload reductions by directly compressing the inferior vena cava. The pressure-
conductance catheter was connected to a Sigma-SA signal processor (CD Leycom, 
Zoetermeer, The Netherlands) for on-line display and registration of LV pressure and 
volume signals. All data were acquired at 2000Hz using Conduct-NT software (CD 
Leycom) and analyzed off-line by custom-made software (CircLab). LV pressure-volume 
signals were acquired in steady state to quantify general hemodynamic conditions: heart 
rate (HR), stroke volume (SV), cardiac output (CO), end-diastolic volume (EDV), end-
systolic volume (ESV), ejection fraction (EF), end-diastolic pressure (EDP), and end-
systolic pressure (ESP). Stroke work (SW) was determined as the area of the pressure-
volume loop, and the maximal and minimal rate of LV pressure change, dP/dtMAX and 
dP/dtMIN, were obtained. Effective arterial elastance (EA) was calculated as ESP/SV. 
Relaxation time τ was calculated as the time-constant of mono-exponential pressure 
decay during isovolumic relaxation24. To obtain load-independent indices of LV function, 
we determined pressure-
volume relations by recording 
pressure-volume loops during 
a gradual preload reduction. 
The slopes of end-systolic 
pressure-volume relation (end-
systolic elastance, EES) and 
end-diastolic pressure-volume 
relation (end-diastolic stiffness, 
EED) quantify systolic and 
diastolic function, 
respectively25. This approach is 
illustrated in figure 2. 
 
Infarct area, morphometry and 
immunohistochemistry  
After hemodynamic 
measurements, a cannula was 
inserted into the aorta, and the 
heart was stopped in diastole 
by injection of 0.1M cadmium 
chloride, followed by perfusion 
of the heart with sodium 
nitroprusside (0.1mg/mL 
saline) for two minutes and 
perfusion fixation using 4% p-
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Figure 2. Typical pressure-volume loops to illustrate our 
methodology. End-systolic and end-diastolic pressure-volume 
relations (ESPVR, EDPVR) were determined from pressure-
volume loops obtained during gradual preload reduction by 
vena cava occlusion. The slopes of these relations (EES and EED) 
are load-independent parameters of systolic and diastolic LV 
function. Steady state hemodynamic parameters were derived 
from pressure-volume loops just prior to vena cava occlusion. 
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formaldehyde. The heart was then removed, fixed overnight in p-formaldehyde, and cut 
into six 1 mm-thick slices, perpendicular to the long axis of the heart. These slices were 
flat-embedded in paraffin and 3 µm-thick sections were prepared. Sections were stained 
by the haematoxylin-phloxin-saffran (HPS) method for general histology. To delineate 
the infarcted area, sections were stained immunohistochemically with a mouse 
monoclonal antibody against cardiac Troponin T (Lab Vision Co, Fremont, CA; 
NeoMarkers cat # MS-295-P), and with Sirius red F3B for collagen to delineate the 
infarcted area. On paraffin sections from the six 1 mm-slices the infarct area and the 
total LV wall area (including the septum) were measured by morphometry (Leitz Qwin 
system). The LV area was measured on HPS-stained sections. The infarcted area was 
measured on Sirius red stained sections. Sirius red staining and Troponin T-
immunohistochemical staining were generally fully overlapping, but delineation was 
easier with Sirius-Red staining and therefore preferred for infarct quantification. The 
infarct area was expressed as percentage (vol/vol) of the LV wall volume. The volumes 
were calculated as measured area multiplied by slice thickness. COX-2 immunoreactivity 
was visualized immunohistochemically26, using an affinity-purified polyclonal antibody 
against COX-2 (Cayman Chemical Co, Ann Arbor, MI, cat # 160126). 
 
Plasma assays 
At randomization and at sacrifice total cholesterol (Roche Diagnostics, No-1489437) and 
total triglycerides (Roche Diagnostics, No-1488872) were determined. 
 
Statistical analysis  
Differences between groups were analyzed by one-way ANOVA followed by post-hoc 
Bonferroni correction for multiple comparisons using SPSS for Windows (version 12.0, 
SPSS Inc, Chicago IL). Differences were considered significant at p<0.05. All data are 
presented as mean±SD (unless otherwise indicated). To specifically test whether the 
effect of rofecoxib was significantly altered by the absence or presence of S18886 we 
applied a full factorial univariate linear regression model. If the S18886*rofexocib 
interaction term included in this model reached significance, this indicated that 
presence of S18886 significantly influenced the effect of rofecoxib (or vice versa). 
 
 
Results 
 
Body weight and plasma values  
Body weights increased during the dietary study phase, and slightly decreased 
postoperatively, most likely due to the ischemic insult. Plasma cholesterol and 
triglyceride levels were equal in all groups both at surgery (week 3) and at sacrifice 
(week 5) (table 1). 
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Ventricular volume and infarct size  
LV myocardial volume and infarct size did 
not differ between groups (figure 3). In 
the control group, the 7-day-old infarct 
constituted 9.0±3.9% of the LV wall 
volume.  
 
Cardiac function  
The results of the cardiac function 
measurements are shown in table 2. 
ANOVA indicated significant differences 
between groups for CO, ESV and EF. SW 
just failed to reach statistical significance 
(P=0.067). These indices are presented as 
bar graphs in figure 4 (left panels). 
Between-group comparisons showed that 
the rofecoxib group had significantly 
lower CO, higher ESV and lower EF 
compared to the control group, indicating 
reduced global and systolic LV function. 
No other significant effects were present, 
except for a significantly higher CO in the 
S18886+rofecoxib group compared to the 
rofecoxib group. The finding that neither 
Control S18886 ROF ROF + 
S18886
Body weight (gram) 22.9 ± 1.9 23.0 ± 1.6 24.2 ± 2.5 23.6 ± 2.1
Cholesterol (mmol/L) 12.4 ± 2.8 13.2 ± 7.1 11.6 ± 4.2 12.7 ± 4.7
Triglycerides (mmol/L) 2.1 ± 0.6 1.9 ± 0.8 1.8 ± 0.7 2.1 ± 0.9
Body weight (gram) 22.4 ± 1.4 23.0 ± 1.6 24.9 ± 2.2 23.8 ± 1.7
Cholesterol (mmol/L) 11.9 ± 3.5 14.3 ± 3.0 11.8 ± 6.5 12.1 ± 2.1
Triglycerides (mmol/L) 1.9 ± 0.6 2.0 ± 0.5 1.8 ± 0.6 2.1 ± 0.5
At sacrifice
At randomization
 
Table 1. Body weight and plasma lipids. Body weight and plasma cholesterol and triglycerides were 
measured at randomization and at sacrifice. No significant differences between groups were observed 
at any time point. 
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Figure 3. The effect of S18886, rofecoxib (ROF), 
and their combination on infarct size and LV wall 
volume. No differences were observed between 
the groups. Data are presented as mean ± SD. 
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the S18886 nor the group with combined S18886+rofecoxib treatment showed 
significant differences with the control group suggests an interactive effect by which the 
negative effects of rofecoxib are prevented by combined treatment with S18886. To 
specifically test the rofecoxib-S18886 interactive effects we applied a univariate 
analysis. The results are presented in table 2 and for the indices that showed 
significance also displayed in figure 4 (right panels). The results show significant 
interaction for CO, SW and EF, and marginally significant interaction (p=0.074) for ESV. 
The significant interaction indicates that the effect of rofecoxib is different in the 
absence and presence of S18886. In all cases the significant negative effect of rofecoxib 
on cardiac function in absence of S18886 (-S18886) was reversed in presence of S18886 
(+S18886).  
 
Immunohistochemistry of COX-2 
 Immunohistochemical staining for COX-2 showed minor or no reactivity in the 
myocardium remotely from the infarct area, but was upregulated in cardiomyocytes and 
vascular smooth muscle cells adjacent to an infarcted area (figure 5). Occasionally COX-
2 was expressed in scattered cells in the infarcted area (most clearly in conjunction with 
signs of recent inflammatory activity). No differences were observed between the 
groups in the present study, as could be expected because infarct size was similar. 
ROF + ANOVA S18886 ROF Inter-
S18886 P effect effect action
General
HR (beats/min) 385 ± 51 369 ± 42 350 ± 58 377 ± 62 0.437 0.735 0.372 0.181
CO (mL/min) 4.5 ± 0.8 3.9 ± 1.3 3.2 ± 1.1* 4.6 ± 1.3# 0.017 0.254 0.393 0.004
SW (mmHg.µL) 800 ± 160 668 ± 260 584 ± 294 819 ± 232 0.067 0.464 0.651 0.012
EA (mmHg/µL) 6.2 ± 1.3 7.2 ± 3.7 7.8 ± 3.7 5.9 ± 1.9 0.345 0.616 0.860 0.084
Systolic
ESV (µL) 18.6 ± 5.7 23.2 ± 10.7 28.6 ± 9.0* 24.4 ± 7.0 0.044 0.909 0.025 0.074
ESP (mmHg) 70.3 ± 8.7 64.9 ± 16.4 61.9 ± 13.8 66.5 ± 9.3 0.533 0.900 0.354 0.175
EF (%) 40.4 ± 8.1 33.4 ± 9.4 27.0 ± 11.0** 35.2 ± 7.5 0.008 0.810 0.032 0.006
dP/dtmax (mmHg/ms) 6.0 ± 1.9 4.7 ± 1.7 4.5 ± 2.2 5.5 ± 2.3 0.263 0.799 0.527 0.063
EES (mmHg/µL) 2.1 ± 0.8 1.8 ± 0.6 2.0 ± 1.0 1.7 ± 0.5 0.510 0.158 0.650 0.794
Diastolic
EDV (µL) 29.8 ± 6.5 33.3 ± 13.0 37.1 ± 10.1 35.8 ± 8.8 0.293 0.705 0.092 0.396
EDP (mmHg) 8.4 ± 3.2 9.5 ± 5.3 9.9 ± 5.4 6.7 ± 1.8 0.280 0.400 0.618 0.091
-dP/dtmin (mmHg/ms) 4.8 ± 1.1 3.9 ± 9.6 3.8 ± 1.4 4.3 ± 1.3 0.195 0.650 0.442 0.049
τ (ms) 11.5 ± 2.1 12.9 ± 1.4 13.3 ± 3.1 13.3 ± 3.0 0.269 0.353 0.139 0.345
EED (mmHg/µL) 0.43 ± 0.20 0.49 ± 0.25 0.47 ± 0.31 0.33 ± 0.15 0.315 0.532 0.376 0.125
Groups Univariate linear 
Cardiac function Control S18886 ROF
 
 
Table 2. Cardiac function: general, systolic and diastolic indices. * p<0.05 vs Control group; ** p<0.005 
vs Control group; # p<0.05 vs Rofecoxib group (ROF). HR = heart rate; CO = cardiac output; SW = 
stroke work; EA = arterial elastance (afterload); ESV = end-systolic-volume; ESP = end-systolic-
pressure; dP/dtMAX = maximal rate of pressure increase; EES = end-systolic elastance; EDV = end-
diastolic-volume; EDP = end-diastolic-pressure; -dP/dtMIN = maximal rate of pressure decline; τ = 
relaxation time constant; EED = diastolic stiffness.  
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Discussion 
In line with previous studies, the 
present study showed significant 
negative effects of daily 
rofecoxib treatment on global 
and systolic LV function in mice 
seven days after ischemia 
reperfusion injury. The main 
new aspect of our study is the 
finding that these effects may be 
prevented by combining the 
rofecoxib treatment with 
S18886. The groups did not 
show differences in infarct size 
indicating that the hemodynamic 
effects were not primarily 
resulting from altered infarct 
size. 
Beneficial effects of TP 
receptor antagonism have 
previously been reported in 
experimental studies of 
ischemia-reperfusion injury in 
several species27,28. However, the 
mechanism by which TP 
receptor antagonists exert their 
cardioprotective effect is not 
clear. It does not appear to be 
the consequence of increased 
coronary blood flow into 
ischemic region29, nor does it 
appear to be the consequence of 
a reduced neutrophil 
accumulation30. A hypothesis is 
that TXA2 released during 
reperfusion could result in 
vasoconstriction and platelet 
aggregation, contributing to a 
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Figure 4. Cardiac output (A), stroke work (B), end-systolic 
volume (C) and ejection fraction (D) in control (CON) mice and 
in mice treated with S18886, rofecoxib (ROF), or ROF+S18886. 
The bar graphs in the left panels show the results for the four 
groups with ANOVA statistics. The figures in the right panels 
display the same data from the same four groups but focus on 
the interactive effects to illustrate the statistical method as 
described in detail in the text. The P-values refer to the 
significance of the interactive effect. Full statistics are provided 
in table 2. 
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no-reflow phenomenon to parts of ischemic myocardial tissue, despite a completely 
restored blood flow in the large coronary vessels. Other explanations for the benefits of 
TP-receptor antagonism are an enhanced blood flow during reperfusion, which is 
related to the increase in tissue viability, an improved utilization of oxygen in 
myocardial cells31 or a reduced formation of free radicals32. Additionally TP receptor 
antagonist S18886 has shown anti-inflammatory actions in different murine models of 
hyperlipidemia and atherosclerosis19,20,33,34 
In the present study we 
aimed for ‘human like’ conditions 
with regard to plasma lipid levels 
and ischemia-reperfusion mimicking 
clinical revascularization by early 
PTCA or thrombolysis rather than 
permanent coronary occlusion. 
Therefore we used animals with 
slightly elevated plasma lipid levels 
and obtained a relatively small 
infarct size. The area-at-risk after 
ligation of the LAD coronary artery 
was not measured, because the 7-
day interval between the induction 
of the infarct and sacrifice made 
such a measurement of little 
relevance. In previous experiments 
(unpublished data) we acutely 
measured an area-at-risk after 
identical ligation of the LAD of about 
38-40 % (vol/vol) of the LV. This 
would mean that the infarcts 
typically constituted about 23% of 
the area-at-risk, suggesting that the ischemic insult was less severe (but more clinically 
relevant) than in many previous murine myocardial infarction studies, which limits a 
direct comparison. In the present study, S18886 at 10 mg/kg/day seemed to be 
associated with a smaller infarct size than control but the difference was not statistically 
significant (6.1±3.6 vs. 9.0±3.9%, p=NS). Since it has been shown at least in rats35 that 
relatively small infarcts (13% of the LV) do not result in reduced global heart function 
per se, it was not surprising that S18886 did not influence heart function. In fact, if 
anything, there appeared to be some tendency for depressed cardiac function, which 
however did not show statistical significance. Rofecoxib did not affect infarct size by 
itself, but did induce a significant cardiodepression evident from an increased ESV and a 
A                    B 
     
C           D 
     
 
Figure 5. The upper panels show HPS staining (A) and 
immunohistochemical staining for COX-2 (B) of a 
section remote from the infarct area. The lower panels 
show staining for a section adjacent to the infarct. The 
remote cardiomyocytes do not express COX-2 (B), but 
the cardiomyocytes adjacent to the infarct area show 
clear COX-2 reactivity (D). Some COX-2 expression was 
present in scattered cells in the infarcted area. This 
example was from the Control group. No between-group 
differences were observed. 
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reduced EF and CO and a tendency to reduce SW. When rofecoxib treatment was 
combined with S18886 these effects were fully prevented. This provides evidence for 
S18886 to have a significant beneficial interactive effect when added to rofecoxib 
treatment, which was supported by statistical analysis of the interactive effects. 
The use of COX-2 selective inhibitors in animal models of ischemic heart disease 
has been reported to be both beneficial and deleterious. Recent studies have 
demonstrated that COX-2 acts as a cardioprotective protein in the late phase of ischemic 
preconditioning. IP-receptor deficiency led to an increased infarct area36 and COX-2 
expression was associated with a cardioprotective effect after ischemic 
preconditioning37. Recently, impaired systolic function upon COX-2 inhibition was also 
found in a pig model of MI, with infarct size and EF comparable to our study38. 
Conversely, some studies with murine models of MI22,23 and chronic heart failure21 
showed improved cardiac function in the group treated with the selective COX-2 
inhibitors, without affecting the infarct size. However, in these MI studies the LAD was 
permanently ligated, which is not comparable to our study. Scheuren et al.37,39 
demonstrated, in a rat model of myocardial infarction, that a 4-day treatment with 
rofecoxib (3 mg/kg/day) resulted in reduced influx of inflammatory and fibroblast-like 
cells into infarcted tissue, without affecting the infarct size. In line with previous 
findings2, we found presence of COX-2 immunoreactivity in heart muscle after ischemia-
reperfusion injury suggesting that a change in local PGI2 production might be involved in 
the changes in LV function after myocardial infarction. The favorable effects of S18886 
may thus be due to restoring the local TXA2-PGI2 balance. However, it is also possible 
that antagonism of TP-receptors inhibits their activation by ligands such as TXA2 and 
isoprostanes and subsequently prevents the induction pro-inflammatory pathways. As 
presented in figure 1, the metabolic pathway of arachidonic acid is a balanced and 
complex network of different cascades. It has been shown that agonizing the TP-
receptor may also result in a reduced expression of the lipoxin (LX)-receptor40, 
inhibiting the anti-inflammatory effects of the LXs. This might also contribute to the 
protective effect of S18886. 
We conclude that COX-2 inhibition by daily rofecoxib treatment has deleterious 
effects on cardiac function after ischemia-reperfusion injury in APOE*3Leiden mice. 
These negative effects on ESV, CO, EF and SW are prevented by concomitant treatment 
with thromboxane prostanoid-receptor antagonist S18886. This study proves beneficial 
interaction of S18886 and rofecoxib, and might provide clues to further elucidate the 
mechanism underlying the increase in cardiovascular risk associated with COX-2 
inhibiting treatments. 
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Cardiovascular disease (CVD) is the number one cause of death globally and is expected 
to remain the leading cause of death according to figures of the World Health 
Organization1. The single most important contributor to the growing burden of CVD is 
atherosclerosis, a progressive disease characterized by the accumulation of lipids and 
fibrous elements in the large arteries. Atherosclerosis is considered as a multifactorial 
disease in which lipids and inflammation play major roles2-4. This thesis presented and 
discussed a variety of novel pharmaceutical interventions in experimental CVD.  
 
In pre-clinical stages of the development of new anti-atherosclerotic compounds 
appropriate animal models are a major necessitate. In the current thesis we have made 
use of APOE*3Leiden transgenic mice as an animal model for hyperlipidemia and 
atherosclerosis5. The APOE*3Leiden mouse model has been proven to be representative 
for the human situation regarding very low density lipoprotein (VLDL) and LDL 
metabolism, its responsiveness to hypolipidemic drugs (like statins, fibrates etc.) and 
nutrition. In contrast, wild type mice as well as apoE deficient and LDL receptor 
deficient mice do not or only partially respond to these hypolipidemic drugs6. In 
addition, depending on the level of plasma cholesterol, APOE*3Leiden mice develop 
atherosclerotic lesions in the aorta resembling those found in humans with respect to 
cellular composition and morphological and immunohistochemical characteristics. 
Furthermore, the atherosclerosis development in these mice is accelerated upon 
introducing low grade systemic inflammation, for instance by feeding a high-caloric 
western-type diet, containing saturated fat and cholesterol.  
Like wild type mice, the APOE*3Leiden mice do not express cholesteryl ester 
transfer protein (CETP), a protein that is very crucial in high density lipoprotein (HDL) 
metabolism. Consequently, APOE*3Leiden mice are not suitable for studying (the 
regulation of) HDL metabolism, specifically. In order to render the APOE*3Leiden mouse 
also suitable for studying HDL metabolism, we recently crossbred our APOE*3Leiden 
mouse with the human CETP transgenic mouse (APOE*3Leiden.CETP mouse). In these 
APOE*3Leiden.CETP mice the HDL levels are indeed enhanced by hypolipidemic drugs, 
like statins and fibrates, comparable to what is observed in humans7-9.  
Therefore, we used the APOE*3Leiden.CETP mouse model also to clarify the 
mechanistical background of the HDL-cholesterol (HDL-C) raising effect of niacin in 
chapter 3. Niacin is known since the 1950s to beneficially modulate lipid levels and 
lipoprotein composition. Whereas it is the most potent HDL-C increasing compound 
currently available, only its TG and (V)LDL-C decreasing effects are well understood. We 
demonstrated that CETP plays a crucial role in the niacin induced increase in plasma 
HDL-C and apoAI levels. Niacin reduced the CETP dependent transfer of cholesterol from 
HDL to (V)LDL due to a lower hepatic CETP expression as well as a reduced plasma 
(V)LDL pool. It should be taken into account, however, that the HDL raising effect of 
niacin is most likely secondary to its TG and (V)LDL-C lowering effect brought about by 
inhibiting hormone sensitive lipase activity in the adipose tissue10. Despite its very 
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potent lipid modulating effect, niacin has not been a very successful drug thus far, due to 
its side-effect: severe flushing. This problem might be overcome by the current use of an 
extended release form of niacin or analogues like acipimox, by combining niacin with 
prostaglandin D2 (PGD2) receptor antagonists, which receptor mediates this cutaneous 
flushing.  
Currently two trials evaluating effects of this combination drug on lipid lowering 
(HPS2-THRIVE) and carotid intima-media thickness (ACHIEVE) are underway. Post-hoc 
analysis of a subgroup of ARBITER-2, a randomized, placebo-controlled trial, showed 
increases in HDL-C upon daily intake of the extended release form of niacin on top of 
statin treatment (+20%), which were associated with reduced progression of carotid 
intima-media thickness in the setting of both normal glycemic status and diabetes 
mellitus11. Clinical trials evaluating the secondary prevention of CVD by treatment with 
the extended release form of niacin are currently underway12,13. Recently, the niacin 
receptor GPR109A has been identified, which now is a new target for novel niacin 
analogues in order to increase HDL-C10. This has gained much interest because of the 
recent negative results of CETP inhibition by torcetrapib in the ILLUMINATE trial14. 
Whereas torcetrapib had been shown to raise HDL-C in humans, it was unexpectedly 
ineffective in reducing atherosclerosis and it even increased clinical event rate when 
given on top of atorvastatin treatment. In order to clarify these results we recently 
simulated this trial in a study in APOE*3Leiden.CETP transgenic mice, focusing on the 
possible mechanism on the adverse effect15. We showed that torcetrapib alone reduced 
the progression of atherosclerosis, but did not enhance the anti-atherosclerotic potency 
of atorvastatin. In addition, as compared to atorvastatin, torcetrapib caused a more pro-
inflammatory and unstable lesion phenotype, which could explain the unexpected 
results of the ILLUMINATE trial. Assuming that novel CETP inhibitors do not have these 
pro-inflammatory adverse effects and that the effects observed with torcetrapib are 
compound and class related, we speculate that CETP inhibition per se is still a valid 
strategy to reduce cardiovascular risk.   
Decreasing plasma VLDL and LDL cholesterol by reducing their production and 
increasing their clearance (statins and fibrates) or by increasing HDL (niacin, CETP 
inhibition) is currently the major route to treat the lipid component in CVD. However, 
CVD still occurs after these treatments. Therefore, other routes of cholesterol-lowering 
are explored. For instance compounds that inhibit cholesterol absorption in the intestine 
have been developed, like ezetimibe, which was the first of a new class of selective 
cholesterol absorption inhibitors16. Ezetimibe selectively inhibits cholesterol absorption 
in the intestine by inhibition of the cholesterol uptake transporters Niemann-Pick C1 
Like1, confining the cholesterol to the intestinal lumen for subsequent excretion. Clinical 
trials have demonstrated the lipid-lowering properties of ezetimibe as a single agent, 
which was merely -18% due to a compensatory increase in cholesterol synthesis in the 
liver. Strong additive cholesterol-lowering effects were demonstrated when ezetimibe 
was combined with a statin17,18. Surprisingly, however, additional protective effects in 
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retarding surrogate endpoints were not observed when ezetimibe was added to 
simvastatin treatment in the ENHANCE trial, despite a significant lower LDL-C after the 
combination treatment19. The reason for this unexpected result remains to be 
investigated. For instance, it is not known whether this was a consequence of the 
systemic availability of ezetimibe, which is nearly 100% absorbed, and which may have 
effect on cholesterol transport in the other cells, for instance macrophages. New 
cholesterol uptake inhibitors, which are not or poorly absorbed, are under development, 
like AVE5530.  
In chapter 4 the effect of this new cholesterol uptake inhibitor was investigated 
with regards to its LDL-C lowering capacity as well as its anti-atherosclerotic effects in 
APOE*3Leiden transgenic mice. It was compared to an equal dose of ezetimibe. We 
showed that AVE5530 was more potent in reducing cholesterol levels, resulting in less 
systemic and vascular inflammation and less atherosclerosis as compared to ezetimibe. 
The effect of ezetimibe on true clinical endpoints will be investigated in the currently 
ongoing large IMPROVE-IT trial20. Whereas ezetimbe is generally well tolerated, side 
effects have been infrequently reported, mainly in combination treatment with statins. 
This might hypothetically be a consequence of the similar metabolism of the two 
compounds, as both statins and ezetimibe are glucuronidated by the uridine 5’-
diphosphate glucuronosyltransferase isoenzymes. Taking together our results and the 
unexpected and unexplained absence of beneficial effects in the ENHANCE trial, poorly 
absorbed cholesterol uptake inhibitors like AVE5530, entering phase III in the second 
half of 2008, may have advantages over the almost totally absorbed ezetimibe. 
 
Since atherosclerosis is a multifactorial disease, it may be of clinical advantage to lower 
cholesterol and on top of that co-treat other risk factors of CVD development, e.g. 
hypertension. Analysis of data from 29 randomized trials (n=162,341) showed that anti-
hypertensive treatment with any commonly-used regimen reduces the risk of total 
major cardiovascular events, and that larger reductions in blood pressure lead to larger 
reductions in risk21.   
In chapter 2 we describe the potential advantage of combining atorvastatin 
treatment with anti-hypertensive treatment using the calcium channel blocker (CCB) 
amlodipine. This hypothesis was later on confirmed in the Anglo-Scandinavian Cardiac 
Outcomes Trial–Blood Pressure Lowering Arm (ASCOT-BPLA) study, a randomized 
controlled trial (n=19,257), demonstrating that amlodipine prevented major 
cardiovascular events more efficiently than atenolol (β-blocker) and a diuretic after a 
5.5 year follow-up period22. Additionally, a potential interaction between blood-
pressure-lowering treatments and statins was reported in the Lipid Lowering Arm of the 
ASCOT study (ASCOT-LLA) in favor of amlodipine/ atorvastatin treatment above 
atenolol/ atorvastatin treatment.  
In chapter 5 we designed a study to evaluate and characterize the nature of the 
effect of the anti-hypertensive angiotensin II receptor blocker (ARB) olmesartan alone 
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or in combination with statin treatment, on the development of atherosclerosis in 
APOE*3Leiden mice. We aimed at mimicking the clinical situation with respect to 
treatment response (regarding the magnitude of lipid lowering as well as blood pressure 
lowering). Strikingly, olmesartan and pravastatin were equally potent in reducing the 
atherosclerosis development in the mice. While olmesartan had anti-inflammatory 
actions which inhibited the onset of lesion development by decreasing monocyte 
adhesion to the endothelium and the relative amount of macrophages in the lesions, 
pravastatin inhibited the progression of atherosclerosis in terms of less advanced 
lesions. Therefore, combination therapy with olmesartan and pravastatin additively 
reduced atherosclerosis development, resulting in fewer and less severe lesions. The 
effect of combination treatment of olmesartan with pravastatin on cardiovascular 
endpoints in humans has not yet been studied. However, combination therapy of 
atorvastatin with an angiotensin converting enzyme (ACE) inhibitor was shown to be 
more effective in reducing cardiovascular events than statin treatment alone in a post-
hoc analysis of patients of the GREACE study23,24, which is in line with the effects of 
atorvastatin and anti-hypertensive treatment in the mentioned ASCOT-LLA study. These 
latter trials clearly demonstrate additional beneficial effects of combining anti-
hypertensive treatment with anti-hyperlipidemic treatment. We showed that, 
independent of its blood pressure lowering effect, ARB treatment leads to prevention of 
atherosclerosis via anti-inflammatory routes. Therefore, we suggest that combining the 
anti-hypertensive treatment with olmesartan and anti-hyperlipidemic treatment with 
pravastatin may be more effective in the prevention of atherosclerosis than treatment 
with statins alone.  
 
The studies described so far were evaluating the effect of compounds on the progression 
of atherosclerosis in a ‘prevention’ design, which supplies very relevant information 
about the features and potency of the test substances. However, in the clinic treatment 
of CVD is mostly started after atherosclerotic lesions have already developed. The 
established lesions are often accompanied and brought about by a combination of the 
different risk factors like hypertension, hyperlipidemia and diabetes, all characteristics 
of the ‘metabolic syndrome’. As the metabolic syndrome is a constellation of partly 
interrelated risk factors, it is strongly correlated with the development of CVD. Its global 
prevalence has been increasing over the last decades and will probably even double 
within the coming 25 years. New classes of drugs in development that aim on 
ameliorating metabolic syndrome (in this case targeting both hyperlipidemia and insulin 
resistance/ diabetes) and CVD risk are peroxisome proliferator-activated receptorα/γ 
(PPARα/γ) agonists. In previous experiments we already showed that the newly 
developed PPARα/γ agonist tesaglitazar improved plasma lipid levels and insulin 
resistance and inhibited the development of progression atherosclerosis in 
APOE*3Leiden mice25. In chapter 6 we aimed at investigating the anti-atherosclerotic 
effect of tesaglitazar in a more clinically relevant experimental design of reduced 
148
CHAPTER 9__________________________________            ___________________________________________________ 
 148 
progression or atherosclerosis regression, i.e. in an animal model with pre-existing 
atherosclerosis (a ‘treatment’ design). To this end, we first introduced atherosclerosis in 
APOE*3Leiden.CETP transgenic mice by feeding a western type diet resulting in elevated 
plasma cholesterol levels. Thereafter, plasma cholesterol was lowered by reducing 
dietary cholesterol, and subsequently on top of that by pharmacological treatment with 
tesaglitazar. The mice showed an similar response to tesaglitazar treatment as human 
do in terms of reduced VLDL/LDL levels and increased HDL levels. The latter was not 
observed in mice lacking CETP, emphasizing the key role of CETP in the HDL-raising 
effects of tesaglitazar. In contrast to dietary cholesterol lowering alone, tesaglitazar fully 
prevented the progression of pre-existing atherosclerosis and it stabilized lesions, as 
related to reduction of (V)LDL and local anti-inflammatory action in the vessel wall. 
Currently, not any dual PPARα/γ agonist has been approved yet for clinical use, since up 
till now all compounds, including tesaglitazar, have failed in a preclinical stage or in 
clinical trials. Long term clinical effects can therefore only be extracted from clinical 
studies using either PPARα or PPARγ agonists. Whereas PPARα agonists have shown 
beneficial effects on CVD development26-29, the effects of PPARγ agonists are 
contradictory30-33. This might reflect the complex and careful balance in PPAR pathways 
and mechanisms involved in their beneficial and detrimental effects. Despite the clinical 
failure of tesaglitazar due to a decreased creatinine clearance, we demonstrated a 
therapeutic window for PPARα/γ agonists for treatment of diabetic cardiovascular 
complications.  
 
Established CVD has been identified as an independent risk factor for fatal CVD and is 
not included in the SCORE system. Though patients with established CVD are more 
prone to suffer from CVD events and are considered as high risk persons regardless of 
the presence or absence of other risk factors. The majority of the patients suffering from 
CVD events are on an anti-platelet therapy. In chapter 7 we investigated the effect of 
anti-platelet therapy with a new thromboxane prostanoid receptor antagonist S18886 
(terutroban) on pre-existing lesions in APOE*3Leiden mice, again on top of cholesterol 
lowering. This new therapy was compared to treatment with the adenosine diphosphate 
receptor antagonist clopidogrel, a frequently used anti-platelet compound in the clinic. 
We showed that, on top of aggressive cholesterol-lowering, S18886 completely 
prevented the progression of established atherosclerosis, which could be addressed to 
its local anti-inflammatory effects. This was reflected by a dose-dependent reduction in 
adhesion of activated monocytes to the endothelium, which in part may be related to 
inhibition of platelet activation by the compound as clopidogrel also tended to decrease 
the monocyte adhesion. S18886 is currently tested in phase III studies and up till now no 
thromboxane prostanoid-receptor antagonist has been clinically available. Data from 
clinical endpoint studies are only available for the combined inhibitor of thromboxane 
A2 synthase and receptor, picotamide, in the DAVID study34, which was reported to be 
more effective in reducing all cause mortality in diabetic patients as compared to 
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aspirin. Previously, picotamide was shown to inhibit the progression of plaque growth in 
the carotid artery in diabetic patients35. While all the functions and effects of 
thromboxane A2 (TXA2) and its thromboxane prostanoid receptor on platelets and 
peripheral tissue are not fully clarified yet, we provide evidence that their anti-
atherosclerotic properties are a result of interactions with inflammatory pathways. It 
also was hypothesized that TXA2 may be involved in other clinical features of CVD and 
that S18886 may be a compound with features beyond its anti-platelet aggregating 
capacities.  
In chapter 8 we further explored the possible deleterious effects of TXA2 and its 
receptor on heart function after myocardial ischemia reperfusion injury. The selective 
cyclooxygenase-2 (COX-2) inhibitor, rofecoxib, has been developed for the treatment of 
chronic inflammatory diseases like rheumatoid arthritis. Whereas the exact mechanism 
is unknown, a meta-analysis over nine case-control studies and two cohort studies 
showed a relative risk of 1.35 for serious cardiovascular events with rofecoxib 
treatment36. It was hypothesized that selective COX-2 inhibitors shift the balance 
between TXA2 and prostaglandin I2 (PGI2) in the vascular system in favor of TXA2, by 
suppressing the synthesis of (endothelial) COX-2-derived PGI2, without changing the 
(platelet) COX-1-derived TxA2 synthesis. Whereas an increased TXA2 release has been 
shown during myocardial ischemia, it can be speculated that TXA2 exerts a deleterious 
effect during ischemia and reperfusion due to its pro-inflammatory and cytotoxic effects. 
We thus hypothesized that the deleterious effects of rofecoxib after myocardial ischemia 
might be eliminated by co-treatment with S18886.  To create a hyperlipidemic situation 
we used APOE*3Leiden transgenic mice on a western type diet and induced myocardial 
ischemia-reperfusion injury. Whereas treatment with S18886 alone did not affect infarct 
size or cardiac function, we confirmed the reported deleterious effects of rofecoxib on 
cardiac function after ischemia-reperfusion injury found in humans. This was reflected 
by negative effects on cardiac output, ejection fraction and end-systolic volume. 
Concomitant treatment with S18886 prevented these negative effects. This study 
provided clues to further elucidate the mechanism underlying the increase in 
cardiovascular risk associated with selective COX-2 inhibitors. Co-administration of 
thromboxane prostanoid receptor antagonists might be tool to the reduce risks related 
to COX-2 inhibiting treatments, which are of major need for the patients suffering from 
chronic inflammatory diseases. 
 
In conclusion, we have shown a variety of approaches to treat atherosclerosis and CVD. 
Lowering LDL-C remains the primary target to treat according to current guidelines37. 
Whereas statins have become the ‘golden standard’, new compounds are being 
developed aiming at more efficacy and more safety (e.g. by developing non-absorbable 
compounds like AVE5530). Low HDL-C has been identified as a risk factor and especially 
since low HDL-C is one of the characteristics of the increasing prevalent metabolic 
syndrome it has become a target of interest for the prevention of CVD. Because safety 
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(torcetrapib, tesaglitazar) and side effects (niacin) of the new and current HDL-C 
increasing compounds have limited their use in the clinic, this target has gained the 
interest of industry, mainly by inhibiting CETP and agonizing the GPR109A (niacin) 
receptor. As evidence is accumulating that, like the hypertension per se, the mechanism 
beyond hypertension also is a risk factor for the development of CVD, new anti-
hypertensive compounds may focus on these underlying effects. The contribution of the 
renin-angiotesin-aldosteron-system in regulating these different pathways needs to be 
further elucidated, supplying clues to design novel intervention strategies. An equal 
scenario is true for platelets. So far, research has focused on their aggregating capacities, 
whereas their other functions are still partly unclear. Whereas we showed that platelets 
also modulate inflammation, these additional functions need to be identified.  
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Figures of the World Health Organization demonstrate that cardiovascular disease 
(CVD) is the current and future number one cause of death worldwide. The single 
most important contributor to the growing burden of CVD is atherosclerosis, a 
progressive disease characterized by the accumulation of lipids and fibrous 
elements in the large arteries. Novel pharmaceutical therapies to prevent CVD are 
targeting various risk factors, of which a number is examined in this thesis. 
In Chapter 2 we reviewed the effect of current ‘standard’ therapies for the 
treatment of two separate risk factors for CVD, i.e.  hyperlipidemia with atorvastatin 
and hypertension with the calcium channel blocker (CCB) amplodipine. In clinical 
studies monotherapy with CCBs showed attenuation of the first stage of 
atherosclerosis, meaning that the lesions that pre-existed at the start of CCB therapy 
did not demonstrate progression or regression on angiography. Statins have shown 
to reduce CVD events and mortality in numerous clinical trials. Since both kinds of 
drugs act via different mechanisms to protect against the development of CVD, it 
was hypothesized that the combination of both may have synergistic beneficial 
effects. Scientific evidence of in vitro and in vivo studies and clinical trials was 
collected in chapter 2 to illustrate the possible advantage of combining these two 
kind of treatments. Recently, a potential interaction between blood-pressure-
lowering treatments and statins were reported from clinical studies with regard to 
amlodipine/ atorvastatin treatment.  
Although some compounds have proven their benefit in the clinic, their exact 
working mechanism may not always be clarified yet. Niacin (vitamin B3) is one of 
those compounds. In the early 1950s already it was known to strongly decrease TG 
and LDL-C levels and to increase HDL-C, which together results in a remarkable 
reduction of CVD risk. Whereas niacin even is the most potent HDL-C increasing 
drug currently available, the mechanism underlying its HDL-raising effect is not fully 
understood. In chapter 3 we aimed at elucidation of this HDL-C raising capacity of 
niacin. To this end, we treated APOE*3Leiden.CETP mice with incremental doses of 
niacin. We observed a markedly increase of HDL-C, which was brought about by a 
reduction of transfer of cholesterol from HDL to (V)LDL This reduced cholesterol 
transfer is due to a lower hepatic CETP expression and a reduced plasma (V)LDL 
pool.  
In chapter 4 we compared the anti-atherosclerotic potential of a newly 
developed and poorly absorbable cholesterol uptake inhibitor AVE5530 with that of 
the clinically available drug ezetimibe in APOE*3Leiden transgenic mice.  In contrast 
to AVE5530, ezetimibe is nearly 100% absorbed in the intestine and might also be 
active on cholesterol transport in macrophages. The consequence of this systemic 
activity is unclear and remains to be investigated. We showed that AVE5530 was 
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more efficient in lowering (V)LDL-C than ezetimibe and in addition, AVE5530 had 
stronger anti-inflammatory effects. As a consequence AVE5530 was clearly more 
potent in preventing atherosclerosis development in APOE*3Leiden transgenic mice 
than ezetimibe.  
 As described in chapter 2, combination therapy targeting two risk factors of 
CVD might have synergistic or additive effects in the prevention of CVD and 
atherosclerosis. An example of such a study was presented in chapter 5, where 
APOE*3Leiden mice were treated with either the anti-hypertensive angiotensin II 
receptor blocker (ARB) olmesartan or the antihyperlipidemic drug pravastatin 
alone or with the combination of both compounds. Treatment with olmesartan or 
pravastatin reduced the development of atherosclerosis to a similar extent as 
compared to the control group, albeit via different anti-inflammatory and anti-
atherosclerotic mechanisms. Whereas olmesartan inhibited the onset of lesion 
development, pravastatin hampered the lesion progression towards more severe 
lesions. Combining and thereby gathering the strength of the two drugs additively 
reduced atherosclerosis development, resulting in both fewer and less severe 
lesions. 
In chapter 6 again two risk factors for CVD were targeted, i.e. hyperlipidemia 
and insulin resistance. The effect of a dual PPARα/γ agonist, tesaglitazar, was 
investigated on pre-existing atherosclerotic lesions in APOE*3Leiden.CETP 
transgenic mice, a study design of more clinical significance, since in the clinical 
setting lesions will have developed before treatment is started. We showed that the 
presence of CETP was crucial for the HDL-raising effect of tesaglitazar, which also 
markedly reduced (V)LDL-C.  Additionally, tesaglitazar turned down the cholesterol-
induced vessel wall-specific inflammation. These combined actions resulted in 
complete inhibition of progression and stabilization of pre-existing atherosclerotic 
lesions in E3L.CETP transgenic mice. This is in contrast to dietary cholesterol 
lowering alone, which could not halt lesion progression. 
A similar study design was used for the experiment presented in chapter 7 
where APOE*3Leiden mice had developed mild lesions before cholesterol-lowering 
with or without additional anti-platelet therapy was started. We evaluated the effect 
of incremental doses of the thromboxane-prostanoid receptor antagonist S18886 
(terutroban). Adenosine diphosphate (ADP) receptor antagonist clopidogrel was 
used as an anti-platelet control, a compound which is already used in the clinic. 
Cholesterol-lowering alone decreased levels of inflammation markers, reduced the 
number of lesions and improved the lesion stability. Simultaneous treatment with 
clopidogrel did not significantly add to the effect of cholesterol-lowering. In 
contrast, S18886 reduced additionally and dose-dependently the lesion area, the 
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progression of lesion severity and the amount of adhering monocytes when 
compared to the control. This suggests anti-inflammatory effects of S18886. 
 Not all functions and effects of thromboxane A2 (TXA2) and its receptor on 
platelets and peripheral tissue are fully clarified yet. However, evidence is 
accumulating that they indeed interact with inflammatory pathways and affect 
atherosclerosis and CVD endpoints. It has been observed that selective 
cyclooxygenase-2 (COX-2) inhibition by rofecoxib is associated with increased risk 
of cardiovascular events. We hypothesized that this could be due to a locally 
disrupted TXA2 - prostacyclin (PGI2) balance and that this may be prevented by 
concomitant treatment with the thromboxane-prostanoid receptor antagonist 
S18886, which then may ameliorate possible negative effects.  This was investigated 
in chapter 8 in APOE*3Leiden mice with ischemia reperfusion injury of the 
myocardium. After myocardial infarction, the mice were daily treated with either 
S18886, rofecoxib or with the combination of both. After one week the cardiac 
function was quantified and the ischemic area was measured. Whereas none of the 
treatments affected the infarct size, the heart function was different between the 
groups. As observed in human studies rofecoxib worsened the heart function. This 
was measured by a decreased cardiac output and ejection fraction, and an increased 
end-systolic volume. These negative effects were prevented when S18886 was co-
administered; suggesting that indeed the local TXA2-PGI2 balance plays a role in the 
deleterious effects of rofecoxib treatment.  
158
 158 
 
159
 
          
 
 
 
 
Samenvatting 
 
160
 160 
161
_______________________________________________ __________________________________SAMENVATTING 
 161 
Cijfers van de Wereld Gezondheid Organisatie (World Health Organization) laten 
zien dat hart- en vaatziekten wereldwijd doodsoorzaak nummer één zijn en 
waarschijnlijk zullen blijven in de toekomst. De belangrijkste veroorzaker van hart- 
en vaatproblemen is atherosclerose (ook wel ‘aderverkalking’ genoemd), een 
progressieve ziekte gekarakteriseerd door stapeling van vetten (lipiden) en fibreus 
weefsel in de grote arteriën. Nieuwe farmaceutische therapieën ter voorkoming van 
hart- en vaatziekten richten zich op de verschillende risicofactoren. Een aantal van 
deze therapieën is geëvalueerd in dit proefschrift. 
In hoofdstuk 2 hebben we het effect van de huidige ‘standaard’ therapieën 
voor de behandeling van twee risico factoren voor hart- en vaatziekten bekeken: 
cholesterolverlaging met een cholesterolsynthese remmer (statine) en 
bloeddrukverlaging met een calciumkanaal blokker. Behandeling met een 
calciumkanaal blokker alleen heeft in klinische studies een vermindering van 
progressie van atherosclerose laten zien. De lesies die reeds aanwezig waren bij de 
start van de therapie vertoonden noch progressie noch regressie na angiografische 
analyse. In een groot aantal klinische studies is inmiddels aangetoond dat statines 
hart- en vaatziekten al dan niet met sterfte tot gevolg, verminderen. Omdat beide 
medicijnen beschermen tegen hart- en vaatziekten via verschillende onderliggende 
mechanismen, is het mogelijk dat de combinatie van deze geneesmiddelen 
synergistisch werken. In hoofdstuk 2 hebben wij wetenschappelijke data 
verzameld om zo de mogelijke voordelen van deze combinatietherapie in kaart te 
brengen. Uit recent in vitro, dierexperimenteel en klinisch onderzoek blijkt een 
synergistische werking van bloeddrukverlagende therapieën en behandeling met 
statines inderdaad te bestaan. Deze studies hadden vooral betrekking op de 
combinatie amlodipine/ atorvastatine.  
Hoewel van sommige medicijnen de effectiviteit al is bewezen in de kliniek, is 
het werkingsmechanisme niet altijd even duidelijk. Niacine (vitamine B3) is een van 
die stoffen. Al in de jaren ’50 was bekend dat deze stof een sterke triglyceride en 
(V)LDL-cholesterol verlagende werking heeft en tegelijkertijd het HDL-cholesterol 
verhoogt. Tezamen resulteert dit in een aanzienlijke verlaging van het risico op  
hart- en vaatziekten door dit medicijn.  Ondanks het feit dat niacine de meest 
potente HDL-cholesterolverhoger is in de kliniek, is het werkingsmechanisme van 
deze stof is nog steeds onbekend.  
In hoofdstuk 3 hebben we geprobeerd het mechanisme van deze HDL-
verhogende capaciteit op te helderen. Daartoe hebben we APOE*3Leiden.CETP 
transgene muizen behandeld met oplopende doseringen van niacine. We zagen een 
zeer significante stijging van het HDL-cholesterol, die werd veroorzaakt door een 
verlaging van het CETP-afhankelijke cholesterol transport van HDL naar (V)LDL. Dit 
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werd deels veroorzaakt door een verlaagde CETP expressie in de lever en deels door 
een daling in het plasma (V)LDL niveau. In deze studie kwam duidelijk naar voren 
dat CETP een sleutelrol speelt in het HDL-verhogende effect van niacine.  
Verlaging van het plasma cholesterol kan ook verkregen worden door de 
absorptie van cholesterol in de darm te remmen. In hoofdstuk 4 hebben we in 
APOE*3Leiden transgene muizen de cholesterolverlagende en anti-
atherosclerotische werking van een nieuw ontwikkelde remmer van de cholesterol 
absorptie (AVE5530) bestudeerd en vergeleken met de absorptieremmer ezetimibe, 
wat een al geregistreerd geneesmiddel is. In tegenstelling tot AVE5530 wordt 
ezetimibe bijna volledig geabsorbeerd in de darm en kan het daarom ook werkzaam 
zijn op het cholesterol homeostase in de macrofagen in de circulatie en in de lesie. 
Wij hebben laten zien dat AVE5530 effectiever het (V)LDL-cholesterol verlaagt dan 
ezetimibe. Daarnaast had het ook een sterker anti-inflammatoir effect. AVE5530 was 
ook aanzienlijk meer potent in het remmen van de atherosclerose-ontwikkeling in 
de APOE*3Leiden transgene muizen dan ezetimibe. Of deze verbeterde anti-
atherosclerotische werking van AVE5530 ten opzichte van ezetimibe een gevolg is 
van de niet- systemische beschikbaarheid van AVE5530 is nog niet duidelijk en zal 
verder onderzocht moeten worden. 
 Zoals beschreven is in hoofdstuk 2, een combinatie therapie, welke zich richt 
op meerdere risico factoren voor de ontwikkeling van hart- en vaatziekten, kan 
synergistisch of additief werken in de preventie van atherosclerose. Dergelijk 
onderzoek is uitgevoerd in hoofdstuk 5, waarin het effect is beschreven van de 
behandeling van APOE*3Leiden transgene muizen met de nieuwe 
bloeddrukverlager (een angiotensine II receptor blokker) olmesartan, de 
cholesterolverlager pravastatine, of met de combinatie van beide medicijnen. 
Behandeling met alleen olmesartan of alleen pravastatine remde de ontwikkeling 
van atherosclerose in vergelijking met de controle groep even effectief. Echter, deze 
remming werd veroorzaakt door een verschillend anti-inflammatoir en anti-
atherosclerotisch werkingsmechanisme van beide medicijnen. Olmesartan remde 
vooral het ontstaan van de lesies in de beginfase van het atherosclerotisch proces, 
terwijl pravastatine juist de progressie van de ernst van de lesies remde. Door beide 
stoffen te combineren werden de krachten gebundeld, wat additief werkte en leidde 
tot nog meer reductie van de atherosclerose-ontwikkeling. In deze combinatie groep 
werd een nog kleiner aantal lesies en nog minder ernstige lesies gemeten in 
vergelijking met monotherapie.  
In hoofdstuk 6 werd ook een combinatie therapie toegepast, die gericht was 
tegen twee risicofactoren, namelijk hyperlipidemie en insuline resistentie of 
diabetes type 2. In deze studie werd het effect van de duale PPARα/γ agonist 
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tesaglitazar onderzocht in APOE*3Leiden.CETP transgene muizen met reeds 
bestaande atherosclerotische lesies. De opzet van deze studie was klinisch 
relevanter dan de studie beschreven in hoofdstuk 5, omdat ook in de kliniek 
atherosclerose al ontwikkeld is vóórdat de patiënt behandeld wordt. In deze studie 
lieten we zien dat CETP een cruciale rol speelt in het HDL-verhogende effect van 
tesaglitazar, wat tegelijkertijd ook triglycerides en (V)LDL sterk verlaagt. Daarbij 
verlaagde tesaglitazar ook de cholesterol geïnduceerde vaatwandactivatie. Deze 
acties resulteerden in complete remming van atheroscleroseprogressie en leidde 
zelfs tot stabieler fenotype van de bestaande lesies. Cholesterolverlaging alleen 
remde de lesie voortgang niet.  
Eenzelfde studieopzet gebruikten wij in de studie gepresenteerd in hoofdstuk 
7. APOE*3Leiden muizen met reeds mild ontwikkelde atherosclerose ondergingen 
een cholesterolverlagende therapie door middel van cholesterolverlaging in het 
dieet, al dan niet gecombineerd met bloedplaatjesremmende therapie. We 
bestudeerden het effect van oplopende doseringen van de thromboxane-prostanoid 
receptor antagonist S18886 (terutroban). De adenosine diphosphate (ADP) receptor 
antagonist clopidogrel, een plaatjesremmer die vaak toegepast wordt in de kliniek, 
werd gebruikt als controle stof voor de plaatjesremming. Cholesterolverlaging 
alleen verlaagde de ontstekingsmarkers in het plasma, verminderde het aantal lesies 
en verbeterde de lesie-stabiliteit. Wanneer bovenop de cholesterolverlaging 
clopidogrel werd gegeven, vond er voor geen van de parameters een extra 
verandering plaats. Additieve therapie met S18886 daarentegen, verminderderde 
dosisafhankelijk de lesie-oppervlakte, de lesie-ernst en het aantal monocyten dat 
aangehecht was aan het vaatwandendotheel. Deze resultaten duiden op anti-
inflammatoire effecten van S18886. 
 De functies van thromboxaan A2 (TXA2) en de thromboxane-prostanoid 
receptor op bloedplaatjes en in de perifere weefsels zijn nog niet helemaal duidelijk. 
Echter, er komen  steeds meer aanwijzingen dat beide een interactie hebben met 
ontstekingsroutes en dat ze atherosclerose en het vóórkomen van hart- en 
vaatziekten beïnvloeden. Uit klinische studies is gebleken dat het gebruik van de 
selectieve cyclooxygenase-2 (COX-2) remmer rofecoxib, een ontstekingsremmer, 
geassocieerd is met een toegenomen risico op hart- en vaatziekten. In theorie zou 
dit het gevolg kunnen zijn van een verstoorde lokale TXA2 - prostacycline (PGI2) 
balans. Indien dit het geval is, zouden de negatieve effecten van rofecoxib verholpen 
kunnen worden door tegelijkertijd een thromboxane-prostanoid receptor 
antagonist zoals S18886 toe te dienen. Deze hypothese werd onderzocht in 
hoofdstuk 8, waarin APOE*3Leiden transgene muizen ischemie-reperfusie schade 
in het hart toegebracht kregen. Na dit myocardinfarct, werden de muizen dagelijks 
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behandeld met ofwel S18886, of rofecoxib, of met de combinatie van beide stoffen. 
Een controle groep bleef onbehandeld. Na een week werden de hartfunctie en het 
infarctoppervlak gemeten. Terwijl de infarctgrootte niet veranderde door welke van 
de drie behandelingen dan ook, was er wel een verschil in hartfunctie tussen de 
groepen. Zoals waargenomen in de humane studies verslechterde rofecoxib de 
hartfunctie ook in muizen. Dit werd veroorzaakt door een verminderde 
hartcapaciteit en ejectiefractie en een toegenomen eind-systolisch volume. Deze 
negatieve effecten van rofecoxib konden worden voorkomen door de muizen 
tegelijkertijd met rofecoxib S18886 te geven. Dit suggereert dat de lokale TXA2-PGI2 
balans inderdaad een rol speelt bij de nadelige effecten van rofecoxib behandeling.  
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